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ABSTRACT 
Escherichia coli O157:H7 is an enteric pathogen that can cause severe 
gastrointestinal disease, sometimes leading to hospitalization and death. These bacteria 
have a variety of virulence factors that can be encoded for on pathogenicity islands 
(PAIs). The goal of this study was to characterize specific E. coli O157:H7 PAI deletion 
mutants using three methods: Phentotype Microarrays (PM), growth curves and survival 
curves were used to elucidate possible roles for the PAIs.  Results from the PM study 
suggest that PAIs have a role in carbon substrate utilization; i.e., four of the O-island (OI) 
deletion mutants (OI-87, 98, 102 and 172) and an S-Loop (SL-72) deletion mutant 
exhibited differences in substrate utilization (gains and losses in utilization) compared to 
parental O157:H7 strains EDL933 (OI) and Sakai (SL), respectively. All of the mutants 
with the exception of the OI-135 mutant exhibited differences in level of substrate 
utilization for substrates shown to have important roles in the bacterium. Cell growth 
results showed that three OI deletion mutants (OI-55, 87 and 102) and the SL (SL-72) 
mutant exhibited a difference in rate of growth compared to the parental strains. Cell 
viability results showed that seven of the OI deletion mutants (OI-51, 55, 98, 108, 135, 
172 and 176) exhibited different rates of decline in cell number when transferred to 
sterile water compared to the parental strain. The results show that removal of PAIs from 
E. coli O157:H7 can affect carbon utilization, growth and survival demonstrating the 
importance of PAIs in the ecology of these bacteria. 
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Chapter I 
 Hypothesis and Objectives 
1.0 Introduction  
  Escherichia coli (E. coli) O157:H7 is an enteric human pathogen that can cause 
severe bouts of gastrointestinal disease, sometimes leading to hospitalization and death 
(Karmali 2005). The bacteria contain a variety of virulence factors that can be encoded 
for on pathogenicity islands (PAIs). Characterization of PAIs found in E. coli O157:H7 is 
important to help clarify the roles these islands have in regulation of gene expression in 
these bacteria. Investigation of these PAIs could also help elucidate possible approaches 
to prevention and mitigation of O157:H7 outbreaks and could help us to identify possible 
roles PAI have in  contributing to the virulence of E. coli O157:H7.   
The hypothesis of the thesis is that the removal of a PAI from E. coli O157:H7 
will result in a deletion mutant that will have differences in carbon utilization, growth and 
survivability compared to the O157:H7 parental strain.  
In this study, 13 deletion mutants of E. coli O157:H7  strains EDL933 and Sakai 
were examined and compared to their parental strains and the reference E. coli K12 strain 
DH5α. The PAIs in E. coli O157:H7 strain EDL933 are called O-islands (OI) and in E. 
coli O157:H7 strain Sakai they are called S-Loops (SL) (Perna et al. 2001; Hayashi et al. 
2001). The main objectives of the study were to: 
 
I) Characterize the O157:H7 deletion mutants using phenotypic profiling (the 
BiologTM PM plate system) to allow identification of substrate utilization 
patterns and, to identify differences in these patterns that could be used to 
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elucidate the role of the deleted PAIs in the bacteria.  Specifically the study 
was used to: 
1) Determine the PM profiles for 13 mutants and 3 controls (O157:H7 
pathogenic strains EDL933 and Sakai plus the reference control E. coli 
K12 strain DH5α) 
2)  Determine if differences in substrate utilization confer a role to the 
specific OI or SL removed from the bacteria.  
3)  Determine if removal of a PAI results in a deletion mutant that uses 
subtrates in a manner more resembling a reference K-12 strain. 
 
II) Examine the growth of OI and SL deletion mutants in order to determine if the 
extra-chromosomal DNA contained within the OIs and SLs of E. coli 
O157:H7 strains EDL933 and Sakai have an effect on the growth of the 
pathogen in a laboratory setting. Specifically: 
1)   Assess the differences in growth for the 13 deletion mutants and the 3 
controls 
2)  Determine if removal of a PAI resulted in a mutant that grew more like a 
reference K-12 strain 
 
III) Examine the survivability of OI and SL deletion mutants in order to determine 
if extra-chromosomal DNA contained within the OI and SL of E. coli 
O157:H7 strains EDL933 and Sakai contributed to its survival in water. 
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Chapter II 
 Literature Review 
2.0  Background 
 E. coli is a gram-negative bacterium that is normally found as part of the gut 
microbiota of humans (Kuntz and Kuntz 1999).  Many different strains have been 
characterized that generally can be sorted into three main categories: 1. commensal E. 
coli consisting of those that do not cause disease, 2. pathogenic E. coli that cause 
gastrointestinal disease and, 3. extra-intestinal E. coli that cause other forms of disease 
such as blood and urinary tract infections (Russo et al. 2003). Pathogenic E. coli can be 
further separated by the type of disease caused; e.g., sepsis, meningitis, and enteric or 
diarrheal disease (Nataro and Kaper 1998). The enteric group of pathogenic E. coli can 
be further divided into 6 sub-pathotypes that cause diarrhea (Table 2.1) (Nataro and 
Kaper 1998). One of these sub-pathotypes is enterohemorrhagic E. coli (EHEC), which is 
a subset of the Shiga-toxin producing E. coli (STEC) (Cleary 2004).   
 
2.1  STEC and EHEC 
STEC is a class of enteropathogens that produce a toxin or toxins that are closely 
related to the Shiga toxin produced by Shigella dysenteriae serotype 1. Not all STEC 
enteropathogens cause human disease, e.g., some STEC strains cause pig edema disease 
and are unlikely to cause human disease due to differences in virulence (Sonntag et al, 
2005).  EHEC is an example of a STEC that is capable of causing human disease. By 
contrast, EHEC forms an important class of STEC that are intestinal pathogens that have 
potential to cause severe infections such as hemolytic uremic syndrome (HUS),  
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Table 2.1:  Sub-pathotypes of diarrheagenic E. coli and their defining characteristics*.  
 
Pathotypes Defining characteristics 
Enterotoxigenic      
E. coli (ETEC) 
Strains contain a heat stable enterotoxin or Shiga toxin  
and heat-labile enterotoxin groups 
Enteropathogenic     
E. coli (EPEC) 
Produces intestinal histopathology with characteristic 
attaching and effacing lesions (A/E lesions) 
Enterohemorrhagic 
E. coli (EHEC) Produce a Shiga-like toxin and A/E lesions 
Enteroaggregative 
E. coli (EAEC) Display aggregative adherence patterns 
Enteroinvasive       
E. coli (EIEC) 
Strains are biochemically, genetically and 
pathogenetically similar to Shigella spp. 
Diffusely adherent 
E. coli (DAEC) Display diffuse adherence patterns 
* adapted from Nataro and Kaper (1998) 
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hemorrhagic colitis (HC) and can lead to complications such as seizures and even coma 
(Cleary 2004; Karch et al. 2005).  EHEC frequently associated with human disease 
include the serotypes O26:H11, O103:H2, 0111:H8, O145:H28, O157:H- and O157:H7 
(Yoon and Hovde 2008).  EHEC serotypes have been classified into four seropathotypes 
based on their ability to infect humans and the frequency of disease (Table 2.2; Karmali 
2005).   E. coli O157:H7 is one of the most important serotypes in this grouping, as it 
typically is associated with exceptionally virulent strains (Cleary 2004) and are widely 
known and recognized (Karch et al. 2005). In Canada and the United States of America 
(USA), E. coli O157:H7 is the serotype most commonly implicated in causing HUS 
(Yoon and Hovde 2008). However, non-O157:H7 EHEC infections in humans do occur, 
but are more prevalent in continental Europe, Australia and Latin America. 
 
2.2   Reservoirs of EHEC 
One of the major reservoirs of EHEC is cattle (Gannon et al. 2002).  Although 
cattle are a major reservoir, other animals such as sheep, poultry, goats and dogs can also 
act as reservoirs for EHEC (Karch et al. 2005).   
Transmission to humans occurs via three possible routes; i.e., 1) by ingesting 
contaminated material such as food and drink, 2) by person to person contact and, 3) by 
zoonosis or animal contact.  Ingestion of contaminated meat and unpasteurized milk 
represents one of the main ways that EHEC pathogens enter the food chain (Karch et al. 
1999). Contamination of processed meat products such as ground beef has been 
responsible for various outbreaks of E. coli O157:H7 including an outbreak in France in  
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Table 2.2. Classification of serotypes into seropathotypes*.  
 
Seropathotype 
Relative 
incidence Outbreaks 
Severe 
disease 
(e.g., HUS) Serotypes (examples) 
A High Common Yes O157:H7, O157:NM 
B Moderate Uncommon Yes 
O26:H11, O103:H2, 
O111:NM, O111:H8, 
O121:H19 and O145:NM 
C Low Rare Yes 
O91:H21, O104:H21 and 
O113:H21 
D Low Rare No Multiple 
 
*(Adapted from Karmali 2005) 
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2005 (King et al. 2009) and in the state of Washington in the USA in 1992 and 1993 
(Bell et al. 1994).  In both cases the source was frozen hamburger patties.   E. coli 
O157:H7 outbreaks have also occurred by contamination of fresh produce like lettuce, 
berries and bean sprouts (Sivapalasingam et al. 2004).  In September of 2006 an outbreak 
of EHEC strain O157:H7 in the USA was associated to spinach; multiple states were 
affected (Grant et al. 2008). There were 205 confirmed infection cases and 3 deaths; of 
the cases where people were hospitalized (103 cases) 31 of those patients developed HUS 
(Uhlich et al. 2008). 
Contamination of fresh water can lead to high levels of infection and outbreaks. 
This is a cause for concern because pathogenic bacteria can be spread over a large 
geographic area and to a wide range of people in a short period of time (Olsen et al. 
2002).  In Alpine, Wyoming in the summer of 1998 a waterborne outbreak of O157:H7 
occurred (Olsen et al. 2002).  The main cause of this outbreak was due to drinking un-
chlorinated water from the town’s water supply; 157 people were infected. In May of 
2000 a water-borne outbreak of E. coli O157:H7 and Campylobacter jejuni was seen in 
Walkerton, Ontario; over 2000 people were infected and seven people died (Holme 
2003).  This outbreak resulted in changes to drinking water regulations in Canada (Holme 
2003) and emphasized the importance of water safety in management of disease even 
within developed regions such as urban centers found within Canada and the United 
States of  America (USA) (Olsen et al. 2002).  
Transmission of bacterial pathogens from person to person is one of the main 
ways to transmit infections in households (Ludwig et al. 2002) and within other 
populated areas such as daycare facilities where person to person contact is common 
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(Karch et al. 2005). Snedeker et al. (2009) studying transmission of the bacteria found 
that person to person transmission occurred in settings such as nurseries and day care 
facilities where there is interaction between young children among themselves and their 
caregivers.  The study focused on secondary transmission and it was found that 19 % of 
cases in an outbreak are secondary cases where an infected person passes the disease on 
to another individual either in the same household or work environment.  The main age 
group to be affected by secondary infections is children under the age of six; this is 
thought to be due to their immature immune systems and poor hygiene practices. Social 
interactions and common use of space by contaminated and/or infected individuals likely 
results in spread of most types of infectious agents. Proof of infectious routes requires 
both good epidemiological evidence as well as molecular confirmation provided by use 
of microbial source tracking tools (Meyer et al. 2005).  
Outbreaks have also occurred via zoonosis or direct transmission of bacteria from 
animals or their environments to humans; e.g., contaminated animals from farms and 
petting zoos are known to have infected humans (Crump et al. 2002). E. coli O157:H7 is 
known to survive for up to 10 months in some environments; therefore risk of infection 
can still be high even if the main source of the bacteria is removed (Karch et al. 2005).   
 
2.3  Diseases caused by EHEC 
When EHEC infections occur they can be asymptomatic, or have milder 
symptoms such as watery diarrhea (Cleary 2004). Hemorrhagic colitis (HC) occurs when 
large amounts of blood are seen in the stools of individuals especially when accompanied 
by cramping and vomiting. Progress from a milder infection to HC can take 1-2 days 
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(Paton and Paton 1998). Bloody diarrhea is more commonly associated with E. coli 
serotype O157:H7 than with any other E. coli serotype (Klein et al. 2002).  HC can be 
life-threatening in severe cases, especially in young and old people (Coia 1998).  HC is 
not the only complication associated with EHEC infections.  Other problems include 
intussusceptions, where  one segment of the intestine is enfolded into the other (Spalding 
and Evans 2004); colonic perforation, where a hole in the intestinal wall is formed as a 
result of the bacterial infection (De Bartolomeis et al. 2005); gangrene, resulting in decay 
of the body’s tissues and peritonitis, an inflammation of the peritoneum (a serous 
membrane which lines the abdominal cavity) and, sepsis and rectal prolapse, where the 
rectum protrudes from the anal orifice (Huber et al. 1995); pancreatitis, which involves 
inflammation of the pancreas, leading to coma and, hemiplegia, where one side of the 
body is weak, subject to seizures, and uncontrolled convulsions; and HUS, a condition 
which is a sign of damage to the kidneys and other organs in the body (Cleary 2004).  
HUS is the major complication associated with EHEC infections (Cleary 2004). 
Typically, it is characterized by the presence of three traits; i.e., acute renal failure, 
hemolytic anaemia and thrombocytopaenia (Clarke 2001).   HUS occurs when the walls 
of small blood vessels (endothelial cells) are damaged, leading to hemolysis of the red 
blood cells that pass through them and may result in vascular thrombosis or clotting in 
the blood vessels (McCarthy et al. 2000). Toxin-damaged endothelial cells can swell 
narrowing glomerular capillaries within the kidney (Moake 1994).  Fibrin thrombi also 
can form and block capillaries as the intoxication progresses, leading to ischemic damage 
due to an inadequate blood supply (Proulx et al. 2001; Moake 1994).  Blocking of renal 
capillaries can lead to renal failure which is seen in later stages of the disease.  
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Symptoms of HUS range from a subclinical illness which often is mild and 
escapes diagnosis, to a life threatening process. It can occur in any age group but occurs 
more frequently in children and the elderly (Paton and Paton, 1998), perhaps due to the 
presence of an under-developed immune system in children or a declining immune 
system in the elderly. In some cases, teenagers also can develop HUS where a severe 
EHEC infection is involved (Cleary 2004). Development of HUS is always preceded by a 
bout of bloody diarrhea or HC. Typically, HUS presents itself as an acute renal 
insufficiency, resulting in a rapid breakdown in kidney function. However, only 5-8% of 
children who develop HC will develop HUS and in most cases HUS is not fatal (less than 
5%) if treated appropriately. A larger proportion of the affected children and/or adults 
who develop HUS will suffer some permanent damage from the condition (Cleary 2004).   
Risk of developing HUS as a result of an E coli O157:H7 infection is low, but 
does vary from one outbreak to the next, as well as with the serotype of EHEC involved 
in the outbreak. Studies that looked at infections in the elderly and children have shown 
that the risk of developing HUS can be as high as 22% when associated with an E. coli 
O157:H7 outbreak (Cleary 2004). In some EHEC outbreaks where HUS is seen, other 
serotypes of EHEC also can be found (predominantly in Europe) (Karch et al. 2005). 
However, these non-O157 serotypes often are associated with a milder form of the 
disease (Cleary 2004).   
 
2.4  E. coli O157:H7 
Over 200 EHEC serotypes cause human disease but, E. coli O157:H7 has been 
associated with most outbreaks of EHEC globally (Karmali 2005). Despite an increasing 
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incidence of other E. coli serotypes being found in HUS patients, the most common 
serotype found is still O157:H7. In Europe E. coli O157:H7 is found in approximately 50 
% of all HUS cases, while in North America it is found in over 95% of cases (Karch et al. 
2005).  
The bacterium, E. coli O157:H7 have some specific biochemical properties which 
are often associated with them and can be used in identification and isolation of the 
bacteria from clinical and environmental samples (Yoon and Hovde 2008). The two main 
characteristics are an inability to ferment sorbitol in less than 24 h and the inability to 
produce β-glucoronidase.  Other characteristics such as an ability to use dulcitol and 
raffinose can be used to distinguish O157:H7 from other E. coli (Ratnam et al. 1988). 
 
2.5  Genes found in E coli O157:H7 and the mechanism used for infection 
The E. coli serotype O157:H7 is an unusually virulent bacterial strain in humans 
and is the most frequent EHEC serotype associated with HUS and HC (Cleary 2004). E. 
coli O157:H7 bacteria express a variety of virulence factors or proteins that cause disease 
that are encoded for on pathogenicity islands (PAIs) or on virulence plasmids which often 
can be incorporated as regions of chromosomal DNA (Kaper and Hacker 1999). One of 
the key systems that EHEC strains such as O157:H7 possess that is essential for virulence 
is a type III secretion system (TTSS) (Campellone and Leong 2003).  This bacterial 
secretion system is needed for contact dependent translocation of bacterial proteins 
(effectors) into a host cell.  
 The TTSS is functionally conserved in most bacteria such as E. coli O157:H7 and 
acts as a “molecular syringe” (Tomoyasu et al. 2005). This system is encoded for within 
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the locus of enterocyte effacement (LEE) which is located on a PAI (Elliot et al. 2000). 
The LEE PAI is commonly found in many virulent human and plant pathogens (Deng et 
al. 2004). The TTSS secretes proteins that are involved in modulating the host’s 
cytoskeleton, as well as other effectors such as Tir, which is also encoded for by LEE 
(Campellone and Leong 2003). Tir is the receptor for intimin, an adhesion factor needed 
for the bacteria to attach to the surface of cells. Association of the bacteria with the host 
cell surface is referred to as attachment and effacement (A/E) of the bacteria with the host 
(Paton and Paton 1998) and is required for E. coli O157:H7 to infect its host. Tir plays a 
major role in the formation of a pedestal on the host cell surface where the bacteria bind 
and flatten or thin the host epithelium forming an attaching and effacing lesion (as a 
pedestal holding a bacterium is formed) (Campellone and Leong 2003; Elliot et al. 2000).   
Formation of an attaching and effacing lesion (A/E) is central to pathogenesis of 
E. coli O157:H7 on host intestinal epithelial cells (Elliot et al. 2000). This lesion is 
characterized by the bacteria’s ability to attach itself to intestinal cell membranes, to 
destroy the microvilli (effacing) and to induce the formation of the pedestal structures, 
where the bacteria sit (Tomoyasu et al. 2005; Deng et al. 2004).  One of the key proteins 
needed for attaching of the bacteria is intimin (Nataro and Kaper 1998). Intimin is 
encoded for by the eae gene which is located on LEE, the same island that codes for 
TTSS. The O157:H7 serotype produces extensive A/E lesions which demonstrate the 
bacteria’s ability to intimately adhere to intestinal epithelial cells. In O157:H7 strains 
where the eae gene is knocked out, the bacteria are unable to colonize intestinal epithelial 
cells, demonstrating the importance of intimin to the progression of the disease (Nataro 
and Kaper 1998). However, not all EHEC serotypes have the eae gene indicating that 
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other adherence factors also can be involved in bacterial virulence; i.e., infections with 
these strains can still cause HUS and HC. During the course of the disease A/E lesions 
disappear, but are always present at onset of the disease (Nataro and Kaper 1998); e.g., in 
rabbits and piglets development of intestinal symptoms mimicking HC is due to the 
presence of A/E lesions. In EHEC strains, including O157:H7 the A/E lesions are only 
present in the large intestine while in other E. coli classes, A/E lesions can also be found 
in the small intestine.   
 A/E lesions are not the only contributors to the development of HUS and HC. It 
has been speculated that while A/E lesions are needed to produce diarrheal or intestinal 
disease symptoms, Shiga toxin (Stx) is required to produce bloody diarrhea and HC. Stx 
is the major factor and defining virulence characteristic of EHEC (Nataro and Kaper 
1998).  E. coli O157:H7 produces at least one Stx that is similar to the Stx produced by S. 
dysenteriae. In fact, Stx1 from E. coli O157:H7 differs from the Stx of S. dysenteriae by 
only one amino acid (Yoon and Hovde 2008).  Before the toxin produced by pathogenic 
forms of E. coli was characterized and found to be similar to the toxin produced by S. 
dysenteriae, Stx was referred to as a verotoxin because of the toxigenic effect it had on 
cultured Vero cells. Bacteria producing this toxin were called verotoxigenic E. coli 
(VTEC) resulting in the VT nomenclature seen in older literature (Nataro and Kaper 
1998; Paton and Paton 1998). Since then, E. coli producing these toxins have been called 
STEC and, now the two terms STEC and VTEC are used interchangeably. EHEC is a 
subset of STEC/VTEC that causes human illness (Karch et al. 2005). Exposure to Stx can 
potentially lead to complications or death in patients who have contracted HUS.  
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Sequencing of the E. coli O157:H7 genome (Perna et al. 2001) has revealed other 
possible virulence factors, many of which are found on the 9 large OIs of the bacteria 
(Table 2.3) (Perna et al. 2001). Discovery of these islands (Shen et al. 2004) has led to 
speculation that different O-islands may contribute to differences in virulence of E. coli 
O157:H7 and other EHEC serotypes.  Shen et al. (2004) showed that the EHEC serotype 
O113:H21 has acquired parts of two OIs from the especially virulent serotype O157:H7 
(OI #48 and OI#122).  This acquisition of OIs that have a role in virulence from O157:H7 
by non-O157:H7 strains could elucidate or explain the increasing virulence of non-
O157:H7 strains and why some STEC outbreaks with cases of HUS are not due to the 
O157:H7 serotype but due to non-O157:H7 serotypes. 
 
2.6  Shiga toxins in E. coli O157:H7 
 Stx is a compound toxin composed of five glycolipid binding β-subunits (7.7 kDa 
monomers) and one catalytically active α−subunit (32 kDa) (Karch et al. 2005; Paton 
and Paton 1998). There are two main types of Stx (Stx1 and Stx2) with at least three 
variants existing for Stx2 (Table 2.4) (Paton and Paton 1998).  One or both of these Stx 
(Stx1 or Stx2, or variants) can be present in EHEC serotypes; i.e., E. coli O157:H7 
isolates produce one or both of these toxins (Kuntz and Kuntz 1999). It appears that Stx2 
and its variants are more important to the cytotoxicity associated with HUS than Stx1 
(Nataro and Kaper 1998); i.e., humans infected with O157:H7 strains just producing Stx2 
appear more prone to HUS than strains having Stx1 alone or both Stx1 and Stx2. 
In an EHEC infection, once the bacteria adhere to a cell Stx needs to be 
translocated across the intestinal epithelium into the blood stream of the host in order to  
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Table 2.3.  O-islands encoding putative virulence factors in E. coli O157:H7 strain 
EDL933*. 
 
 
The O-island The putative virulence factor 
OI #7 Macrophage toxin and ClpB-like chaperon 
OI #28 
RTX- toxin like exoprotein and transport 
system 
OI #43/48 Two urease gene clusters 
OI #47 
An adhesion polypeptide and/or fatty acid 
biosynthesis system 
OI # 115 
TTSS and secreted proteins similar to 
Salmonella-Shigella inv-spa host cell invasion 
system 
OI #122 Two toxins and PagC like virulence factor 
OI #138 Fatty acid biosynthesis system 
OI #148 LEE 
       * Adapted from Perna et al. (2001) 
 
 
Table 2.4.  Main types of Stx and variant forms*.   
 
Previous nomenclature 
Proposed new 
nomenclature 
Gene Protein 
Shiga toxin (Stx) stx Stx 
Shiga-like toxin I (SLT-I) or verotoxin 1 
(VT1) stx1 Stx1 
SLT-II or VT2 stx2 Stx2 
SLT-IIc or VT2c stx2c Stx2c 
SLT-IIe or VT2e stx2e Stx2e 
         *Adapted from Paton and Paton (1998). 
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reach the target cells (Paton and Paton 1998). The target cells for the toxin are cells that 
have high levels of the globotriaosylceramide (Gb3) receptor; i.e., the glycolipid receptor 
that can bind to Stx.  In humans many Gb3 receptors are found in the kidneys. The Stx 
works by binding to the glycolipid receptors of target cells and then enters the cells by 
receptor mediated endocytosis (Paton and Paton 1998). Once in the cell, one of two 
events can occur: 1) The Stx is either degraded by fusion with lysosomes or 2) the Stx is 
transported to the Golgi apparatus, where it subsequently gets directed back into the 
endoplasmic reticulum, and then to the cytosol. During the course of this transfer process, 
the α−subunit of the stx is nicked by a protease (furin) which activates the toxin. The 
activated toxin interrupts protein production by inhibiting peptide elongation; this can 
eventually lead to cell death.   
Another complication seen associated with HUS is vascular damage due to the 
toxin (Matussek et al. 2003). The toxin induces an inflammatory response in host tissues 
by activating tumor necrosis factor alpha (TNF-α) as well as interleukins (IL-8 and IL-6) 
(Nataro and Kaper 1998). These factors (TNF-α, IL-8 and IL-6) enhance the effect of the 
toxin on human endothelial cells because they induce expression of Gb3 and therefore 
increase binding of toxin to these cells. This immune response to the toxin could result in 
the vascular damage seen associated with HUS (Matussek et al. 2003).   
 
2.7 Use of Phenotype Microarrays to assess bacteria 
 Phenotype microarrays (PMs) can be used to find functions for genes 
(Zhou et al. 2003) and to see how genes network together by testing various cellular 
phenotypes simultaneously (Potera 2006a). PMs provide a physiological assessment of a 
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cell which can complement genomic and proteomic studies studying bacteria (Bochner 
2003). PMs can be used to test a wide range of basic cellular activities ranging from 
nutritional pathways, to osmotic response, pH and chemical sensitivity. These arrays also 
allow researchers to test for more than one cell phenotype at a time (broad testing); e.g., 
some mutations/loss of function can affect other cell phenotypes that may not be 
expected. These changes can be seen with PMs since they test a wide variety of 
phenotypes at the same time (Bochner 2003; Zhou et al. 2003).   
PMs measure cell respiration calorimetrically using a tetrazolium dye (Bochner et 
al., 2001). When the dye is reduced, it turns purple (reduction is irreversible) and 
accumulates in the test mixture. This accumulation can be measured using a 
spectrophotometer and translated as an absorption measurement, reflecting cell 
respiration over time. This change in color is easy to monitor, quantify and reproduce. 
Each PM plate has 96 wells with 95 different substrates and a negative control (water).  A 
cell mixture including tetrazolium dye is then used to inoculate the wells, after which the 
plates are incubated for 24 to 48 hr.  The plates are read using a plate reader; i.e., a 
positive reaction will turn the inoculums purple because of the tetrazolium dye, meaning 
that the substrate was metabolized by the bacteria. This color change is quantified using 
the plate reader and is used to create a PM profile. 
 PMs can be used in comparative genomic studies to compare mutant bacteria to 
wild type cells. They provide a straightforward way to determine the effects of a mutation 
on a genome-wide scale (Zhou et al. 2003).  Zhou et al. (2003) created mutations to study 
two-component regulatory systems in E .coli K12 by making 37 different two-component 
mutants and studying the effects of these mutations using PM plates. They found that 22 
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out of  the 37 two-component mutants they made exhibited phenotypic differences. In 
one of the two-component systems studied, the role of the CusS/CusR system in copper 
ion efflux from the cell was examined. In this system cusRS mutants showed 
hypersensitivity to 1, 10-phenanthroline, a chelator with high affinity for copper ions.  
Their results supported the hypothesis that the CusS/CusR system plays a role in copper 
efflux from the cell. These arrays can be used to characterize phenotypic or observed 
traits found in cells by helping to identify the phenotypic range of traits affected by 
mutations and in some cases can help focus in on a domain within a genome responsible 
for a phenotypic trait (Bochner 2003). 
PMs have also been used to compare pathogenic and non-pathogenic isolates of 
E. coli (Bochner 2003). When Murthy (2006) looked at differences between non-
pathogenic E. coli K12 and uropathogenic E. coli, they identified 37 differences in 
substrate utilization between the two bacterial strains, suggesting that some of the 
metabolic pathways used by the bacteria are different. They suggested there were 
examples of environmental adaptation by bacteria. PMs have also been used to help 
clarify the roles of pathogenicity islands (PAIs) and the phenotypes they confer to a cell 
(Bochner 2003).  Chouikha et al. (2006) used PMs to elucidate the role of a new genomic 
island (AGI-3) inserted into the selC locus (a “hot spot” for insertion of PAIs) of the 
extra-intestinal avian pathogenic E. coli BEN2908 strain.  The role of the AGI-3 genomic 
island was studied by removing parts of the island and by performing various tests to 
characterize the island, including PMs.  It was found that parts of AGI-3 are also present 
in other pathogenic E. coli, as well as other pathogenic species and that it had a role in 
carbon assimilation and virulence. These differences in carbon source utilizations can 
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help clarify the roles of PAIs and identify possible PAIs by determining differences with 
non-pathogenic strains and/or similarities between pathogenic strains of bacteria.  
The PM method has been used successfully in comparative genomics by 
comparing selected mutant cells to wild type controls as seen with the above mentioned 
experiment by Zhou et al. (2003) looking at two component regulatory systems.  Ito et al. 
(2005) also used PMs to study knock out mutants from the KO library (Mori et al, 2000) 
and compare it to the wildtype parental strain BW25113 [lacIq rrnBT14 DlacZWJ16 
hsdR514 DaraBADAH33 DrhaBADLD78] which was used to create all the null mutants.  
They found that these mutants affected various systems in the wildtype strains and often 
the substrates affected were for mannose, acetate and α-ketoglutarate.  The regulatory 
network for utilization of these substrates may be important. 
 As well, phenotypic profiling has been used to compare different strains of the 
same bacterial species such as environmental and clinical isolates of E. coli and 
Salmonella (Bochner, 2003). The profiles of some bacterial species can be found in the 
BiologTM core database which is being developed commercially for the purpose of 
bacterial identification (Bochner 2003). One example where PMs were used to compare 
different strains from the same species was done by Durso et al. (2004), who looked at 
commensal and pathogenic E. coli strains. They found that differences in substrate 
utilization did occur between E. coli K-12 strains and E. coli O157:H7 strains. For 
example the substrates D-saccharic acid and D-serine are used by ~80% of commensal 
strains while only ~15 % of the O157:H7 strains use these two substrates. Their results 
indicate that for these substrates as well as others, there are differences between strains of 
the same species.  
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2.8  Growth Curves 
 
       Growth curves are an important tool to study bacteria and are often used to monitor 
bacterial growth under defined conditions (Fujikawa et al. 2004). Bacterial growth 
curves, including those for E. coli typically are sigmoidal in shape (Coleman et al. 2003). 
They are characterized as having a lag phase, an exponential growth phase, a stationary 
phase and a death phage where the bacteria die. Duplication of identical growth 
conditions is extremely important since different conditions affect growth of bacteria and 
need to be taken into account when using growth curves to study bacteria.  Roszak and 
Colwell (1987) mentioned that the normal state of bacteria is quite different than the 
laboratory state of bacteria and that, laboratory conditions are radically different from the 
natural growth conditions of the natural habitat where the studied bacteria are found; 
these conditions need to be taken into account when comparing bacterial growth to their 
natural habitat because bacteria grow differently under different conditions. 
E. coli O157:H7 growth has been monitored under different conditions, such as 
variation in pH and agitation of the culture (i.e., with agitation and without agitation) and 
with different strains initially isolated under different conditions (Coleman et al. 2003).  
For example at 10 °C, the rate of growth changed depending on whether a low or high 
density of bacteria was used to inoculate the growth medium; differences across 3 
bacterial strains were seen in each case.  Valero et al. (2010) looked at growth of 
different E. coli serotypes under the same conditions; i.e., pH, temperature and inoculum 
levels. It was found that under all conditions, E. coli serotype O158:H23 had a faster 
growth than all the other serotypes tested, including O157:H7. They also found that 
O157:H7 could not grow at a temperature of 8 °C in a pH of 5.5 with a low inoculum 
 
 
20
  
 
level, while serotypes O55:H6 and O158:H23 grew under those same conditions. This 
indicates that growth curves generated under identical growth conditions can be used to 
elucidate differences between species of the same bacteria. 
 
2.9  Survivability Curves 
 
E. coli O157:H7 can survive for long periods of time in water making it an 
important pathogen when involved in waterborne outbreaks (Flint 1987). Studies looking 
at survival of E. coli O157:H7 in different water environments have been undertaken.  
Cook et al. (2007) compared the survival of E. coli O157:H7 and Campylobacter jejuni 
in ground water and found that E. coli O157:H7 could survive just as well in nutrient free 
water as in water containing carbon or nitrogen while C. jejuni died off 2.5 to 13 times 
quicker than E. coli in groundwater.  Smith et al. (1994) conducted experiments with E. 
coli in polar marine environments for 54 days; at the conclusion of the experiment it was 
found that the cells were no longer able to grow on selective medium but direct viable 
counts indicated that cells were still present but in a viable but not culturable (VBNC) 
state.  E. coli can enter a VBNC state when exposed to stresses such as changes in pH, 
available nutrients and/or temperature or in starvation conditions (Liu et al. 2008). 
One method used to study survivability of E. coli in water is the BacLight 
Live/Dead Bacterial Viability kit by Invitrogen.  Liu et al. (2008) used the kit to count the 
number of E. coli O157:H7 cells present in water in a starvation experiment designed to 
force E. coli O157:H7 into a VBNC state for subsequent tests. After 13 weeks, cells were 
no longer culturable but were still viable using the Live/Dead staining; these cells were 
still viable after 16 weeks.  Lisle et al. (1998) used the Live/Dead kit to assess the effect 
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of starvation on E. coli O157:H7 prior to testing resistance to chlorine to examine 
drinking water safety.  They used the Live/Dead kit to assess membrane integrity while 
inducing starvation and found no difference in the BacLight assay in comparison to other 
assays for number of bacteria in the culture during starvation. Petit et al. (2000), used the 
BacLight kit to measure membrane integrity of E. coli cells in 2 different microcosms 
with river water; they found that neither light or starvation affected bacterial counts and 
that the counts remained stable during the course of the experiment. 
The BacLight Live/Dead kit uses a mixture of a SYTO 9 green-fluorescent 
nucleic acid stain and a propidium iodide red-fluorescent nucleic acid stain.  The SYTO-9 
penetrates the membranes of all bacteria, living or dead, intact or damaged and the 
propidium iodide only penetrates damaged or dead cells.  This results in a mixture of 
cells that are either, alive and stained green, or dead and stained red. This allows the 
researcher to perform direct bacterial counts using fluorescence microscopy.  The counts 
can then be used to create survivability curves to compare different strains of bacteria 
such as E. coli to each other. 
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Chapter III 
Effect of Pathogenicity Islands on Substrate Utilization in E. coli O157:H7 
3.1  Introduction  
The E. coli serotype O157:H7 is an unusually virulent bacterial strain that is the 
most frequent EHEC serotype isolated that is known to be involved in HUS and HC 
(Cleary 2004).   E. coli O157:H7 express a variety of factors that can be encoded for on 
pathogenicity islands (PAIs) or on plasmids, such as pO157 (Kaper and Hacker 1999).  
Pathogenicity islands (PAIs) are segments/regions of DNA found within the 
chromosomal DNA, where virulence and fitness genes often are grouped together (Kaper 
and  Hacker 1999). These genomic blocks of DNA differ between pathogenic and non-
pathogenic strains of bacteria from the same or closely-related species (Maurelli et al. 
1998; Gal-Mor and Finlay 2006). They usually span a large continuous genomic region, 
ranging in size from ~10 to 200 kb (Wang et al. 2010).  Generally, genes associated with 
adhesions, invasins, iron uptake systems, toxins and type II, III and IV secretion systems 
are found on PAIs (Kaper and Hacker 1999).   
Characterization of PAIs is important not only to development of an 
understanding of pathogenesis and the development of O157:H7 disease, but also to 
allow for development of vaccines or new methods to identify the bacterium (Wang et al. 
2010).  One method available to characterize these PAIs is through use of gene deletions. 
A gene deletion involves removal of a gene or a group of genes from the organism, 
effectively knocking out gene function (Kabir et al. 2005).  This method has been used in 
our laboratory to create a series of O157:H7 deletion mutants, missing specific PAIs, also 
known as OIs and SLs (Perna et al. 2001; Hayashi et al. 2001). These OIs and SLs are 
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DNA segments unique to the strains they are found in; i.e., OIs (OI) were first identified 
in E. coli O157:H7 EDL933 while, SLs (SL) were first identified in E. coli O157:H7 
Sakai (Perna et al. 2001; Hayashi et al. 2001). The O157:H7 deletion mutants each are 
missing one OI or one SL.  In this study we examine 13 deletion mutants in total, 12 of 
which are O157:H7 EDL933 OI mutants and one of which is a Sakai SL mutant. All 
islands appear to be O157:H7 specific; i.e., they appear to be found only in O157:H7 
bacterial isolates.  
One approach to characterization of bacterial mutants is through use of 
phenotypic microarrays (Bochner 2003). Phenotype microarrays (PMs) can be used to 
find functions for genes (Zhou et al. 2003) and to see how genes network together by 
testing various cellular phenotypes simultaneously (Potera 2006a). Deletion of as yet 
uncharacterized pieces of DNA such as OI’s may lead to a change in function in more 
than one phenotype; this change in function can be assessed using PMs since they test a 
wide variety of phenotypes, and not just one (Bochner 2003; Zhou et al. 2003).   
PMs can also be used in comparative genomics to compare mutant phenotypes to 
that of wild type cells.  They provide a straightforward way to determine the effects of a 
mutation on a genome-wide scale (Zhou et al. 2003).  They can also be used to help 
isolate and characterize mutations that have occurred in a cell by narrowing the 
phenotypic range and in some cases can be used to narrow the domain of the mutation 
(Bochner 2003).  Zhou et al. (2003) created mutations to study E .coli K12’s two-
component regulatory systems by making 37 different two-component mutants and 
studying the effects of the mutations using PM plates. They found that 22 of the two-
component mutants exhibited phenotypic differences while 15 did not.  One example of a 
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two-component system that was studied is the CusS/CusR membrane transport system 
which is thought to play a role in a copper ion efflux from the cell.  The cusRS mutant 
showed hypersensitivity to 1, 10-phenanthroline, which is a chelator with high affinity for 
copper.  These results supported the hypothesis that the CusS/CusR system plays a role in 
a copper efflux cell transport.  
PMs have also been used to compare pathogenic and non-pathogenic E. coli 
(Bochner 2003). Murthy (2006) looked at differences between non-pathogenic E. coli 
K12 and uropathogenic E. coli strain OPE013 using Biolog’s PM plates. They found 37 
differences in substrate utilization between the two, suggesting that the metabolic 
pathways are different for these two strains. Durso et al. (2004) compared E. coli 
O157:H7 strains to commensal E. coli strains and found that there was a difference in 
carbon source utilization pattern between the two groups.  There were 19 carbon sources 
that were used by E. coli O157:H7 in comparison to commensal E. coli strains.  Chouikha 
et al. (2006) used PMs to help elucidate the role of the genomic island, AGI-3 which was 
inserted into the selC locus (a “hot spot” for insertion of PAIs) of an extra-intestinal avian 
pathogenic E. coli strain BEN2908. The role of the AGI-3 genomic island was studied by 
removing parts of the island and by performing various tests to characterize the island, 
including PMs. It was found that parts of this island are also present in other pathogenic 
E. coli, as well as other pathogenic species and that it had a role in carbon assimilation 
and virulence. These differences in carbon source utilization can help clarify the roles of 
pathogenicity islands (PAIs) and identify possible PAIs by identifying differences with 
non-pathogenic strains and/or similarities between pathogenic strains of bacteria.     
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In this study the PM profiles for 13 PAI deletion mutants and three controls 
(O157:H7 strains EDL933 and Sakai plus the E. coli K-12 reference strain DH5α) were 
determined.  The mutants were compared to their respective O157:H7 control as well as 
the E. coli K-12 reference strain DH5α.  Specific objectives of this study were: 
1) To create PM profiles for each of the mutants and the three controls. 
2) To compare O157:H7 strains EDL933 and Sakai to the E. coli K-12 reference 
strain DH5α. 
3) To compare O157:H7 strains EDL933 and Sakai to each other. 
4) To compare the OI deletion mutants and the SL deletion mutant to the E. coli 
K-12 reference strain DH5α and their respective parental strains EDL933 and 
Sakai. 
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3.2  Materials and Methods 
3.2.1  Bacteria and Cultures 
 Bacteria used in this study included the E. coli K-12 reference strain DH5α, and 
the pathogenic E. coli O157:H7 strains EDL933 and Sakai (both isolated from humans), 
as well as 13 OI and one SL deletion mutant; i.e., OI-39, OI-51, OI-55, OI-59, OI-87, OI-
89, OI-98, OI-102, OI-108, OI-135, OI-172, OI-176 and SL 72 (OI deletion mutants were 
created by removing an OI from E. coli O157:H7 strain EDL933 and the SL deletion 
mutant was created by removing an SL from E. coli O157:H7 strain Sakai). Single 
colonies of bacteria were streaked on to Tryptic Soy Agar (TSA) and grown overnight for 
12-16 h at 37 °C; this was repeated twice in order to ensure purity of the cultures and to 
ensure the bacteria are in the same physiological state.  After the final overnight 
incubation, 2 colonies from each TSA plate containing pure cultures was streaked on to 
Biolog Universal Growth MediumTM (BUG) plus 5 % sheep blood (BUG+B).  The 
BUG+B plates were incubated overnight for 16-18 h at 37 °C. 
 
3.2.2  The BiologTM System 
 The following protocols for the BiologTM system were adapted from an M. Sc.  
thesis study, “Enterococci as Source-Tracking Agents” by Lang (2005), and from “PM 
Procedures for E. coli and other GN Bacteria” (Biolog Inc. 2005). 
 
3.2.3 Preparation of PM inoculating fluids. 
 The inoculating fluid (IF-0) was prepared by adding 25 ml of sterile water into the 
bottle containing 125 ml of 1.2 x IF-0.  From this bottle 16 ml of 1x IF-0 was removed 
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and stored into a sterile tube, this tube was then put aside for future use.  To the bottle 
containing the IF-0 solution, 1.8 ml of dye mix (dye mix A) and 23.2 ml of water were 
added to make an IF-0 + dye mixture.   Then 25 ml of this IF-0 + dye mixture was 
dispensed into a sterile reservoir and stored until future use. 
 
3.2.4 Preparation of cell suspension cultures for inoculation of BiologTM plates 
 PM1 plates (BiologTM, Catalogue # 12111) were removed from refrigeration and 
stored at room temperature until needed. A turbidity meter (BiologTM) was calibrated 
prior to making the cultures for inoculation of the phenotypic plates (BiologTM).  An 
uninoculated tube containing 16 ml of IF-0 was prepared while making the inoculating 
fluid, cleaned with a paper tissue (KimwipeTM), inserted into the turbidity meter and the 
instrument set to 100 % transmittance (%T).  A bacterial turbidity standard (BiologTM) 
pre-calibrated for 85 % ± 3 % transmittance was mixed and then used to calibrate the 
turbidity meter. After calibration a clean IF-0 tube was inserted into the turbidity meter 
and the machine set to 100 % T.  This was done for each new tube of IF-0 used to dilute a 
bacterial culture in to as the tubes were not optically uniform. Then a long sterile swab 
(~30 mm in length) was moistened with IF-0 medium and then gently scraped over the 
BUG+B agar with an overnight culture so as to pick up some bacterial cells but, not any 
nutrients from the agar.  The swab was then twirled inside the IF-0 tube just below the 
fluid level to mix in the bacteria.  After depositing the cells, the tube was mixed with the 
swab in an up and down motion so as to not introduce any bubbles in the tube.  The 
above was continued until the IF-0 tube had a %T of 42 % ± 3 %.  This mixture was used 
to create the final inoculum for the plates.  In the reservoir containing 25 ml of IF-0 + dye 
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mixture, 5 ml of the IF-0 with bacteria with a %T of 42 % ± 3 % was added and mixed 
gently so as to not introduce any bubbles in the reservoir, creating a uniform solution.  
The final cell density of this mixture was 85 % T ± 3 %. 
 
3.2.5  Inoculation of the PM plates (PM1) 
  The prepared culture with a %T between 82 – 88 % was used to inoculate the 
PM1 plates.  A multichannel repeating pipettor (8 channels) was set to dispense 100 µl of 
culture.  The pipettor was primed by taking up the cell suspension and dispensing 100 µl 
of culture back into the reservoir.  After priming the 8-channel pipettor 100 µl of cell 
suspension was dispensed into the wells of the PM plate until all 96 wells were filled.  
The PM1 wells all contained carbon sources except for well A1 which was a blank / 
control which contained distilled water.  The tetrazolium in the inoculum was used to 
measure substrate utilization and turned from clear to purple when the substrate was 
utilized.  Inoculated plates were incubated overnight for 72 h at 37 ºC with readings taken 
every 24 h. 
 
3.2.6   Reading the PM plates (PM1) 
 Following overnight incubation, the PM plates were read using a Biolog 
MicroStationTM.  The MicroStation read each well of the plate at 590 nm and then again 
at 750 nm to measure the color change.  The value from the A1 well (blank) was 
subtracted from the reading obtained from the substrate-containing wells in order to 
account for any carry over from the BUG+B agar that might have contaminated over the 
wells. The final output values were calculated by subtracting the value at 750 nm from 
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the value at 590 nm.  Results were then entered into an Excel spreadsheet for analysis. 
This protocol was followed for each strain and was repeated 2 times for a total of 3 
measurements for each E. coli strain tested. 
 
3.2.7  Analysis of PM data 
 All data was analyzed using Excel and statistical functions from this program.   
This allowed the data from each of the strains to be compared for similarities and 
differences.  A positive result was considered one that had an absorbance value of 0.100 
or higher; a negative result was considered one that had an absorbance value lower than 
0.100. The data was also analyzed for significant differences in levels of substrate 
utilization, when comparing the mutants and the O157:H7 parental controls EDL933 and 
Sakai. A significant difference in either substrate utilization or in level of substrate 
utilization was determined by a two-tailed T-test assuming equal variance with a P value 
of 0.05. 
 After evaluation of collected data only data collected after 48 h of incubation was 
used because some of the substrates required 48 h for full color development and by 72 h, 
background color had developed which interfered with the plate readings. The O157:H7 
control EDL933 was used to assess the OI-mutants, while the O157:H7 control Sakai was 
used to assess the SL mutant.  The reference K-12 strain DH5α was used to assess 
differences with both the O157:H7 parental strains and their deletion mutants. 
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3.3  Results 
3.3.1 Phenotypic profiling 
  In order to characterize the metabolic capabilities of different strains of E. coli 
O157:H7, cells were grown on phenotypic microarray (PM1) plates (BiologTM) for 48 h 
and the results assessed to identify similarities and differences among the bacterial 
isolates examined.  
 
3.3.2  Confirmation of known properties of E. coli O157:H7  
 E. coli O157:H7 is known to have specific biochemical properties (Figure. 3.1) 
that can be used for identification and isolation of the bacteria; e.g., most E. coli 
O157:H7 are able to ferment the sugar, dulcitol, but cannot ferment the sugar sorbitol 
(Ratnam et al. 1988).  PM1 plates (BiologTM) contain the substrates, dulcitol and sorbitol.  
When E. coli O157:H7 control strains EDL933 and Sakai, as well as the thirteen OI and 
SL deletion mutants used in this study were grown on PM1 plates, all cells were positive 
for dulcitol utilization (Figure. 3.2), but negative for sorbitol utilization (Figure. 3.3).  
 Absorbance values for dulcitol utilization were not the same in the control strains. 
On average values varied from 0.3 in Sakai to 0.5 in EDL933 (Figure. 3.2) while values 
in the OI deletion mutants of EDL933 ranged from 0.1 to 0.6, a six fold range in activity 
and, averaged 0.1 in the SL 72 deletion mutant produced from the Sakai strain. These 
results suggest that dulcitol utilization in E. coli O157:H7 can be influenced by the 
presence and/or absence of O islands and SLs in the bacteria.  
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Figure. 3.1:  Biochemical properties associated with most E. coli O157:H7. 
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Figure. 3.2: Dulcitol utilization in E. coli O157:H7 strains EDL933 and Sakai plus thirteen OI and SL deletion mutants.  All strains 
were tested 3 times using BiologTM PM1 plates and the average absorbance at 48 h plotted. Values > 0.1 were considered positive.
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Figure. 3.3:  Sorbitol utilization in E. coli O157:H7 strains EDL933 and Sakai plus thirteen OI and SL deletion mutants.  All strains 
were tested 3 times using PM1 plates (BiologTM) and the average absorbance at 48 h plotted. Values > 0.1 were considered positive.
 
 
34
  
 
3.3.3 Confirmation of known properties of E. coli strains using the metabolic 
pathway for glycolysis. 
 
 Glycolysis involves conversion of glucose to pyruvate to produce ATP in the 
absence of oxygen (Figure. 3.4).  Bacteria, including E. coli which undergo these 
processes should be positive for substrate intermediates associated with this process.  
PM1 plates contain three of the substrates found in the glycolytic pathway; i.e., glucose, 
glucose-6-phosphate, fructose-6-phosphate and the product of glycolysis pyruvic acid.  
All of the E. coli strains tested were positive for utilization of these substrates (Figure. 
3.5).  
 
3.3.4  Comparison of substrate utilization patterns in E. coli DH5α and E. coli 
O157:H7 strain EDL933  
 
 Substrates used by both E. coli DH5α and E. coli O157:H7 strain EDL933 were 
similar.. However, significant differences in substrate utilization were observed for 15 
substrates (P < 0.05). E. coli O157:H7 strain EDL933 was positive for use of the 
substrates (above threshold value of > 0.100) dulcitol, α-keto-butyric acid, α-D-lactose, 
lactulose, sucrose, α-hydroxy butyric acid and propionic acid (Figure.3.6), while E. coli 
DH5α was negative for these substrates (below threshold value of < 0.100). The opposite 
was seen for the substrates D-saccharic acid, D-serine, D-sorbitol, L-glutamic acid, D-
galactonic acid-γ-lactone, M-tartaric acid, glycolic acid and L-lyxose (Figure.3.7); i.e., E. 
coli DH5α was positive for these substrates while E. coli O157:H7 strain EDL933 was 
negative (P < 0.05).   
Significant differences (P < 0.05) in levels of substrate utilization where both 
strains were positive for a substrate also were seen (Table 3.1). E. coli O157:H7 strain  
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Figure. 3.4. The glycolysis pathway.
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Figure. 3.5. PM results for E. coli O157:H7 strains and E. coli DH5α for substrates involved in glycolysis. 
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Figure.3.6 Comparison of E. coli O157:H7 strain EDL933 and the E. coli K-12 reference strain DH5α for the substrates dulcitol, α-
keto-butyric acid, α-D-lactose, lactulose, sucrose, α-hydroxy butyric acid and propionic acid. The threshold value for substrate 
utilization was <0.100. The EDL933 strain is above the threshold value in each case and the DH5α strain is below the threshold value.   
 
 
38
  
 
-0.100
0.000
0.100
0.200
0.300
0.400
0.500
0.600
Substrates
P
M
 
P
l
a
t
e
 
A
b
s
o
r
b
a
n
c
e
 
V
a
l
u
e
EDL933 CONTROL
DH5α CONTROL
EDL933 CONTROL 0.000 0.055 0.032 0.059 -0.009 0.044 -0.004 -0.041
DH5α CONTROL 0.523 0.448 0.349 0.169 0.370 0.313 0.188 0.252
D-
sacchari
c acid
D-serine D-sorbitol
L-
glutamic 
acid
D-
galactoni
c acid -γ-
M-tartaric 
acid
glycolic 
acid L-lyxose
 
Figure. 3.7 Comparison of E. coli O157:H7 strain EDL933 and the E. coli K-12 reference strain DH5α for the substrates D-saccharic 
acid, D-serine, D-sorbitol, L-glutamic acid, D-galactonic acid-γ-lactone, M-tartaric acid, glycolic acid and L-lyxose. The threshold 
value for substrate utilization was <0.100. The DH5α strain is above the threshold value in each case and the EDL933 strain is below 
the threshold value.
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Table 3.1.  Percentage difference* in levels of substrate utilization for the pathogenic E. 
coli O157:H7 EDL933 strain and the reference E. coli K-12 strain DH5α where all 
substrates were used by both bacteria.   
 
PM # of 
Substrate SOURCE 
EDL933 
Control  
DH5α 
Control 
Percentage 
Difference (%) 
2 L-arabinose 0.461 0.289 37.4 
3 N-acetyl-D-glucosamine 0.529 0.272 48.5 
5 succinic acid 0.614 0.422 31.2 
6 D-galactose 0.517 0.297 42.6 
7 L-aspartic acid 0.655 0.412 37.2 
8 L-proline 0.629 0.265 57.9 
9 D-alanine 0.597 0.386 35.3 
10 D-trehalose 0.721 0.302 58.1 
11 D-mannose 0.528 0.350 33.7 
15 glycerol 0.564 0.351 37.8 
16 L-fucose 0.615 0.325 47.1 
19 D,L-α-glycerol-phosphate 0.436 0.261 40.1 
20 D-xylose 0.660 0.303 54.1 
21 L-lactic acid 0.495 0.318 35.8 
25 glucose-6-phosphate 0.826 0.607 26.5 
27 D,L-malic acid 0.714 0.382 46.4 
28 D-ribose 0.566 0.290 48.8 
33 α-D-glucose 0.436 0.290 33.4 
34 maltose 0.540 0.377 30.3 
35 D-melibiose 0.678 0.405 40.3 
36 thymidine 0.722 0.464 35.8 
37 L-asparagine 0.647 0.400 38.2 
44 α-methyl-D-galactoside 0.534 0.348 34.8 
48 uridine 0.698 0.527 24.5 
49** L-glutamine 0.234 0.388 39.6 
51 glucose-1-phosphate 0.805 0.545 32.3 
52 Fructose-6-phosphate 0.781 0.615 21.2 
56 β-methyl-D-glucoside 0.433 0.300 30.7 
58 maltotriose 0.610 0.414 32.1 
59 2-deoxy adenosine 0.904 0.560 38.0 
60 adenosine 0.755 0.456 39.5 
61 glycyl-L-aspartic acid 0.607 0.415 31.6 
65 fumaric acid 0.574 0.280 51.2 
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66 bromo succinic acid 0.636 0.228 64.2 
72 inosine 0.766 0.426 44.3 
75 L-serine 0.532 0.373 29.9 
77 L-alanine 0.501 0.304 39.4 
80 
N-acetyl-β-D-
mannosamine 0.354 0.242 31.6 
82 methyl pyruvate 0.588 0.326 44.6 
84 L-malic acid 0.641 0.329 48.6 
92 pyruvic acid 0.642 0.236 63.3 
93 L-galactonic acid-γ-lactone 0.607 0.221 63.6 
94 D-galacturonic acid 0.793 0.582 26.6 
*All values were significantly different (P < 0.05). 
** Bolded value is the case where DH5α has a higher level of substrate utilization. 
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EDL933 utilized significantly higher levels of 42 of the 43 positive-testing substrates.  
These substrates were L-arabinose, N-acetyl-D-glucosamine, succinic acid, D-galactose, 
L-aspartic acid, L-proline, D-alanine, D-trehalose, D-mannose,  glycerol, L-fucose, D,L-
α-glycerol phosphate, D-xylose, L-lactic acid, glucose-6-phosphate, D,L,-malic acid, D-
ribose, α-D-glucose, maltose, D-melibiose, thymidine, L-asparagine, α-methyl-D-
galactoside, uridine, glucose-1-phosphate, fructose-6-phosphate, β-methyl-D-glucoside, 
maltotriose, 2-deoxy adenosine, adenosine, glycyl-L-aspartic acid, fumaric acid, bromo 
succinic acid, inosine, L-serine, L-alanine, N-acetyl-β-D-mannosamine, methyl pyruvate, 
L-malic acid, pyruvic acid, L-galactonic acid-γ-lactone and D-galacturonic acid.  In 
contrast, strain DH5α used significantly more L-glutamine than E. coli EDL933. 
Percentage differences in utilization for each of these substrates were 37.4%, 48.5%, 
31.2%, 42.6%, 37.2%, 57.9%, 35.3%, 58.1%, 33.7%, 37.8%, 47.1%, 40.1%, 54.1%, 
35.8%, 26.5%, 46.4%, 48.8%, 33.4%, 30.3%, 40.3%, 35.8%, 38.2%, 34.8%, 24.5%, 
32.3%, 21.2%, 30.7%, 32.1%, 38.0%, 39.5%, 31.6%, 51.2%, 64.2%, 44.3%, 29.9%, 
39.4%, 31.6%, 44.6%, 48.6%, 63.3%, 63.6%, 26.6% and 39.6% respectively (Table. 3.1). 
 
3.3.5 Comparison of substrate utilization patterns in E. coli DH5α and E. coli 
O157:H7 strain Sakai  
 
 Substrate utilization for the E. coli DH5α and E. coli O157:H7 strain Sakai also 
was similar.  However, significant differences in substrate utilization (P < 0.05) were 
seen for 18 substrates. E. coli O157:H7 strain Sakai was positive (above threshold value 
of 0.100) for α-keto-butyric acid, α-D-lactose, lactulose, sucrose, α-hydroxy butyric acid 
and propionic acid (Figure. 3.8). By contrast, E. coli DH5α was negative (below the 
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Figure.3.8 Comparison of E. coli O157:H7 strain Sakai and the reference E. coli K-12 strain DH5α for the substrates, α-keto-butyric 
acid, α-D-lactose, lactulose, sucrose, α-hydroxy butyric acid and propionic acid. The threshold value for substrate utilization was 
0.100. The Sakai strain is above the threshold value and the DH5α strain is below in each case.   
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threshold value of 0.100) for these substrates but, positive for D-saccharic acid, D-serine, 
D-sorbitol, L-glutamic acid, D- galactonic-acid-γ-lactone, tween 20, tween 40, α-keto-
glutaric acid, L-glutamine, M-tartaric acid, glycolic acid and L-lyxose (Figure.3.9) while 
Sakai was negative.  
Significant differences (P < 0.05) in levels of substrate utilization also were seen 
for 25 other substrates (Table 3.2). E. coli O157:H7 strain Sakai utilized significantly 
higher levels of N-acetyl-D-glucosamine, succinic acid, D-alanine, D-trehalose, glycerol, 
L-fucose, D,L-α-glycerol phosphate, L-lactic acid, D-ribose, acetic acid, maltose, 
thymidine, L-asparagine, α-methyl-D-galactoside, β-methyl-D-glucoside, maltotriose, 2-
deoxy adenosine, adenosine, fumaric acid, bromo succinic acid, inosine, L-alanine, L-
alanyl-glycine, methyl pyruvate and pyruvic acid than E. coli DH5α. Percentage 
differences in utilization for each of these substrates were 30.9%, 26.3%, 38.2%, 48.4%, 
40.8%, 37.2%, 42.3%, 42.9%, 44.3%, 20.3%, 20.5%, 40.7%, 26.0%, 29.0%, 22.7%, 
28.1%, 21.0%, 38.3%, 26.8%, 56.7%, 35.8%, 46.0%, 42.8%, 33.7% and 60.5% 
respectively (Table. 3.2). 
 
 
3.3.6 Comparison of substrate utilization patterns in E. coli O157:H7 strains 
EDL933 and Sakai 
 
 Substrate utilization profiles for the two O157:H7 strains EDL933 and Sakai were 
similar.  Only one difference in substrate utilization (P < 0.05) was noted. The EDL933 
strain was positive for L-glutamine (above the threshold of 0.100) while Sakai was 
negative for this substrate (below the threshold value) (Figure 3.10).  Both EDL933 and 
Sakai had nearly identical substrate utilization profiles. The main difference between the 
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Figure. 3.9 Comparison of E. coli O157:H7 strain Sakai and the E. coli K-12 reference strain DH5α for the substrates, D-saccharic 
acid, D-serine, D-sorbitol, L-glutamic acid, D-galactonic-acid-γ-lactone, tween 20, tween 40, α-keto-glutaric acid, L-glutamine, M-
tartaric acid, glycolic acid and L-lyxose. The threshold value for substrate utilization was 0.100. The DH5α strain is above the 
threshold value in each case and the Sakai strain is below the threshold value.
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Table 3.2.  Percentage difference* in levels of substrate utilization for the pathogenic E. 
coli O157:H7 Sakai strain and the reference E. coli K-12 strain DH5α where all 
substrates were used by both bacteria.   
 
# of 
Substrate SOURCE 
Sakai 
Control 
DH5α 
Control Percentage difference (%) 
3 N-acetyl-D-glucosamine 0.394 0.272 30.9 
5 Succinic acid 0.573 0.422 26.3 
9 D-alanine 0.625 0.386 38.2 
10 D-Trehalose 0.585 0.302 48.4 
15 glycerol 0.593 0.351 40.8 
16 L-fucose 0.518 0.325 37.2 
19 
D,L-α-glycerol-
phosphate 0.453 0.261 42.3 
21 L-lactic acid 0.556 0.318 42.9 
28 D-ribose 0.520 0.290 44.3 
32 acetic acid 0.347 0.276 20.3 
34 maltose 0.474 0.377 20.5 
36 thymidine 0.781 0.464 40.7 
37 L-asparagine 0.541 0.400 26.0 
44 α-methyl-D-galactoside 0.491 0.348 29.0 
56 β-methyl-D-glucoside 0.389 0.300 22.7 
58 maltotriose 0.576 0.414 28.1 
59 2-deoxy adenosine 0.709 0.560 21.0 
60 adenosine 0.740 0.456 38.3 
65 fumaric acid 0.383 0.280 26.8 
66 bromo succinic acid 0.527 0.228 56.7 
72 inosine 0.664 0.426 35.8 
77 L-alanine 0.563 0.304 46.0 
78 L-alanyl-glycine 0.592 0.339 42.8 
82 methyl pyruvate 0.491 0.326 33.7 
92 pyruvic acid 0.597 0.236 60.5 
*All values were significantly different (P < 0.05). 
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Figure. 3.10 Comparison of E. coli O157:H7 strains EDL933 and Sakai for the substrate L-glutamine. The threshold value for 
substrate utilization was 0.100. EDL933 is above the threshold value in each case and Sakai is below the threshold value
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two was in levels of utilization where both strains were positive for a substrate (Table 
3.3). Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were seen where EDL933 utilized significantly higher levels 
(P < 0.05) of 12 substrates than Sakai; i.e., EDL933 utilized significantly more L-
arabinose, N-acetyl-D-glucosamine, L- aspartic acid, L-proline, α-D-glucose, maltose, 
sucrose, 2-deoxy adenosine, glycyl-L-aspartic acid, fumaric acid, glycyl-L-proline and D-
galacturonic acid than Sakai.  Percentage differences in utilization for each of these 
substrates were 26.0%, 25.5%, 29.3%, 31.6%, 19.7%, 12.3%, 40.4%, 21.6%, 24.1%, 
33.3%, 49.6% and 17.7% respectively. 
 
3.3.7  Metabolism in O157:H7 strain EDL933 and its OI deletion mutants 
3.3.7.1 Comparison of O157:H7 strain EDL933 with the deletion mutant OI-135  
 The OI-135 island contains two open reading frames (ORFs) of unknown 
function. The OI-135 deletion mutant was the only mutant that did not show either a loss 
or gain in substrate utilization when compared to the parental strain, O157:H7 strain 
EDL933; i.e., no significant differences in levels of substrate utilization were observed 
between the OI-135 mutant and the EDL933 parental strain.  Consequently, under the 
growth conditions used in these experiments, no role for the OI-135 island was identified. 
 
3.3.7.2 Comparison of deletion mutants OI-55, OI-59, OI-87 and OI-108 with EDL933. 
 
The OI 55, 59, 87 and 108 contain ORFs for various functions (Perna et al, 2001).  
The OI 55 contains ORFs of unknown function and ORFs that have a transport role.  The  
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Table 3.3.  Percentage difference* in levels of substrate utilization for the pathogenic E. 
coli O157:H7 strains EDL933 and Sakai.   
 
# of 
Substrate SOURCE 
EDL933 
Control 
Sakai 
Control 
Percentage Difference 
(%) 
2 L-arabinose 0.461 0.341 26.0 
3 
N-acetyl-D-
glucosamine 0.529 0.394 25.5 
7 L-aspartic acid 0.655 0.463 29.3 
8 L-proline 0.629 0.430 31.6 
33 α-D-glucose 0.436 0.350 19.7 
34 maltose 0.540 0.474 12.3 
47 sucrose 0.617 0.367 40.4 
59 2-deoxy adenosine 0.904 0.709 21.6 
61 glycyl-L-aspartic acid 0.607 0.461 24.1 
65 fumaric acid 0.574 0.383 33.3 
85 glycyl-L-proline 0.347 0.175 49.6 
94 D-galacturonic acid 0.793 0.652 17.7 
*All values were significantly different (P < 0.05). 
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OI-59 has an ORF of unknown function and an ORF thought to code for a regulator.  The 
OI 87 has an unclassified ORF and an ORF of unknown function.  The OI-108 has 
unknown ORFs that are phage or prophage related; i.e., ORFs  that code for proteins that 
are phage or prophage related and ORFs similar to transposases.  The deletion mutants 
corresponding to each of these OI (55, 59, 87 and 108) were compared to the parental 
strain EDL933.  The patterns of substrate utilization (+ or -) for OI-55, 59, 87 and 108 
deletion mutants and the O157:H7 parental strain were similar in most cases; i.e., the 
same substrates were either used or not used in each of these mutant strains as well as in 
the parental strain EDL933.  However, differences were observed in levels of substrate 
utilization. Two substrates that appeared to show differences in substrate utilization were 
tween 20 and tween 40 (Figure. 3.11). Levels of substrate utilization for tween 20 and 
tween 40 fell below the threshold value of 0.100 in EDL933 while mutant levels of 
substrate utilization were above the threshold value; this suggests that the four mutants 
(OI-55, 59, 87 and 108) had gained the ability to use tween 20 and tween 40 when 
compared to the parental strain. However comparison of numerical values for these levels 
using a T-test showed that the differences in substrate utilization for tween 20 and tween 
40 between most of the mutants and the EDL933 control were not different (P > 0.05). 
Only the OI-87 mutant used significantly higher (P < 0.05) levels of tween 40 than 
EDL933 suggesting that the OI-87 mutant did gain the ability to use tween 40 as a carbon 
source. 
Significant differences (P < 0.05) in levels of substrate utilization also were seen 
in the OI-55 deletion mutant and the parental strain (Figure. 3.12). The OI-55 mutant 
utilized significantly higher levels of the three substrates D,L-α-glycerol-phosphate, 
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Figure. 3.11. Comparison of E. coli O157:H7 parental strain EDL933, the OI-55, 59, 87 and 108 deletion mutants and the E. coli K-12 
reference strain DH5α for the Substrates tween 20 and tween 40. The threshold value for substrate utilization was < 0.100. The 
absorbance mean + S.E. for each substrate is shown. Mean values for substrate utilization also are identified at the bottom of the 
figure. The only significant difference was seen for the OI-87 mutant and the EDL933 parental for tween 40.
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Figure. 3.12. Differences in substrate utilization in the E. coli O157:H7 parental strain EDL933 and the OI-55 deletion mutant.  All 
values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for substrate 
utilization are identified at the bottom of the figure. 
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thymidine and glycyl-L-glutamic acid and decreased levels of fructose-6-phosphate 
compared to the EDL933 parental control (P < 0.05). Percentage differences in utilization 
for each of these substrates were 32.5%, 22.0%, 39.5% and 10.5% respectively. 
By comparison the OI-59 mutant (Figure 3.13) used increased levels of five 
substrates, D,L-α-glycerol-phosphate, thymidine, α-keto-butyric acid, α-hydroxy butyric 
acid and glycyl-L-glutamic acid and decreased levels of glycerol as carbon sources in 
comparison to the EDL933 control (P < 0.05). The percentage difference in utilization for 
each of these substrates was 34.1%, 18.8%, 35.8%, 30.4%, 40.9% and 17.6%, 
respectively.  
The OI-87 deletion mutant differed in use of five substrates (Figure. 3.14). In all 
cases, this mutant used significantly more D,L-α-glycerol-phosphate, D-ribose, 
thymidine, α-hydroxy butyric acid and glycyl-L-glutamic acid as carbon sources in 
comparison to the EDL933 control (P < 0.05).  Percentage differences in utilization for 
each of these substrates were 29.9%, 7.9%, 21.6%, 31.7% and 41.4% respectively.  
The OI-108 deletion mutant and the EDL933 control differed in use of two 
different substrates (Figure 3.15). In both cases, the OI-108 mutant used significantly 
more succinic acid and D-xylose as carbon sources in comparison to the EDL933 control 
(P < 0.05).  Percentage differences in utilization for each of these substrates were 24.5% 
and 15.7% respectively. 
 In summary, each of the OI-55, OI-59 and OI-87 deletion mutants used 
significantly higher levels of D, L-α-glycerol-phosphate, thymidine and glycyl-L-
glutamic acid control (P < 0.05) than EDL933, while the OI-108 deletion mutant did not. 
Only the OI-87 mutant appeared to gain the ability to use the substrate tween 40, in 
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Figure.3.13. Differences in levels of substrate utilization for the E. coli O157:H7 parental control EDL933 and the OI-59 deletion 
mutant. All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization are identified at the bottom of the figure.  
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Figure.3.14. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-87 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization are identified at the bottom of the figure. 
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Figure.3.15. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-108 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization are identified at the bottom of the figure.  
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comparison to the EDL933 parental strain. Based on the ORFs found on these OIs use of 
these substrates may be related to regulation of phage / prophage mobilization which 
could influence nucleic acid (thymidine), energy (D, L-α-glycerol-phosphate) and protein 
synthesis precursor (and glycyl-L-glutamic acid) demand and/or utilization within the 
cells; i.e., regulation of known genes coded for on these OI.  Presence of tween 20 or 
tween 40 in the medium can affect membrane permeability which also might influence 
phage / prophage mobilization and growth of these mutants.  
 
3.3.7.3 Comparison of the deletion mutant OI-51 with EDL933. 
The OI 51 contains ORFs from the prophage CP-933C; most of these ORFs code 
for unknown proteins.  The OI 51 deletion mutant was compared to the parental strain 
EDL933.  The pattern of substrate utilization for the OI-51 deletion mutant and the 
O157:H7 parental strain was similar.  The main differences observed were in levels of 
substrate utilization. However, two exceptions appeared to occur for utilization of L-
glutamic acid and tween 20 (Figure. 3.16); i.e., levels of L-glutamic acid and tween 20 
substrate utilization in EDL933 fell below the threshold value of <0.100 used in this 
study while OI-51 deletion mutant levels of substrate utilization were above the threshold 
value, suggesting that the mutant gained the ability to use L-glutamic acid and tween 20.  
Further comparison of these utilization levels using a T-test showed that the differences 
in substrate utilization for L-glutamic acid and tween 20 between the OI-51 deletion 
mutant and the EDL933 control were not significantly different (P > 0.05). This suggests 
that the mutant did not gain the ability to use L-glutamic acid and tween 20 as carbon 
sources. 
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Figure.3.16. Comparison of E. coli O157:H7 parental strain EDL933, the OI-51 deletion mutants and the E. coli K-12 reference strain 
DH5α for the substrates L-glutamic acid and tween 20. The threshold value for substrate utilization was <0.100. The absorbance mean 
+ S.E. for each substrate is shown. Mean values for substrate utilization also are identified at the bottom of the figure. There was no 
significant difference in ability to use this substrate. 
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Significant differences (P < 0.05) in levels of substrate utilization were seen for 
other substrates where both the mutant and the parental strain were positive (above the 
threshold) for a given substrate (Figure 3.17).  The OI-51 mutant utilized significantly 
higher levels of the three substrates D-ribose, thymidine and glycyl-L-glutamic acid and 
decreased levels of L-arabinose compared to the EDL933 parental control.  Percentage 
differences in utilization for each of these substrates were 11.6%, 19.2%, 42.2% and 
19.4% respectively. 
In summary, despite the OI-51 mutant substrate levels for L-glutamic acid and 
tween 20 being above the threshold value in each case and the EDL933 parental strain 
levels being below the threshold value, there was not a significant difference in ability to 
use these substrates and therefore no gain in function.  However, changes in utilization of 
the substrates D-ribose, thymidine and glycyl-L-glutamic acid may be related to changes 
in regulation of phage / prophage mobilization in the OI-51 mutant which could result in 
differences in growth of the mutant relative to the EDL933 parental strain.   
 
3.3.7.4 Comparison of the deletion mutant OI-89 with EDL933. 
 
The OI 89 contains ORFs of unknown function.  The OI-89 deletion mutant was 
compared to the parental strain EDL933 and the pattern of substrate utilization for the OI-
89 deletion mutant and the O157:H7 parental strain was similar. The main differences 
observed were in levels of substrate utilization with one exception (Figure. 3.18); i.e., 
utilization levels of tween 40 in EDL933 fell below the threshold value of <0.100 while 
OI-89 deletion mutant levels of substrate utilization were above the threshold value. This 
suggests that the mutant gained the ability to use tween 40 as a carbon source.  However, 
comparison of these utilization levels using a T-test showed that the difference in
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Figure.3.17. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-51 deletion mutant.  
All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for substrate 
utilization also are identified at the bottom of the figure. 
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Figure.3.18. Comparison of E. coli O157:H7 parental strain EDL933, the OI-89 deletion mutants and the E. coli K-12 reference strain 
DH5α for the substrate tween 40. The threshold value for substrate utilization was 0.100. The absorbance mean + S.E. for each 
substrate is shown. Mean values for substrate utilization also are identified at the bottom of the figure. There was no significant 
difference in ability to use this substrate between the OI-89 deletion mutant and the EDL933 parental.  
 
 
  
 
substrate utilization for tween 40 between the OI-89 deletion mutant and the EDL933 
control was not different (P > 0.05) suggesting that this mutant did not gain the ability to 
use tween 40 as a carbon source. 
In contrast, significant differences (P < 0.05) in levels of substrate utilization were 
seen for other substrates where both the mutant and the parental strain were positive 
(above the threshold) for a given substrate (Figure 3.19).  The OI-89 mutant utilized 
significantly higher levels of D-ribose and decreased levels of L-arabinose compared to 
the EDL933 parental control.  Percentage differences in utilization for each of these 
substrates were: 14.6% and 7.6% respectively. 
In summary, despite the OI-89 mutant substrate levels being above the threshold 
value for tween 40 and the EDL933 parental strain levels being below the threshold 
value, there was not a significant difference in ability to use this substrate; therefore no 
gain in ability to use tween 40 as a carbon source was observed.  However, changes in 
levels of substrate utilization for D-ribose and L-arabinose may be due to changes in 
regulation of sugar degradation due to the removal of the island which could result in 
changes in levels of substrate utilization compared to the parental strain EDL933.  Also, 
D-ribose is a precursor in RNA synthesis; this suggests that synthetic activity of the OI-
89 deletion mutant may be higher than that of EDL933. This may be related to growth 
potential of these bacteria. 
 
3.3.7.5 Comparison of the deletion mutant OI-176 with EDL933. 
 
The OI 176 contains an ORF of unknown function. Comparison of the OI-176 
deletion mutant and the parental strain EDL933 showed that the pattern of substrate  
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Figure.3.19. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-89 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization also are identified at the bottom of the figure. 
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utilization for the OI-176 deletion mutant and the O157:H7 parental strain was similar. 
The main differences observed were in levels of substrate utilization; two exceptions 
appeared to occur for utilization of D-serine and tween 20 (Figure. 3.20). Levels of D-
serine and tween 20 substrate utilization in EDL933 fell below the threshold value of 
0.100 used in this study while OI-176 deletion mutant levels of substrate utilization were 
above the threshold value, suggesting that the mutant gained the ability to use D-serine 
and tween 20 as carbon sources. However, comparison of these utilization levels using a 
T-test showed that the difference in substrate utilization for D-serine and tween 20 
between the OI-176 deletion mutant and the EDL933 control were not different (P > 
0.05); this suggests that this mutant did not gain the ability to use D-serine and tween 20 
as carbon sources. However, significant differences (P < 0.05) in levels of substrate 
utilization were seen for other substrates where both the mutant and the parental strain 
were positive (above the threshold) for a given substrate (Figure 3.21). In all cases the 
OI-176 mutant utilized significantly less D-xylose, maltotriose, adenosine, N-acetyl-β-D-
mannosamine, pyruvic acid and L-galactonic acid-γ-lactone compared to the EDL933 
parental control.  Percentage differences in utilization for each of these substrates were 
16.3%, 26.4%, 9.8%, 20.6%, 16.8% and 14.1% respectively. 
In summary, the OI-176 mutant levels of substrate utilization were above the 
threshold value for D-serine and tween 20, and EDL933 parental strain levels were below 
the threshold value but there was not a significant difference in substrate utilization for 
these two substrates. However, changes in levels of substrate utilization for D-xylose, 
maltotriose, adenosine, N-acetyl-β-D-mannosamine, pyruvic acid and L-galactonic acid-
γ-lactone may be due to changes in regulation of sugar degradation or 
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Figure.3.20. Comparison of E. coli O157:H7 parental strain EDL933, the OI-176 deletion mutants and the E. coli K-12 reference 
strain DH5α for the Substrates D-serine and tween 20. The threshold value for substrate utilization was 0.100. The absorbance mean + 
S.E. for each substrate is shown. Mean values for substrate utilization also are identified at the bottom of the figure. There is no 
significant difference in substrate utilization for D-serine or tween 20 between the OI-176 mutant and the EDL933 parental.
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Figure.3.21. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-176 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization also are identified at the bottom of the figure. 
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nitrogen degradation due to the removal of the genes which are found on this island 
which could result in changes in levels of substrate utilization compared to the parental 
strain EDL933. Genes on OI-176 appear to up-regulate utilization of a broad range of 
sugars. This up-regulation may be a specific adaptation to the human host for EDL933 
which is known to often have high levels of sugar in its diet. 
 
3.3.7.6 Comparison of the deletion mutant OI-39 with EDL933. 
 
 The OI 39 contains ORFs of unknown function.  The OI-39 deletion mutant was 
compared to the EDL933 parental strain. The pattern of substrate utilization for the OI-39 
deletion mutant and the O157:H7 parental strain was similar. The main differences 
observed were in levels of substrate utilization; i.e., three exceptions appeared to occur 
for utilization of α-keto-glutaric acid, mono methyl succinate and glucuronamide (Figure. 
3.22). Levels of α-keto-glutaric acid and glucuronamide substrate utilization in EDL933 
were above the threshold value of <0.100 used in this study while OI-39 deletion mutant 
levels of substrate utilization were below the threshold value. By contrast, levels of mono 
methyl succinate were below the threshold level in EDL933 and above the threshold level 
in the OI-39 deletion mutant, suggesting that the mutant had lost the ability to use α-keto-
glutaric acid and glucuronamide but, gained the ability to use mono methyl succinate as a 
carbon source.  However, comparison of these utilization levels using a T-test showed 
that the difference in substrate utilization for α-keto-glutaric acid, mono methyl succinate 
and glucuronamide between the OI-39 deletion mutant and the EDL933 control were not 
significantly different (P > 0.05) suggesting that this mutant did not lose or gain the  
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Figure.3.22. Comparison of E. coli O157:H7 parental strain EDL933, the OI-39 deletion mutants and the E. coli K-12 reference strain 
DH5α for the Substrates α-keto-glutaric acid, mono methyl succinate and glucuronamide. The threshold value for substrate utilization 
was 0.100. The absorbance mean + S.E. for each substrate is shown. Mean values for substrate utilization also are identified at the 
bottom of the figure. There is no significant difference in substrate utilization for any of the substrates when comparing the OI-39 
mutant and EDL933.
 
 
68
  
 
ability to use of α-keto-glutaric acid, mono methyl succinate and glucuronamide as 
carbon sources. 
By contrast, significant differences (P < 0.05) in levels of substrate utilization 
were seen for other substrates where both the mutant and the parental strain EDL933 
were positive (above the threshold) for a given substrate (Figure 3.23).  In all cases the 
OI-39 mutant utilized significantly less acetic acid, fructose-6-phosphate, maltotriose, 
pyruvic acid and L-galactonic acid-γ-lactone compared to the EDL933 parental control.  
Percentage differences in utilization for each of these substrates were 35.0%, 7.4%, 
10.7%, 7.1%, and 7.2% respectively.  Note that acetate, fructose-6-phosphate and pyruvic 
acid all are substrates and products found in glycolytic and fermentation pathways.  
Maltotriose is a tri-saccharide consisting of three glucose molecules linked by 1,4-
glycosidic bonds, while L- galactonic acid-γ-lactone typically is converted to ascorbate 
for use in anaerobic biochemical pathways.  
In summary, there was no significant difference in substrate utilization for keto-
glutaric acid, mono methyl succinate and glucuronamide between the OI-39 deletion 
mutant and the EDL933 parental strain. However, the differences seen in the level of 
substrate utilization for acetic acid, fructose-6-phosphate, maltotriose, pyruvic acid and 
L-galactonic acid-γ-lactone suggest a possible change in sugar degradation due to the 
removal of this island compared to the levels of substrate utilization for these substrates 
in EDL933; i.e., genes on this OI appear to promote more efficient utilization of sugars 
and their metabolites in EDL933.   
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 Figure.3.23. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-39 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization also are identified at the bottom of the figure.  
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3.3.7.7 Comparison of the deletion mutant OI-98 with EDL933. 
 
The OI 98 contains an ORF of unknown function and comparison of the OI-98 
deletion mutant to the parental strain EDL933 showed that the pattern of substrate 
utilization for the OI-98 deletion mutant and the O157:H7 parental strain was similar. 
The main differences observed were in levels of substrate utilization; i.e., five exceptions 
appeared to occur (Figure. 3.24). Levels of D-serine, L-glutamic acid, tween 20, tween 40 
and mono methyl succinate substrate utilization in EDL933 fell below the threshold value 
of 0.100 used in this study while OI-98 deletion mutant levels of substrate utilization 
were above the threshold value. This suggests that the mutant had gained the ability to 
use D-serine, L-glutamic acid, tween 20, tween 40 and mono methyl succinate as carbon 
sources.  However, comparison of these utilization levels using a T-test showed that the 
difference in substrate utilization for D-serine, tween 20, tween 40 and mono methyl 
succinate  between the OI-98 deletion mutant and the EDL933 control were not different 
(P > 0.05). In contrast, substrate levels were significantly different (P < 0.05) for L-
glutamic acid. This suggests that the mutant OI-98 did not gain the ability to use D-
serine, tween 20, tween 40 and mono methyl succinate as a carbon sources but did gain 
the ability to use L-glutamic acid as a carbon source. 
Furthermore, a significant difference (P < 0.05) in the level of substrate utilization 
was seen for one other substrate where both the mutant and the parental strain were 
positive (above the threshold) for this substrate (Figure 3.25). The OI-98 mutant utilized 
significantly less L-rhamnose compared to the EDL933 parental control.  The percentage 
difference in utilization for this substrate was 20.7%.  
In summary, the only significant difference in substrate utilization between the 
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Figure.3.24. Comparison of E. coli O157:H7 parental strain EDL933, the OI-98 deletion mutants and the E. coli K-12 reference strain 
DH5α for the Substrates D-serine, L-glutamic acid, tween 20, tween 40 and mono methyl succinate. The threshold value for substrate 
utilization was <0.100. The absorbance mean + S.E. for each substrate is shown. Mean values for substrate utilization also are 
identified at the bottom of the figure. The only significant difference in substrate utilization between the OI-98 mutant and the 
EDL933 parental is for L-glutamic acid. 
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Figure.3.25. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-98 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization are identified at the bottom of the figure.  
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OI-98 mutant and the EDL933 was for L-glutamic acid, where the mutant was above the 
threshold value and the EDL933 parental strain was below the threshold value. Use of L-
glutamic acid as a carbon source may be related to metabolism of the bacteria suggesting 
this island could have a role in regulating/suppressing metabolism. Also the increase in 
the level of substrate utilization for L-rhamnose compared to the parental strain EDL933 
suggests the ORF found on this island may also have a role in sugar utilization, which 
suggests that this island may play a role in regulation of glutamic acid and L-rhamnose 
utilization in the bacterium. 
 
3.3.7.8 Comparison of the deletion mutant OI-102 with EDL933. 
 The OI 102 also contains ORFs of unknown function, as well as ORFs 
coding for putative prophage DNA injection proteins, an ORF coding for a putative 
resolvase, a sucrose permease, a D-fructokinase, a sucrose hydrolase and a sucrose 
specific transcriptional regulator (Appendix I). The deletion mutant corresponding to OI 
102 was compared to the parental strain EDL933. The pattern of substrate utilization for 
the OI-102 deletion mutant and the O157:H7 parental strain was similar. The main 
differences observed were in levels of substrate utilization; i.e., five exceptions appeared 
to occur (Figure. 3.26). Levels of D- serine, tween 20, tween 40 and D-threonine 
substrate utilization in EDL933 fell below the threshold value of 0.100 used in this study 
while OI-102 deletion mutant levels of substrate utilization were above the threshold 
value. For sucrose the opposite was seen. This suggests that the mutant gained the ability 
to use D-serine, tween 20, tween 40 and D-threonine as carbon sources but, lost the 
ability to use sucrose as a carbon source.  Further comparison of these utilization levels 
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Figure.3.26. Comparison of E. coli O157:H7 parental strain EDL933, the OI-102 deletion mutants and the E. coli K-12 reference 
strain DH5α for the substrates D-serine, tween 20, tween 40, sucrose and D-threonine. The threshold value for substrate utilization 
was <0.100. The absorbance mean + S.E. for each substrate is shown. Mean values for substrate utilization also are identified at the 
bottom of the figure. The only significant differences in substrate utilization between the OI-102 mutant and the EDL933 parental 
were seen for D-serine, D-threonine and sucrose.  
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using a T-test showed that the difference in substrate utilization for tween 20 and tween 
40 between the OI-102 deletion mutant and the EDL933 control were not different (P > 
0.05). However the substrate levels were significantly different (P < 0.05) for D-serine, 
D-threonine and sucrose.  This suggests that this mutant did not gain the ability to use 
tween 20 and tween 40 as carbon sources but, gained the ability to use D-serine and D-
threonine as carbon sources and lost the ability to use sucrose as a carbon source. 
Furthermore, significant differences (P < 0.05) in levels of substrate utilization 
were seen for five other substrates where both the mutant and the parental strains were 
positive (above the threshold) for a given substrate (Figure 3.27). The OI-102 mutant 
utilized significantly less L-arabinose and D-xylose and used significantly more α-
methyl-D-galactoside, glycyl-L-glutamic acid and pyruvic acid compared to the EDL933 
parental control.  Percentage differences in utilization for these substrates were 11.6%, 
15.4%, 11.5%, 19.8% and 8.5% respectively.  
In summary, the only significant differences in substrate utilization between the 
OI-102 mutant and the EDL933 parental strain were for D-serine, D-threonine and 
sucrose. Mutant values were above the threshold level for D-serine and D-threonine but, 
below the threshold value for sucrose.  The EDL933 parental strain was below the 
threshold value for D-serine and D-threonine but, above the threshold for sucrose. The 
loss in ability of the deletion mutant to use sucrose is most likely due to the removal of 
this OI containing various ORFs coding for genes relating to sucrose utilization. The gain 
in ability to use D-serine and D-threonine may be due to the removal of transcriptional 
regulators which could be suppressing the bacteria’s ability to use these substrates due to 
a preference for sucrose and loss of this regulation has restored ability to use D-serine 
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Figure.3.27. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain EDL933 and the OI-102 deletion 
mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for 
substrate utilization also are identified at the bottom of the figure.
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and D-threonine as carbon sources.  Also the increase in the level of substrate utilization 
for α-methyl-D-galactoside, glycyl-L-glutamic acid and pyruvic acid and decrease in 
level of utilization for L-arabinose and D-xylose compared to EDL933 suggests the ORFs 
found on this island on the parental line may also have a role in sugar consumption.  
 
3.3.7.9 Comparison of the deletion mutant OI-172 with EDL933. 
The OI 172 contains ORFs unknown function, ORFs coding for two putative 
intergrases, a transposase, a putative resolvase, a putative ATP-dependent helicase and 
two putative helicases; i.e., genes likely involved in bacteriophage propagation and DNA 
synthesis, as well as regulation of cell growth and cell division (Appendix I).  The OI-172 
deletion mutant  was compared to the parental strain EDL933. The pattern of substrate 
utilization for the OI-172 deletion mutant and the O157:H7 parental strain was similar. 
The main differences observed were in levels of substrate utilization; seven exceptions 
appeared to occur in substrate utilization (Figure. 3.28). Levels of tween 20, tween 40, 
M-tartaric acid and mono methyl succinate substrate utilization in EDL933 fell below the 
threshold value of <0.100 used in this study while OI-172 deletion mutant levels of 
substrate utilization were above the threshold value. The opposite was seen where mutant 
levels of α-keto-glutaric acid, α-keto-butyric acid and α-hydroxy butyric acid fell below 
the threshold level while levels in EDL933 were above the threshold value, suggesting 
that the mutant had gained the ability to use tween 20, tween 40, M-tartaric acid and 
mono methyl succinate as carbon sources but, lost the ability to use α-keto-glutaric acid, 
α-keto-butyric acid and α-hydroxy butyric acid as carbon sources.  Further comparison of 
these utilization levels using a T-test showed that the difference in substrate utilization 
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Figure.3.28. Comparison of E. coli O157:H7 parental strain EDL933, the OI-172 deletion mutants and the E. coli K-12 reference 
strain DH5α for the substrates tween 20, tween 40, α-keto-glutaric acid, α-keto-butyric acid, M-tartaric acid, α-hydroxy butyric acid 
and mono methyl succinate. The threshold value for substrate utilization was <0.100. The absorbance mean + S.E. for each substrate is 
shown. Mean values for substrate utilization also are identified at the bottom of the figure. The only significant differences in substrate 
utilization were for tween 20, α-keto-butyric acid, M-tartaric acid and α-hydroxy butyric acid. 
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for tween 40, α-keto-glutaric acid and mono methyl succinate between the OI-172 
deletion mutant and the EDL933 control were not different (P > 0.05). However the 
substrate levels were significantly different (P < 0.05) for tween 20, α-keto-butyric acid, 
M-tartaric acid and α-hydroxy butyric acid.  This suggests that this mutant did not gain 
the ability to use tween 40 and mono methyl succinate or lose the ability to use α-keto-
glutaric acid as carbon sources but, did gain the ability to use tween 20 and M-tartaric 
acid as carbon sources and lost the ability to use α-keto-butyric acid and α-hydroxy 
butyric acid as carbon sources. 
Furthermore, significant differences (P < 0.05) in levels of substrate utilization 
were seen for forty other substrates where both the mutant and the parental strain were 
positive (above the threshold) for a given substrate. In all cases the OI-172 mutant used 
significantly less L-arabinose, N-acetyl-D-glucosamine, succinic acid, D-galactose, L-
aspartic acid, L-proline, D-trehalose, glycerol, D-glucuronic acid, D,L-α-glycerol 
phosphate, D-xylose, glucose-6-phosphate, D,L,-malic acid, D-ribose, acetic acid, α-D-
glucose, D-melibiose, L-asparagine, α-methyl-D-galactoside, lactulose, sucrose, uridine, 
glucose-1-phosphate, fructose-6-phosphate, β-methyl-D-glucoside, maltotriose, 2-deoxy 
adenosine, adenosine, glycyl-L-aspartic acid, fumaric acid, bromo succinic acid, 
propionic acid, inosine, L-serine, L-alanine, N-acetyl-β-D-mannosamine, L-malic acid, 
pyruvic acid, L-galactonic acid-γ-lactone and D-galacturonic acid compared to the 
EDL933 parental control.  Percentage differences in level of utilization for these 
substrates were 24.4%, 15.8%, 38.3%, 22.9%, 49.6%, 28.2%, 27.8%, 21.4%, 27.8%, 
34.9%, 30.2%, 11.8%, 41.2%, 26.4%, 36.0%, 15.6%, 21.5%, 49.7%, 22.8%, 31.3%, 
24.3%, 21.5%, 21.9%, 20.1%, 30.9%, 14.7%, 19.9%, 19.7%, 31.5%, 44.3%, 39.9%, 
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66.8%, 31.6%, 21.0%, 19.5%, 23.1%, 40.9%, 26.6%, 27.1% and 13.0% respectively 
(Figure 3.29 - 3.32 and Table 3.4). 
 In summary, the only significant differences in substrate utilization were for the 
substrates tween 20, M-tartaric acid , α-keto-butyric acid and α-hydroxy butyric acid.  
The mutant was above the threshold value for tween 20 and M-tartaric acid and below the 
threshold value for α-keto-butyric acid and α-hydroxy butyric acid.  The EDL933 
parental strain showed the opposite result for these substrates.  The use of tween 20 
suggests that this OI could have a role in membrane integrity.  If the island does have a 
role in membrane function it could help explain why the mutant had so many differences 
in level of substrate utilization compared to EDL933 and why in each case the mutant 
had a lowered ability to use a substrate compared to the parental strain.   
 
3.3.8  Metabolism in the E. coli K-12 reference strain DH5α and the O157:H7 OI    
  deletion mutants 
 
3.3.8.1 Comparison of DH5α with the OI-39 deletion mutant 
Comparison of the OI-39 deletion mutant and the DH5α strain showed many of the 
same differences seen when the parental O157 strain EDL933 was compared with DH5α. 
There were 15 cases where differences were seen between the two strains using a T-test. 
Seven of these cases were no longer significantly different (P > 0.05) in level of substrate 
utilization in the DH5α and OI-39 comparison but, were in the DH5α and EDL933 
comparison.  The substrates involved were succinic acid, L-proline, dulcitol, glucose-6-
phosphate, fructose-6-phosphate, glycyl-L-aspartic acid and L-serine. This suggests that 
the mutant behaved more like DH5α for these substrates than the parental strain EDL933. 
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Figure.3.29. Differences in levels of substrate utilization (substrates 2- 19) for the E. coli O157:H7 parental strain EDL933 and the OI-
172 deletion mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. 
Mean values for substrate utilization also are identified at the bottom of the figure. 
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Figure.3.30. Differences in levels of substrate utilization (substrates 20- 46) for the E. coli O157:H7 parental strain EDL933 and the 
OI-172 deletion mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. 
Mean values for substrate utilization also are identified at the bottom of the figure. 
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Figure.3.31. Differences in levels of substrate utilization (substrates 47-65) for the E. coli O157:H7 parental strain EDL933 and the 
OI-172 deletion mutant.  All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. 
Mean values for substrate utilization also are identified at the bottom of the figure.
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Figure.3.32. Differences in levels of substrate utilization (substrates 66-94) for the E. coli O157:H7 parental strain EDL933 and the 
OI-172 deletion mutant.  All values were significantly different (P < 0.05).The absorbance mean + S.E. for each substrate is shown. 
Mean values for substrate utilization also are identified at the bottom of the figure.
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Table 3.4. Percentage difference* in levels of substrate utilization for the OI-172 deletion 
mutant and the EDL933 parental. 
 
SOURCE EDL933 control 
OI-172 
mutant 
Percentage Difference 
(%) 
L-arabinose 0.461 0.349 24.4 
N-acetyl-D-glucosamine 0.529 0.445 15.8 
succinic acid 0.614 0.379 38.3 
D-galactose 0.517 0.399 22.9 
L-aspartic acid 0.655 0.330 49.6 
L-proline 0.629 0.451 28.2 
D-trehalose 0.721 0.520 27.8 
Glycerol 0.564 0.443 21.4 
D-glucuronic acid 0.741 0.535 27.8 
D,L-α-glycerol-phosphate 0.436 0.284 34.9 
D-xylose 0.660 0.461 30.2 
glucose-6-phosphate 0.826 0.728 11.8 
D,L-malic acid 0.714 0.420 41.2 
D-ribose 0.566 0.417 26.4 
acetic acid 0.364 0.233 36.0 
α-D-glucose 0.436 0.368 15.6 
D-melibiose 0.678 0.532 21.5 
L-asparagine 0.647 0.326 49.7 
α-methyl-D-galactoside 0.534 0.412 22.8 
Lactulose 0.521 0.358 31.3 
Sucrose 0.617 0.467 24.3 
Uridine 0.698 0.548 21.5 
glucose-1-phosphate 0.805 0.628 21.9 
fructose-6-phosphate 0.781 0.624 20.1 
β-methyl-D-glucoside 0.433 0.299 30.9 
Maltotriose 0.610 0.520 14.7 
2-deoxy adenosine 0.904 0.724 19.9 
Adenosine 0.755 0.606 19.7 
glycyl-L-aspartic acid 0.607 0.415 31.5 
fumaric acid 0.574 0.320 44.3 
bromo succinic acid 0.636 0.383 39.9 
propionic acid 0.342 0.114 66.8 
Inosine 0.766 0.524 31.6 
L-serine 0.532 0.420 21.0 
L-alanine 0.501 0.404 19.5 
N-acetyl-β-D-mannosamine 0.354 0.272 23.1 
L-malic acid 0.641 0.379 40.9 
pyruvic acid 0.642 0.471 26.6 
L-galactonic acid-γ-lactone 0.607 0.443 27.1 
D-galacturonic acid 0.793 0.689 13.0 
*All values were significantly different (P < 0.05). 
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The remaining eight cases were for substrates where there were significant differences in 
either substrate utilization (+ or -) or level of substrate utilization. 
Significant differences (P < 0.05) in substrate utilization were found where the OI-
39 deletion mutant was negative (below threshold of <0.100) and DH5α strain was 
positive (above threshold) for three substrates, tween 20, tween 40 and α-keto-glutaric 
acid (Figure 3.33).  It appears that DH5α has the ability to use tween 20, tween 40 and α-
keto-glutaric acid as a carbon source and the OI-39 deletion mutant does not. 
Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.5). The OI-39 deletion mutant used 
significantly higher levels of D-mannitol, D-fructose, mucic acid and D-malic acid while 
DH5α used significantly higher levels of acetic acid.  Percentage differences in utilization 
for each of these substrates were 26.0%, 25.5%, 29.3%, 31.6% and 17.7% respectively 
(Table 3.5). 
 
3.3.8.2 Comparison of DH5α with the OI-51 deletion mutant 
Comparison of the OI-51 deletion mutant from EDL933 and the DH5α strain 
showed many of the same differences in substrate utilization (+ or -) and levels of 
substrate utilization seen when the parental strain EDL933 was compared with DH5α. 
There were 10 cases where significant differences were seen using a T-test. Half of those 
cases were no longer significantly different (P > 0.05) in level of substrate utilization in 
the DH5α and OI-51 comparison but were in the DH5α and EDL933 comparison.  They 
were for L-arabinose, α-D-glucose, L-glutamine, fructose-6-phosphate and L-serine. This  
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Figure. 3.33 Comparison of E. coli OI deletion mutant OI-39 and E. coli DH5α for the 
substrates tween 20, tween 40 and α-keto-glutaric acid. The threshold value for substrate 
utilization was <0.100. DH5α is above the threshold value in each case and the OI-39 
deletion mutant is below the threshold value. 
 
 
Table 3.5.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-39 and the E. coli DH5α strain.   
 
# of 
Substrate 
Source 
 
OI-39 mutant  DH5α Control Percentage 
difference* (%) 
23 
D-
mannitol 0.585 0.457 21.9 
31 D-fructose 0.588 0.420 28.5 
32** 
acetic 
acid 0.237 0.276 14.4 
68 mucic acid 0.548 0.420 23.3 
83 
D-malic 
acid 0.556 0.328 41.0 
*All values were significantly different (P < 0.05). 
** Bolded value is the case where DH5α has a higher level of substrate utilization.
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suggests that the mutant behaved more like DH5α for these substrates than the parental 
strain EDL933. The remaining five cases were for substrates where there were significant 
differences in either substrate utilization (+ or -) or the level of substrate utilization. 
A significant difference (P < 0.05) in substrate utilization was found for one 
substrate.  The OI-51 deletion mutant was positive (above threshold of 0.100) and DH5α 
negative (below the threshold) for glucuronamide utilization (Figure 3.34). It appears that 
the OI-51 mutant has the ability to use glucuronamide as a carbon source while DH5α 
does not. 
Significant differences (P < 0.05) in levels of substrate utilization where both strains were 
positive for a substrate were also seen (Table 3.6). The OI-51 deletion mutant used 
significantly higher levels of D-mannitol, acetic acid, glycyl-L-glutamic acid and D-malic 
acid compared to DH5α.  Percentage differences in utilization for each of these substrates 
were 28.6%, 17.2%, 51.5% and 42.4% respectively (Table. 3.6). 
 
3.3.8.3  Comparison of DH5α with the OI-55 deletion mutant 
 
Comparison of the OI-55 deletion mutant and DH5α strain show many of the 
same differences in either substrate utilization or levels of substrate utilizations as seen 
when comparing the parental O157 strain EDL933 with the E. coli K-12 reference strain 
DH5α. There were nine cases where differences were seen between the two bacterial 
strains using a T-test. In two cases significant differences (P > 0.05) in level of substrate 
utilization seen in DH5α and EDL933 were no longer seen when DH5α and the OI-55 
deletion mutant were compared; i.e., use of L-arabinose and fructose-6-phosphate 
changed, suggesting that the mutant behaved more like DH5α for these substrates than 
the parental strain EDL933.  The remaining seven cases were for substrates where there  
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Figure. 3.34 Comparison of E. coli OI deletion mutant OI-51 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-135 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
 
 
Table 3.6.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-51 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-51 mutant DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.640 0.457 28.6 
32 acetic acid 0.334 0.276 17.2 
73 
glycyl-L-glutamic 
acid 0.497 0.241 51.5 
83 D-malic acid 0.570 0.328 42.4 
*All values were significantly different (P < 0.05). 
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were significant differences in either substrate utilization (+ or -) or level of substrate 
utilization. Significant differences (P < 0.05) in substrate utilization were found for one 
substrate.  The OI-55 deletion mutant was positive (above threshold of >0.100) and 
DH5α was negative (below threshold) for glucuronamide (Figure 3.35).  It appears that 
the OI-55 mutant had the ability to use glucuronamide as a carbon source while DH5α 
did not. 
 Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.7). The OI-55 deletion mutant used 
significantly higher levels of D-mannitol, acetic acid, glycyl-L-glutamic acid, L-alanyl-
glycine and D-malic acid while DH5α used significantly higher levels of mucic acid.  
Percentage differences in utilization for each of these substrates were 25.6%, 16.8%, 
49.3%, 29.4% and 76.1% respectively (Table. 3.7).  
 
3.3.8.4 Comparison of DH5α with the OI-59 deletion mutant 
Comparison of the OI-59 deletion mutant with the DH5α strain showed many of 
the same differences in substrate utilization (+ and -) and levels of substrate utilization as 
seen when the parental strain EDL933 was compared with DH5α. There were nine cases 
where differences were seen using a T-test. In three of these cases levels of substrate 
utilization for L-arabinose, α-D-glucose and fructose-6-phosphate were no longer 
significantly different (P > 0.05) when DH5α and the OI-59 mutant were compared but, 
were different when DH5α and EDL933 were compared.  This suggests that the OI-59 
mutant behaved more like DH5α for these substrates than like the parental strain 
EDL933; interestingly two of these substrates are part of the glycolysis pathway. A  
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Figure. 3.35. Comparison of E. coli OI deletion mutant OI-55 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-135 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
 
Table 3.7.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-55 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-55 mutant DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.614 0.457 25.6 
32 acetic acid 0.332 0.276 16.8 
68 mucic acid 0.100 0.420 76.1 
73 
glycyl-L-glutamic 
acid 0.474 0.241 49.3 
78 L-alanyl-glycine 0.480 0.339 29.4 
83 D-malic acid 0.517 0.328 36.5 
*All values were significantly different (P < 0.05). 
** Bolded values are cases where DH5α has a higher substrate utilization level. 
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significant difference (P < 0.05) in substrate utilization also was found where 
glucuronamide use in the OI-59 deletion mutant was positive (above threshold of >0.100) 
while its use in DH5α was negative (below the threshold) (Figure 3.36).  It appears that 
the OI-59 mutant has the ability to use glucuronamide as a carbon source while DH5α 
does not. 
 In addition, significant differences (P < 0.05) in levels of substrate utilization where 
both strains were positive for a substrate were seen (Table 3.8). The OI-59 deletion 
mutant used significantly higher levels of D-mannitol, acetic acid, α-keto-glutaric acid, 
glycyl-L-glutamic acid and D-malic acid in comparison to DH5α.  Percentage differences 
in utilization for each of these substrates were 25.5%, 22..2%, 21.1%, 50.4% and 42..2% 
respectively (Table. 3.8).  
 
3.3.8.5 Comparison of DH5α with the OI-87 deletion mutant 
Comparison of the OI-87 deletion mutant with the DH5α strain showed many of the 
same differences in substrate utilization (+ and -) and levels of substrate utilization seen 
when the parental strain EDL933 was compared with DH5α. There were nine cases 
where differences were seen using a T-test. In three of these cases levels of substrate 
utilization for L-arabinose, fructose-6-phosphate and L-serine were no longer 
significantly different (P > 0.05) when DH5α and the OI-87 mutant were compared but, 
were different when DH5α and EDL933 were compared. This suggests that the OI-87 
mutant behaved more like DH5α for these substrates than like the parental strain 
EDL933.  
A significant difference (P < 0.05) in substrate utilization was found for  
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Figure. 3.36. Comparison of E. coli OI deletion mutant OI-59 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-59 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
 
 
 
Table 3.8.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-59 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-59 mutant  DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.613 0.457 25.5 
32 acetic acid 0.355 0.276 22.2 
42 α-keto-glutaric acid 0.447 0.353 21.1 
73 
glycyl-L-glutamic 
acid 0.486 0.241 50.4 
83 D-malic acid 0.568 0.328 42.2 
*All values were significantly different (P < 0.05). 
. 
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glucuronamide. In this case the OI-87 deletion mutant was positive (above threshold of 
<0.100) for glucuronamide but, negative (below threshold) in the E. coli K-12 reference 
strain DH5α (Figure 3.37).  It appears that the OI-87 mutant had the ability to use 
glucuronamide as a carbon source while DH5α did not. 
 Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.9). The OI-87 deletion mutant used 
significantly higher levels of D-mannitol, acetic acid, glycyl-L-glutamic acid, L-alanyl-
glycine and D-malic acid in comparison to DH5α.  Percentage differences in utilization 
for each of these substrates was 28.2%, 21.9%, 50.9%, 31.2% and 36.2% respectively 
(Table. 3.9).  
 
3.3.8.6 Comparison of DH5α with the OI-89 deletion mutant 
 
Comparison of the OI-89 deletion mutant with the DH5α strain showed many of the 
same differences in substrate utilization (+ and -) and levels of substrate utilization seen 
when the parental strain EDL933 was compared with DH5α. There were 12 cases where 
differences were seen using a T-test. In seven of these cases levels of substrate utilization 
for succinic acid, D-galactose, L-lactic acid, α-D-glucose, fructose-6-phosphate, L-serine 
and L-malic acid were no longer significantly different (P > 0.05) when DH5α and the 
OI-89 mutant were compared but, were different when DH5α and EDL933 were 
compared. This suggests that the mutant behaved more like DH5α for these substrates 
than it behaved like the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization were found for the 
substrate glucuronamide. The OI-89 deletion mutant was positive (above threshold of  
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Figure. 3.37. Comparison of E. coli OI deletion mutant OI-87 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-87 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
 
 
 
Table 3.9.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-87 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-87 mutant DH5α Control  
Percentage 
Difference (%) 
23 D-mannitol 0.636 0.457 28.2 
32 acetic acid 0.354 0.276 21.9 
73 
glycyl-L-glutamic 
acid 0.490 0.241 50.9 
78 L-alanyl-glycine 0.492 0.339 31.2 
83 D-malic acid 0.515 0.328 36.2 
*All values were significantly different (P < 0.05). 
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<0.100) for glucuronamide while, DH5α was negative (below threshold) for this substrate 
(Figure 3.38).  It appears that the OI-89 mutant had the ability to use glucuronamide as a 
carbon source while DH5α did not. 
 Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.10). The OI-89 deletion mutant used 
significantly higher levels of D-mannitol, acetic acid, mucic acid and L-alanyl-glycine in 
comparison to DH5α.  Percentage differences in utilization for each of these substrates 
were 20.1%, 18.2%, 25.7% and 31.7% respectively (Table. 3.10). 
 
 3.3.8.7  Comparison of DH5α with the OI-98 deletion mutant 
Comparison of the OI-98 deletion mutant with the DH5α strain showed many of the 
same differences in substrate utilization (+ and -) and levels of substrate utilization seen 
when the parental strain EDL933 was compared with DH5α. There were 16 cases where 
differences were seen using a T-test. In nine of these cases levels of substrate utilization 
for succinic acid, L-proline, dulcitol, D-serine, glycerol, L-glutamic acid, L-glutamine, 
fructose-6-phosphate and D-galacturonic acid were no longer significantly different (P > 
0.05) when DH5α and the OI-98 mutant were compared but, were different when DH5α 
and EDL933 were compared. This suggests that the mutant behaved more like the DH5α 
reference strain for these substrates than it behaved like the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization were found for the two 
substrates mono methyl succinate and glucuronamide.  The OI-98 deletion mutant was 
positive (above threshold of <0.100) for both mono methyl succinate and glucuronamide 
but, negative (below threshold) for use of DH5α (Figure 3.39).  It appears that the OI-98  
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Figure. 3.38. Comparison of E. coli OI deletion mutant OI-89 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-89 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
 
Table 3.10.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-89 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-89 mutant DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.572 0.457 20.1 
32 acetic acid 0.338 0.276 18.2 
68 mucic acid 0.565 0.420 25.7 
78 L-alanyl-glycine 0.496 0.339 31.7 
*All values were significantly different (P < 0.05). 
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Figure. 3.39. Comparison of E. coli OI deletion mutant OI-98 and E. coli DH5α for the 
substrates mono methyl succinate and glucuronamide. The threshold value for substrate 
utilization was <0.100. The OI-98 deletion mutant is above the threshold for mono 
methyl succinate and glucuronamide and DH5α is below the threshold.  
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mutant had the ability to use mono methyl succinate and glucuronamide as a carbon 
source but, DH5α did not. 
 Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.11). The OI-98 deletion mutant used 
significantly higher levels of D-mannitol, D-fructose, acetic acid, α-keto-glutaric acid and 
L-alanyl-glycine in comparison to DH5α.  Percentage differences in utilization for each 
of these substrates were 27.6%, 33.3%, 28.5%, 22.3% and 27.5% respectively (Table. 
3.11).  
 
3.3.8.8  Comparison of DH5α with the OI-102 deletion mutant 
Comparison of the OI-102 deletion mutant with the DH5α strain showed many of 
the same differences in substrate utilization (+ and -) and levels of substrate utilization 
seen when the parental strain EDL933 was compared with DH5α. There were 16 cases 
where differences were seen using a T-test. In half of these cases levels of substrate 
utilization for D-alanine, dulcitol, D-serine, glycerol, sucrose, uridine, fructose-6-
phosphate and glycyl-L-aspartic acid were no longer significantly different (P > 0.05) 
when DH5α and the OI-102 mutant were compared but, were different when DH5α and 
EDL933 were compared. This suggests that the mutant behaved more like DH5α for 
these substrates than like the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization also were found for the 
substrates D-threonine and glucuronamide.  The OI-102 deletion mutant was positive 
(above threshold of <0.100) for D-threonine and glucuronamide but, negative (below 
threshold) for D-threonine and glucuronamide in DH5α (Figure 3.40).  It appears that the  
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Table 3.11.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-98 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-98 mutant 
DH5α 
Control 
Percentage 
Difference (%) 
23 D-mannitol 0.631 0.457 27.6 
31 D-fructose 0.630 0.420 33.3 
32 acetic acid 0.387 0.276 28.5 
42 
α-keto-glutaric 
acid 0.454 0.353 22.3 
78 
L-alanyl-
glycine 0.467 0.339 27.5 
*All values were significantly different (P < 0.05). 
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Figure. 3.40. Comparison of E. coli OI deletion mutant OI-102 and E. coli DH5α for the 
substrates D-threonine and glucuronamide. The threshold value for substrate utilization 
was <0.100. The OI-102 deletion mutant is above the threshold for D-threonine and 
glucuronamide and DH5α is below the threshold.  
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OI-102 mutant had the ability to use D-threonine and glucuronamide as a carbon source 
but, that DH5α did not. 
 Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.12). The OI-102 deletion mutant 
used significantly higher levels of D-mannitol, D-fructose, acetic acid, glycyl-L-glutamic 
acid, L-alanyl-glycine and D-malic when compared to DH5α.  Percentage differences in 
utilization for each of these substrates were 23.5%, 25.7%, 25.0%, 32.7%, 33.3% and 
35.4% respectively (Table. 3.12).  
 
3.3.8.9  Comparison of DH5α with the OI-108 deletion mutant 
Comparison of the OI-108 deletion mutant with the DH5α strain showed many of 
the same differences in substrate utilization (+ and -) and levels of substrate utilization 
seen when the parental strain EDL933 was compared with DH5α. There were 13 cases 
where differences were seen using a T-test. In seven of these cases levels of substrate 
utilization for succinic acid, L-aspartic acid, glycerol, D, L-malic acid, L-asparagine, 
fructose-6-phosphate and maltotriose were no longer significantly different (P > 0.05) 
when DH5α and the OI-108 mutant were compared but, were different when DH5α and 
EDL933 were compared. This suggests that the mutant behaved more like the E. coli K-
12 reference strain DH5α for these substrates than like the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization were found for one 
substrate.  The OI-108 deletion mutant was positive (above threshold of <0.100) for use 
of glucuronamide but, negative (below threshold) for glucuronamide in DH5α (Figure 
3.41).  It appeared that the OI-108 mutant had the ability to use glucuronamide as a  
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Table 3.12.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-102 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-102 mutant 
DH5α 
Control 
Percentage 
Difference (%) 
23 D-mannitol 0.598 0.457 23.5 
31 D-fructose 0.566 0.420 25.7 
32 acetic acid 0.368 0.276 25.0 
73 
glycyl-L-
glutamic acid 0.358 0.241 32.7 
78 
L-alanyl-
glycine 0.508 0.339 33.3 
83 D-malic acid 0.508 0.328 35.4 
*All values were significantly different (P < 0.05). 
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Figure. 3.41. Comparison of E. coli OI deletion mutant OI-108 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was 0.100. The OI-
102 deletion mutant is above the threshold for glucuronamide and DH5α is below the 
threshold.  
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carbon source while DH5α did not.  
Significant differences (P < 0.05) in levels of substrate utilization where both strains 
were positive for a substrate were also seen (Table 3.13). The OI-108 deletion mutant 
used significantly higher levels of D-mannitol, D-fructose, acetic acid, glycyl-L-glutamic 
acid and L-alanyl-glycine in comparison to DH5α.  Percentage differences in utilization 
for each of these substrates were 27.5%, 25.5%, 21.6%, 40.7% and 33.4% respectively 
(Table. 3.13). 
 
3.3.8.10  Comparison of DH5α with the OI-135 deletion mutant 
Comparison of the OI-135 deletion mutant with the DH5α strain showed many of 
the same differences in substrate utilization (+ and -) and levels of substrate utilization 
seen when the parental strain EDL933 was compared with DH5α. There were 11 cases 
where differences were seen using a T-test. In six of these cases levels of substrate 
utilization for D-alanine, glycerol, α-D-glucose, fructose-6-phosphate, glycyl-L-aspartic 
acid and N-acetyl-β-D-mannosamine were no longer significantly different (P > 0.05) 
when DH5α and the OI-135 mutant were compared but, were different when DH5α and 
EDL933 were compared. This suggests that the OI-135 mutant behaved more like DH5α 
for these substrates than like the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization were found for two 
substrates.  The OI-135 deletion mutant was positive (above threshold of <0.100) for use 
of glucuronamide but, negative (above threshold) for use of glucuronamide in DH5α; the 
opposite was seen for the substrate tween 20 (Figure 3.42).  It appears that the OI-135 
deletion mutant had the ability to use glucuronamide but, not tween 20 as a carbon  
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Table 3.13.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-108 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-108 mutant DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.630 0.457 27.5 
31 D-fructose 0.564 0.420 25.5 
32 acetic acid 0.352 0.276 21.6 
73 
glycyl-L-
glutamic acid 0.406 0.241 40.7 
78 
L-alanyl-
glycine 0.508 0.339 33.4 
*All values were significantly different (P < 0.05). 
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Figure.3.42 Comparison of E. coli OI deletion mutant OI-135 and E. coli DH5α for the 
substrates tween 20 and glucuronamide. The threshold value for substrate utilization was 
<0.100. DH5α is above the threshold value in for tween 20 and the OI-135 deletion 
mutant is above the threshold for glucuronamide.  
 
 
  
 
source. 
Significant differences (P < 0.05) in levels of substrate utilization where both 
strains were positive for a substrate were also seen (Table 3.14). The OI-135 deletion 
mutant used significantly higher levels of D-mannitol, acetic acid and L-alanyl glycine 
compared to DH5α. Percentage differences in utilization for each of these substrates were 
25.5%, 24.7% and 35.4% respectively (Table. 3.14). 
 
3.3.8.11  Comparison of DH5α with the OI-172 deletion mutant 
Comparison of the OI-172 deletion mutant and DH5α strain show many of the same 
differences seen when comparing the parental EDL933 and DH5α; however there were 
more differences between these two strains than any other mutant. There were 24 cases 
where differences were seen using a T-test. In 20 of these cases, levels of substrate 
utilization for succinic acid, D-galactose, L-aspartic acid, L-proline, D-alanine, glycerol, 
D,L-α-glycerol-phosphate, L-lactic acid, glucose-6-phosphate, D,L-malic acid, α-D-
glucose, uridine,glucose-1-phosphate, fructose-6-phosphate, β-methyl-D-glucoside, 
maltotriose, glycyl-L-aspartic acid, fumaric acid, N-acetyl-β-D-mannosamine and L-
malic acid were no longer significantly different (P > 0.05) when DH5α and the OI-172 
mutant were compared but, were different when DH5α and EDL933 were compared. 
This suggests that the OI-172 mutant behaved more like DH5α for these substrates than 
the parental strain EDL933.  
Significant differences (P < 0.05) in substrate utilization were found for three 
substrates.  The OI-172 deletion mutant was positive (above threshold of <0.100) for use 
of mono methyl succinate and glucuronamide but, negative (above threshold) in DH5α;  
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Table 3.14.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-135 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-135 mutant DH5α Control 
Percentage 
Difference (%) 
23 D-mannitol 0.614 0.457 25.5 
32 acetic acid 0.367 0.276 24.7 
78 L-alanyl-glycine 0.524 0.339 35.4 
*All values were significantly different (P < 0.05). 
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the opposite was seen for use of α-keto glutaric acid (Figure 3.43).  It appears that the OI-
172 deletion mutant has the ability to use mono methyl succinate and glucuronamide but, 
not α-keto glutaric acid as a carbon source. 
 A significant difference (P < 0.05) in the “level” of substrate utilization where both 
strains were positive for a substrate was also seen (Table 3.15). The OI-172 deletion 
mutant used significantly higher levels of tween 20 compared to DH5α. The percentage 
difference in utilization of tween 20 was 26.6% (Table. 3.15).  
 
3.3.8.12  Comparison of DH5α with the OI-176 deletion mutant 
Comparison of the OI-176 deletion mutant with the DH5α strain showed many of 
the same differences in substrate utilization (+ and -) and levels of substrate utilization 
seen when the parental strain EDL933 was compared with DH5α. There were 15 cases 
where differences were seen using a T-test. In eleven of these cases levels of substrate 
utilization for D-galactose, D-alanine, dulcitol, D-serine, glucose-6-phosphate, α-D-
glucose, uridine, fructose-6-phosphate, maltotriose, glycyl-L-aspartic acid and N-acetyl-
β-D-mannosamine were no longer significantly different (P > 0.05) when DH5α and the 
OI-176 mutant were compared but, were different when DH5α and EDL933 were 
compared. This suggests that the mutant behaved more like DH5α for these substrates 
than it behaved like the parental strain EDL933.  
The remaining four cases were for substrates where there were significant 
differences in either substrate utilization (+ or -) or level of substrate utilization. 
Significant differences (P < 0.05) in substrate utilization were found for three substrates.  
The OI-176 deletion mutant was positive (above threshold of <0.100) for use of  
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Figure. 3.43 Comparison of E. coli OI deletion mutant OI-172 and E. coli DH5α for the 
substrates α-keto-glutaric acid, mono methyl succinate and glucuronamide. The threshold 
value for substrate utilization was <0.100. DH5α is above the threshold value for α-keto 
glutaric acid and the OI-172 deletion mutant is above the threshold for mono methyl 
succinate and glucuronamide.  
 
Table 3.15.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-172 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE 
OI-172 
mutant  
DH5α 
Control 
Percentage 
Difference 
(%) 
29 tween 20 0.219 0.161 26.6 
*All values were significantly different (P < 0.05). 
 
 
 
 
  
 
glucuronamide but, negative (below threshold) for use of glucuronamide in DH5α 
(Figure 3.44).  It appears that the OI-176 mutant had the ability to use glucuronamide as a 
carbon source but, DH5α did not. 
Significant differences (P < 0.05) in levels of substrate utilization where both 
strains were positive for a substrate were also seen (Table 3.16). The OI-176 deletion 
mutant used significantly higher levels of D-fructose, α-keto-glutaric acid and D-malic 
acid compared to DH5α.  Percentage differences in utilization for each of these substrates 
were 20.6%, 25.5% and 33.1% respectively (Table. 3.16). 
 
3.3.9  Metabolism in O157:H7 strain Sakai and its SL deletion mutant 
The SL 72 contains ORFs coding for hypothetical proteins, tellurium resistance, 
and urease synthesis, as well as ORFs coding for transposases and adhesins, synthesis of 
membrane proteins, regulatory proteins and transcriptional regulators. The deletion 
mutant (SL-72) corresponding to the SL removed was compared to the parental strain 
Sakai. The pattern of substrate utilization (+ or -) for the SL 72 deletion mutant and the 
O157:H7 parental strain was similar in most cases; i.e., the same substrates were either 
used or not used in each of these mutant strains as well as in the parental Sakai strain.  
However, four exceptions appeared to occur for utilization of tween 20, α-keto-glutaric 
acid, L-glutamine and mono methyl succinate.  The SL 72 mutant was above the 
threshold value of <0.100 used in this study for tween 20, α-keto-glutaric acid and L-
glutamine, while the Sakai parent was below the threshold of <0.100 for these substrates. 
The opposite result was seen for mono methyl succinate where the mutant fell below the 
threshold but, Sakai was above the threshold (Figure. 3.45). This suggests that the mutant  
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Figure. 3.44 Comparison of E. coli OI deletion mutant OI-176 and E. coli DH5α for the 
substrate glucuronamide. The threshold value for substrate utilization was <0.100. The 
OI-176 mutant is above the threshold value for glucuronamide and DH5α below  the 
threshold. 
 
 
Table 3.16.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant OI-176 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE OI-176 mutant DH5α Control 
Percentage 
Difference (%) 
31 D-fructose 0.529 0.420 20.6 
42 
α-keto-glutaric 
acid 0.473 0.353 25.5 
83 D-malic acid 0.491 0.328 33.1 
*All values were significantly different (P < 0.05). 
 
  
 
0.000
0.050
0.100
0.150
0.200
0.250
0.300
0.350
0.400
0.450
Substrates
P
M
 
P
l
a
t
e
 
A
b
s
o
r
b
a
n
c
e
 
V
a
l
u
e
SAKAI CONTROL
S-LOOP 72 MUTANT
DH5α CONTROL
SAKAI CONTROL 0.056 0.021 0.084 0.109
S-LOOP 72 MUTANT 0.192 0.132 0.240 0.086
DH5α CONTROL 0.161 0.353 0.388 0.054
tween 20
α-keto-
glutaric acid L-glutamine
mono methyl 
succinate
 
Figure.3.45. Comparison of E. coli O157:H7 parental strain Sakai, the SL 72 deletion mutant and the E. coli K-12 reference strain 
DH5α for the Substrates tween 20, α-keto-glutaric acid, L-glutamine and mono methyl succinate. The threshold value for substrate 
utilization was <0.100. The absorbance mean + S.E. for each substrate is shown. Mean values for substrate utilization also are 
identified at the bottom of the figure. The only significant difference in substrate utilization is for L-glutamine. 
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had gained the ability to use tween 20, α-keto-glutaric acid and L-glutamine and lost the 
ability to use mono methyl succinate as carbon sources compared to Sakai.  Further, 
analysis of these differences using a T-test showed that the differences in substrate 
utilization for tween 20, α-keto-glutaric acid and mono methyl succinate between the S- 
Loop 72 mutant and the Sakai control were not significant (P > 0.05). This suggests that 
the mutant did not gain or lose the ability to use these substrates as carbon sources. In the 
case of L-glutamine, the SL 72 mutant did use significantly higher (P < 0.05) levels of L-
glutamine than Sakai suggesting that the SL 72 mutant did gain the ability to use L-
glutamine as a carbon source. 
Significant differences (P < 0.05) in levels of substrate utilization also were seen 
between the SL 72 mutant and the Sakai parent strain (Figure. 3.46).  The SL 72 mutant 
utilized significantly higher levels of 11 of the 12 substrates; i.e., L-arabinose, N-acetyl-
D-glucosamine, L-proline, D-mannose, glucose-6-phosphate, α-D-glucose,  
maltose, 2-deoxy adenosine, glycyl-L-aspartic acid, fumaric acid and glycyl-L-proline 
and decreased levels of L-alanine compared to the Sakai parental control (P < 0.05).  
Percentage differences in utilization for each of these substrates were 34.7%, 37.5%, 
25.4%, 29.3%, 16.0%, 38.4%, 12.8%, 18.6%, 19.5%, 28.9%, 43.5% and 7.8% 
respectively.  
In summary, the only significant difference in substrate utilization was for the 
substrate L-glutamine.  The SL 72 deletion mutant was above the threshold value for L-
glutamine and the parental strain Sakai was below the threshold for this substrate.  The 
use of L-glutamine suggests that this island could have a role in metabolism, most likely 
in regulating metabolism. Also the differences seen in level of substrate utilization where  
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Figure.3.46. Differences in levels of substrate utilization for the E. coli O157:H7 parental strain Sakai and the SL 72 deletion mutant.  
All values were significantly different (P < 0.05). The absorbance mean + S.E. for each substrate is shown. Mean values for substrate 
utilization also are identified at the bottom of the figure.
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in almost all the cases the deletion mutant had a higher level of substrate utilization 
compared to the parental strain Sakai also suggests that this island has a role in  
regulation/suppression of various processes such as sugar degradation. 
 
3.3.10 Metabolism in E. coli DH5α and the O157:H7 SL 72 deletion mutant 
Comparison of the SL 72 deletion mutant and the DH5α strain resulted in several of 
the same differences seen when the Sakai parent and DH5α strains were compared. There 
were 28 cases where differences were seen between the two comparisons using a T-test. 
In five cases use of tween 20, tween 40, α-keto-glutaric acid, β-methyl-D-glucoside and 
maltotriose was not significantly different (P > 0.05) in DH5α as compared to the SL 72 
mutant but, was different when substrate levels in DH5α and Sakai were compared. This 
suggests that the SL 72 mutant behaved more like DH5α for these substrates than like the 
parental strain Sakai. The remaining 23 substrates looked at exhibited significant 
differences in either substrate utilization (+ or -) or level of substrate utilization. 
Significant differences (P < 0.05) in substrate utilization were found for the two 
substrates, dulcitol and glucuronamide. The SL 72 deletion mutant was positive (above 
threshold of <0.100) for use of dulcitol and glucuronamide but, negative (above 
threshold) for dulcitol and glucuronamide in DH5α (Figure 3.47).  It appears that the SL 
72 deletion mutant had the ability to use dulcitol and glucuronamide as a carbon source.  
Significant differences (P < 0.05) in levels of substrate utilization where both 
strains were positive for a substrate were also seen (Table 3.17). The SL 72 deletion 
mutant used significantly higher levels L-arabinose, D-galactose, L-aspartic acid, L-
proline, D-mannose, D-xylose, D-mannitol, glucose-6-phosphate, D, L-malic acid, D-  
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Figure. 3.47 Comparison of E. coli O157:H7 SL 72 deletion mutant and E. coli DH5α for 
the substrates dulcitol and glucuronamide. The threshold value for substrate utilization 
was <0.100. The SL 72 deletion mutant is above the threshold value for dulcitol and 
glucuronamide and DH5α is below the threshold for these substrates. 
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Table 3.17.  Percentage difference* in levels of substrate utilization for the O157:H7 
deletion mutant SL 72 and the E. coli DH5α strain. 
 
# of 
Substrate SOURCE SL 72 mutant   DH5α Control 
Percentage 
Difference (%) 
2 L-arabinose 0.522 0.289 44.7 
6 D-galactose 0.523 0.297 43.2 
7 L-aspartic acid 0.616 0.412 33.2 
8 L-proline 0.577 0.265 54.1 
11 D-mannose 0.612 0.350 42.7 
20 D-xylose 0.642 0.303 52.8 
23 D-mannitol 0.635 0.457 28.0 
25 glucose-6-phosphate 0.896 0.607 32.2 
27 D,L-malic acid 0.583 0.382 34.4 
31 D-fructose 0.647 0.420 35.0 
33 α-D-glucose 0.567 0.290 48.9 
35 D-melibiose 0.688 0.405 41.2 
48 Uridine 0.706 0.527 25.4 
51 glucose-1-phosphate 0.823 0.545 33.8 
52 fructose-6-phosphate 0.786 0.615 21.7 
61 glycyl-L-aspartic acid 0.572 0.415 27.5 
68 mucic acid 0.655 0.420 35.9 
75 L-serine 0.573 0.373 34.9 
80 N-acetyl-β-D-mannosamine 0.363 0.242 33.4 
93 L-galactonic acid-γ-lactone 0.581 0.221 61.9 
94 D-galacturonic acid 0.750 0.582 22.4 
*All values were significantly different (P < 0.05). 
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fructose, α-D-glucose, melibiose, uridine, glucose-1-phosphate, fructose-6-phosphate, 
glycyl-L-aspartic acid, mucic acid, L-serine, N-acetyl-β-D-mannosamine, L-galactonic 
acid-γ-lactone and D-galacturonic acid compared to DH5α. Percentage differences in 
utilization for each of these substrates were 44.7%, 43.2%, 33.2%, 54.1%, 42.7%, 52.8%, 
28.0%, 32.2%, 34.4%, 35.0%, 48.9%, 41.2%, 25.4%, 33.8% 21.7%, 27.5%, 35.9%, 
34.9%, 33.4%, 61.9% and 22.4% respectively (Table. 3.17). 
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3.4 Discussion 
 
Identification of microorganisms traditionally has been done by assessment of the 
phenotypic properties of species, in particular for their ability to grow on selective media 
containing nutrients needed for growth.  Broad scale phenotypic profiling of bacteria 
allows refinement of this approach so that even sub-groups of a species can be indentified 
based upon groups of nutrients utilized; i.e., identification of their metabolic profile 
(Bochner et al. 2008; Bochner 2009).  The metabolic profile of a bacteria is determined 
by the DNA that bacteria possesses and that in turn is influenced by the environment that 
bacteria is isolated from and the selective pressures that bacteria has encountered (Lang, 
2005).  Research looking at metabolic profiles from different bacteria has shown that 
most individuals within a species utilize a narrow group of core substrates specific to the 
species which can allow for differentiation between strains of a species or between 
mutants of a specific strain (Funchain et al. 2000; Tracy et al. 2002; Lang 2005). These 
differences in species or between strains of the same species could be niche specific or 
due to selective pressures that species has encountered (Lang , 2005).  
Core substrates utilized by E. coli K-12 MG1655 for PM plate #1 (PM1) have 
been identified (www.biolog.com). The PM1 plate contains 95 substrates and MG1655 
utilizes 65 (68.4%) of the substrates. In this thesis study, the E. coli strains used 84.8% + 
3.0% of the same substrates as MG1655 (Table 3.18).  In a different study by Cooper and 
Lenski (2000), they compared a strain of E. coli B to 12 populations generated from this 
original strain using Biolog ES plates after specific generation numbers were reached 
(2,000, 10,000 and 20,000).  They looked at differences in catabolic function of 64 
informative substrates and found that after 10,000 generations there was a decay in the  
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Table 3.18. The percentage of substrates on the PM1 plate utilized by each of the E. coli 
strains (13 O157:H7 deletion mutants and 3 controls O157:H7 EDL933 and Sakai and  
K-12 DH5α) in this study in comparison to the 65 core substrates utilized on the PM1 
plate by the E. coli strain MG1655. 
 
STRAINS 
Percentage Substrate Utilization for Core 
Substrates on PM1 Compared to MG1655 
DH5α 87.7% (57)* 
EDL933 84.6% (55) 
 SAKAI 83.1% (54) 
OI-39 84.6% (55) 
OI-51 84.6% (55) 
OI-55 84.6% (55) 
OI-59 84.6% (55) 
OI-87 84.6% (55) 
OI-89 84.6% (55) 
OI-98 87.7% (57) 
OI-102 86.2% (56) 
OI-108 84.6% (55) 
OI-135 84.6% (55) 
OI-172 81.5% (53) 
OI-176 86.2% (56) 
SL 72 83.1% (54) 
*note: The number in brackets is the number of substrates out of the possible 65 
core substrates utilized by MG1655 that each of the strains in this study utilized 
which was used to calculate the percentage of substrate utilization by the strains 
in comparison to MG1655. 
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ability to use 16 of the 64 informative substrates in the 12 populations in comparison to 
the ancestral strain (E. coli B).  Tracy et al. (2002) used PM1 and PM3 plates to compare 
21 archival strains of Salmonella typhimurium to nine non-archival S. typhimurium 
strains including strain 2004 that was sequenced.  The strain 2004 utilized 86 of the 95 
substrates of the PM1 plate and the archival strains were found to have differences in 
utilization for some of these specific 86 substrates; e.g., sucrose was found to be utilized 
by only five archival strains and α-D-lactose was only utilized by 6 archival strains. 
These studies show the same type of results as my findings since in both cases there are 
differences in substrate utilization between either populations generated from an ancestral 
strain or between strains compared to an ancestral strain of the same species.   
Glycolysis is a metabolic pathway known to be active in enteric bacteria such as 
E. coli (Lodish et al. 2000) and is thought to be involved in colonization of the intestine 
of animals by these bacteria (Miranda et al. 2004).  In my thesis, three substrates and the 
product of the glycolytic pathway were examined for their ability to be used by both a 
laboratory control, E. coli DH5α as well as by clinical isolates and deletion mutants of the 
human pathogen E. coli O157:H7: i.e., utilization of glucose-6-phosphate, α-D-glucose, 
fructose-6-phosphate and pyruvic acid were examined.  All four of these substrates were 
used by each of the O157:H7 mutants, the O157:H7 controls and the E. coli K-12 
reference strain DH5α (Figure. 3.5, results). 
Verification of this well known substrate utilization pattern with the BiologTM 
system was important because it validates the approach used in this study; e.g., 
differences in substrate utilization in the O157:H7 deletion mutants and controls were 
compared. 
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Additional research into substrate utilization in bacteria suggests that in addition 
to core substrates, bacterial isolates from unique environments are likely to use a 
specialized group of substrates highly specific to the environment that they have been 
isolated from (Bochner 1989). Most E. coli O157:H7 are sorbitol negative after 24 h, 
dulcitol positive, Β-glucuronidase negative, and raffinose positive (Ratnam et al. 1988).  
In this study all the O157:H7 mutants (OI and SL) and both controls, EDL933 and Sakai 
were tested for two of the biochemical characteristics, sorbitol and dulcitol. All of the 
O157:H7 mutants and both of the O157:H7 controls were sorbitol negative (Figure. 3.3, 
results) and dulcitol positive (Figure. 3.2, results) confirming the identified characteristics 
of O157:H7. The E. coli DH5α reference strain had the opposite substrate utilization 
pattern compared to the O157:H7 strains (sorbitol positive and dulcitol negative). 
 
3.4.1 Comparison of the substrate utilization in laboratory and clinical isolates of 
E. coli DH5α and E. coli O157:H7 strains EDL933 and Sakai. 
 
 Overall substrate utilization in E. coli O157:H7 strain EDL933, Sakai and in E. 
coli K-12 DH5α was similar.  There were only 15 cases where differences in substrate 
utilization occurred in EDL933 and DH5α (Figure. 3.6 and 3.7, results) and only 18 cases 
in Sakai and DH5α (Figure. 3.8 and 3.9, results).  However, there were 68 cases where 
substrate utilization was significantly increased or decreased relative to the controls, 
suggesting that despite using similar substrates, how these three strains utilize these 
substrates was different (Table 3.1 and 3.2, results).  In cases where differences in 
substrate utilization occurred, three are well recognized; i.e., D-sorbitol, sucrose and D-
serine.  When use of the sugar alcohol, sorbitol was looked at in E. coli O157:H7, the 
bacteria were not able to utilize it (Ratnam et al. 1988).  However, the majority of other 
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E. coli isolates including K-12 are able to use sorbitol (Mukherjee et al. 2006).  The PM 
results for sorbitol confirm this, since E. coli O157:H7 strain EDL933 and Sakai were 
both negative (below the threshold value) for use of D-sorbitol while E. coli DH5α was 
positive (above the threshold value). 
Use of sucrose and D-serine is also important since ability of E. coli to use these 
substrates is thought to be environment based (Moritz and Welch 2006).  It is speculated 
that because hosts of intestinal pathogens such as O157:H7 have a diet rich in sugars such 
as sucrose, these pathogens have evolved to use sucrose, but appear to have lost the 
ability to use other nutrients such as serine.  Mukherjee et al. (2006) studied expression 
of these two phenotypes in the O157:H7 strain EDL933 and in E. coli K-12; they found 
that EDL933 was unable to use serine as a carbon source while E. coli K-12 could and 
the reverse was seen for sucrose.  In the thesis, results for both of these substrates and the 
parental strains reflect these findings; i.e., both EDL933 and Sakai were positive for 
sucrose utilization but, negative for serine utilization while the DH5α control was 
negative for sucrose utilization and positive for use of serine.  These results follow the 
predicted outcomes and also support the theory that intestinal pathogens have evolved to 
use sucrose but, have lost the ability to use serine since both strains can use sucrose as a 
carbon source but not serine. Durso et al. (2004) compared commensal strains of E. coli 
and various strains of E. coli O157:H7 for carbon source utilization.  They found 
differences in utilization between commensal strains and O157:H7. For example, E. coli 
O157:H7 were more likely to use dulcitol, and sucrose than the commensal strains. These 
results also support my results since it was previously shown that my O157:H7 strains 
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were positive for both dulcitol and sucrose and DH5α was shown to be negative for these 
substrates. 
The laboratory control, DH5α and the clinical isolates for both EDL933 and Sakai 
also showed significant differences in levels of substrate utilization supporting the 
hypothesis that environmental differences between commensal strains and pathogenic 
bacteria of the same species will result in selection for phenotypic differences among the 
bacteria that will facilitate their survival within a specific niche. Fabich et al. (2008) 
studied substrate utilization in EDL933 and E. coli K-12 and found that there was a 
difference in sugar affinity between these two strains when they colonized the mouse 
intestine. EDL933 used three sugars that were not used in E. coli strain MG1655. They 
speculated that these differences allow the O157:H7 pathogen EDL933 to colonize the 
intestine in the presence of other commensal bacteria. Of the six sugars that EDL933 
used for colonization based on the assays performed by Fabich et al. (2008) five were 
tested in this study; i.e., arabinose, fucose, galactose, mannose and ribose. Two of above 
mentioned sugars, arabinose and fucose,  E. coli K-12 also uses for colonization.  When 
DH5α and EDL933 were compared in this study, the EDL933 strain used significantly 
higher levels of each of these five sugars (Table 3.1, results). When DH5α and Sakai 
were compared, Sakai was also positive for each of the five sugars but, only showed a 
significant difference in level of utilization for two of the sugars, fucose and ribose 
(Table 3.2, results). The percentage difference between EDL933 and DH5α for arabinose 
and fucose was 37.4% and 47.1% respectively, suggesting that EDL933 would 
outcompete K-12 for use of both these sugars when placed in the same environment due 
to a higher utilization rate for these sugars than DH5α.  Sakai also had a higher level of 
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utilization for fucose than DH5α with a percentage difference of 37.2%.  These results 
also support the theory put forth by Fabich et al. (2008) which suggests that invading 
pathogens such as O157:H7 adopt a “slash and burn” approach to colonization where 
maximum growth is achieved by being inflexible and greedy; i.e., both EDL933 and 
Sakai showed increased levels of utilization for certain sugars relative to the laboratory 
strain DH5α.  This was especially true for the O157:H7 strain EDL933. 
 
3.4.2 Comparison of substrate utilization patterns in different clinical isolates of E. 
coli O157:H7 
 
Substrate utilization in the different clinical isolates of E. coli O157:H7, strains 
EDL933 and Sakai was qualitatively similar.  The only difference in substrate utilization 
between the two strains was for L-glutamine (Figure. 3.10, results); i.e., the EDL933 
strain was positive (above threshold) while Sakai was negative (below threshold). 
However, there were 12 cases where significant differences in the quantitative level of 
substrate utilization were observed (Table 3.3, results). 
The PM system is able to distinguish between two strains of the same serotype by 
finding singular differences in profiles. Mukherjee et al. (2008) also identified some 
variation in substrate utilization in different strains of E. coli O157:H7; i.e., clinical 
isolates that were N-acetyl-D-galactosamine (Aga) negative from a spinach outbreak.  
The majority of O157:H7’s are Aga positive and in the reference collection of 120 strains 
tested only 2 were Aga negative but all the isolates tested from the spinach outbreak were 
Aga negative, a rare phenotype in O157:H7.  The PM system allowed for characterization 
and identification of this group isolated from the outbreak.   
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Comparison of the clinical strains also identified cases where there were 
significant differences in level of utilization of 12 substrates.  In each case, the EDL933 
strain had a higher level of utilization than Sakai.  Three cases where EDL933 had a 
higher utilization were for sucrose, L-arabinose and α-D-glucose. The ability to use 
sucrose is thought to be an acquired trait due to selection pressures of the hosts of these 
bacteria that have sugar rich diets (Moritz and Welch 2006).  Moritz and Welch (2006) 
found that the O157:H7 strain EDL933 was an avid sucrose fermentor compared to other 
O157:H7’s. L-arabinose and α-D-glucose were shown to be important in colonization 
studies of the intestine, where L-arabinose was shown to be important in colonizing 
mouse intestine for both EDL933 and K-12 (Fabich et al. 2008); it was also shown that 
glycolysis is an important pathway involved in colonization, and α-D-glucose is one of 
the substrates utilized in this pathway (Miranda et al. 2004). The percentage difference 
for these substrates, sucrose, L-arabinose and α-D-glucose was 40.4%, 26.0% and 19.7% 
respectively. These increases in levels of substrate utilization could confer an advantage 
to EDL933 and in theory allow the pathogen to reach maximum growth by being more 
inflexible and greedy; then EDL933 should outcompete Sakai despite both having the 
same serotype and could possibly be a better pathogen than Sakai.  Lim et al. (2010) 
compared 3 wild type strains of E. coli O157:H7 as part of their study looking at the 
effect of the removal of the plasmid O157.  They found that there was a difference in 
substrate utilization for 3 carbon substrates when comparing the 3 wild type O157:H7 
strains. Their study showed that O157:H7 strain Sakai grew 3-fold more than the negative 
control for α-keto-butyric acid, α-hydroxy-butyric acid and L-galactonic acid-g-lactone 
while the O157:H7 strain WSU180 grew 2-fold more and the O157:H7 strain 43894 only 
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grew 1-fold more thnn the negative control.  This showed that these 3 wildtype strains 
had differences in level of substrate utilization for the above mentioned 3 substrates. 
Their results support the results seen in my thesis since in their study they also found 
differences in level of substrate utilization between O157:H7 strains. Further studies 
looking at competition between EDL933 and Sakai should be undertaken to elucidate 
other differences between these two strains and other strains of E. coli O157:H7. 
 
3.4.3 Comparison of substrate utilization patterns in E. coli O157:H7 strains 
EDL933 and Sakai with their respective OI and SL deletion mutants for loss 
or gains in substrate utilization. 
 
The majority of the OI deletion mutants (OI-39, 51,55,59,89, 108, 135 and 176) 
did not have any gain or loss of function in substrate utilization compared to the EDL933 
parental control. Lim et al. (2010) created O157:H7 mutants missing the pO157 plasmid.  
In their study they did not find any differences in carbon source utilization using the PM 
plates between the mutants and the parental strains.  They did find differences using 
different PM plates. This suggests that looking at these mutants with other PM plates may 
elucidate possible roles for these mutants. The remaining mutants OI-87, 98, 102 and 172 
OI deletion mutants and the SL 72 deletion mutant did have a gain or loss of function 
compared to the parental strains EDL933 (OI) or Sakai (SL). 
The OI-87 deletion mutant gained the ability to use tween 40 as a substrate 
(Figureure 3.11, results).  Tween 40 a detergent, is also known as polysorbate 40 and is a 
substrate that is known to be a solubilizing agent for membranes and is used in protein 
chemistry to stabilize proteins (Ayorinde et al. 2000; Yao et al. 2009). Looking at Table 
8.1 (Appendix I), the OI-87 mutant has two ORFs of unknown function; these results do 
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not specifically clarify the role of this island but suggest areas for further study.  This 
gain in function for utilization of tween 40 suggests that the island could have proteins 
involved in maintaining membrane integrity or have a role in regulating physical 
properties of the membrane.  Further tests looking at membrane integrity or examining 
proteins in the membrane should be undertaken to see if this gain in substrate utilization 
has an effect on these systems. 
The OI-98 deletion mutant gained the ability to use L-glutamic acid as a substrate 
(Figure. 3.24, results). L-glutamic acid is one of 20 amino acids (Newsholme et al. 2003).  
In mammals, such as humans, L-glutamic acid has been shown to have a role in the 
intestine maintaining gut integrity and promoting cell function (Reeds et al. 2000; 
Newsholme et al. 2003).  Looking at Table 8.1 (Appendix I), OI-98 has one ORF of 
unknown function; gain in substrate utilization suggests that the OI-98 mutant could have 
a role in regulation of L-glutamic acid since the mutant gained the ability to use this 
substrate as a carbon source.  It also suggests that because L-glutamic acid has a role in 
the intestine of mammals this gain in ability could affect colonization of this mutant and 
could potentially make it a better pathogen since it adds a carbon source source for this 
pathogen in the intestine.  Further studies looking at colonization of this pathogen may 
elucidate further roles for this specific OI. 
The OI-102 deletion mutant gained the ability to use D-serine and D-threonine as 
carbon sources but lost the ability to use sucrose as a carbon source (Figure 3.26, results). 
The ability of O157:H7’s to use sucrose as a carbon source and not D-serine has been 
shown by other research groups (Moritz and Welsh 2006; Murkherjee et al. 2006).  The 
OI-102 mutant has the opposite phenotype; it is sucrose negative and D-serine positive.  
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Looking at Table 8.1 (Appendix I), it is seen that the OI-102 mutant contains ORFs 
relating to prophages, ORFs of unknown function, a resolvase, a sucrose permease, a 
fructokinase, a sucrose hydrolase and a sucrose specific transcriptional regulator.   Since 
this OI contains ORFs related to sucrose metabolism the loss in ability to use sucrose by 
this mutant is not unexpected.  The ability to use sucrose as a carbon source is thought to 
be environment based and is an ability that has evolved in O157:H7’s due to the sucrose 
rich diets of their hosts (Moritz and Welsh 2006). Moritz and Welsh (2006) also theorize 
that the ability to use serine could be under a strong state of catabolite repression. The 
results lend support to that theory since by losing the ability to use sucrose the mutant 
gained the ability to use serine which suggests that the ability to use serine is under 
repression by the sucrose genes in O157:H7’s, in other words OI-102 appears to regulate 
the use of D-serine and removal of this regulation allows for utilization of this substrate 
by the deletion mutant. The mutant also gained the ability to use D-threonine as a carbon 
source, a polar amino acid similar to serine (Sawers 1998). This gain in ability could also 
be due to suppression of this gene by this OI. Threonine is degraded by threonine 
dehydratase an enzyme that has the ability to degrade threonine and serine (Sawers 
1998).  This enzyme is coded for by the tdc operon which has been shown to be under 
catabolite repression by glucose and pyruvate.  This suggests that this OI could involved 
in regulating this operon and removal of this OI removes the suppression and the deletion 
mutant gained the ability to use threonine and serine.  Further tests looking at the ORFs 
of unknown function could elucidate a role for these ORFs in regulation of serine and 
threonine metabolism. 
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The OI-172 deletion mutant gained the ability to use tween 20, M-tartaric acid 
and lost the ability to use α-ketobutyric acid and α-hydroxybutyric acid (Figure 3.28, 
results). Tween 20 is a surfactant that is known to be a solubilizing agent for membranes 
and is used in protein chemistry to stabilize proteins (Ayorinde et al. 2000; Yao et al. 
2009), suggesting that this OI could have proteins involved in membrane integrity or 
have other roles involving the membrane. M-tartaric acid is an isomer of tartaric acid 
(Alfredsson et al. 1972).  α-Keto-butyric acid is a substrate that can be converted to 
propionyl-CoA (Sawers 1998) and through subsequent conversions can be converted to 
succinyl-CoA an intermediate in the citric acid cycle (Haller et al. 2000). This suggests 
that the citric acid cycle could be affected by removing a substrate that can eventually be 
converted to a substrate used in this cycle.  α-Hydroxy butyric acid is a derivative of 
butyric acid (Smith and Strang 1958) and butyric acid is one of the principal organic 
acids present in the intestine (Herold et al, 2009).  Herold et al. (2009) studied the 
expression of iha, an adhesin present in O157:H7 strains and it was shown that the 
addition of short chain fatty acids such as butyric acid to growth medium strongly 
induced expression of this adhesin in O157:H7 strain EDL933. This suggests that 
removal of this island could impact colonization of this bacterium in the intestine. 
Looking at Table 8.1 (Appendix I)), the OI 172 contains many ORFs of unknown 
function and a few ORFs thought to be enzymes. Further tests looking at membrane 
integrity, at the citric acid cycle and/or growth in the intestine should be undertaken to 
fully determine the role of these ORFs in E. coli O157:H7. 
The SL 72 deletion mutant gained the ability to use L-glutamine as a carbon 
source (Figure. 3.45, results). L-glutamine is one of the twenty amino acids and has been 
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shown to have a role in the intestine in mammals (Reeds et al. 2000; Newsholme et al. 
2003). Interestingly this is also the same difference in substrate utilization pattern seen 
when comparing the two O157:H7 strains EDL933 and Sakai where EDL933 can also 
use L-glutamine as a carbon source (Figure. 3.10, results). This suggests that the ability to 
use L-glutamine could be regulated or repressed by the SL 72 in Sakai but not in the 
corresponding OI in EDL933 since EDL933 and each of the OI mutants can use L-
glutamine as a carbon source. Looking at Table 8.1 (Appendix I), it is seen that the SL 72 
has many ORFs of unknown function; e.g., ORFs relating to transposons, tellurium 
resistance, membrane proteins, urease proteins, adhesive proteins and a transcriptional 
regulator to name a few. These unknown ORFs, membrane proteins or the transcriptional 
regulator could possibly explain the gain in ability to use L-glutamine when the SL is 
removed from Sakai. Further tests would need to be undertaken to fully characterize all 
of the roles SL 72 has in Sakai. 
The PM system has been used successfully to study mutant phenotypes. Erol et al. 
(2006) created an H-NS mutant of E. coli O157:H7; H-NS is a protein that plays a role in 
condensation of chromosomal DNA and therefore can influence the expression of many 
genes.  It is an important regulator of virulence in several pathogens. They used PM 
plates and found that the H-NS mutant was not able to utilize 42 carbon and 19 nitrogen 
substrates that the wild type parental O157:H7 metabolized. This was a quick and straight 
forward way to study this mutant and showed the protein’s importance.  Another study by 
Quan et al. (2002) compared a Salmonella cysB mutant and an E. coli cysB mutant to 
their respective wild types and to each other. Despite having the same role in each species 
it was found that while for the most part the mutants behaved the same, there were 
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exceptions such as D-glucuronate where the Salmonella CysB mutant showed a decrease 
in function compared to the wild type while in the case of E. coli no decrease was 
observed between wild type and mutant. My results show the same type of results since 
for 5 of the mutants, we were able to find differences in substrate utilization that provide 
insight into the roles of these specific OIs but do not fully elucidate the complete role of 
the islands and SL. Tohsato and Mori (2008) used the PM system to analyze 45 deletion 
mutants with deletions in glycolysis, TCA cycle and pentose phosphate pathway and 
compared their mutants to the wild type parent E. coli K12 strain BW25113.  They found 
that there were 3 clusters (C1, C2 and C3) of mutants surrounding the pathways. i.e., C1 
was located at the beginning of glycolysis, while C2 and C3 represented mutants with up 
and down regulation in respiration due to their mutation.  Overall they found that their 
study did not elucidate roles for genes of uncertain function and further studies were 
needed.  This is also similar to the results of my thesis data since further studies are 
needed to fully elucidate the roles of the OIs and the SL studied because only 5 mutants 
had gains and losses of function and the role of these OIs and SL were not completely 
clear despite the changes in PM profile.  
 
3.4.4 Comparison of substrate utilization patterns in E. coli O157:H7 strains 
EDL933 and Sakai with their respective OI and SL deletion mutants for 
significant differences in level of substrate utilization 
 
 All of the mutants except for OI-135 had significant differences in the 
level of substrate utilization observed compared to the parental O157:H7 strains. Most of 
the mutants had differences in the level of utilization for substrates that are known to 
have an important role in the bacterium or that had differences common only to a few of 
the mutants (Table 3.19).  The OI-39, 55, 102, 172 and 176 and the SL 72 deletion 
  
 
Table 3.19.  Comparison of the O157:H7 parental strain EDL933 and its OI deletion mutants and O157:H7 parental and its SL mutant 
for significant differences in level of substrate utilization for substrates that have an important role in the bacterium. 
 
 E. coli OI and SL deletion mutants 
Substrates OI-39 OI-51 OI-55 OI-59 OI-87 OI-89 OI-98 OI-102 OI-108 OI-172 OI-176 SL 72 
α-D-glucose – – – – – – – – – ↑ – ↓ 
Glucose-6-phosphate – – – – – – – – – ↑ – ↓ 
Fructose-6-phosphate ↑ – ↑ – – – – – – ↑ – – 
Pyruvic acid ↑ – – – – – – ↓ – ↑ ↑ – 
L-arabinose – ↑ – – – ↑ – ↑ – ↑ – ↓ 
D-galactose – – – – – – – – – ↑ – – 
D-ribose – ↓ – – ↓ ↓ – – – ↑ – – 
Thymidine – ↓ ↓ ↑ ↓ – – – – – – – 
D-xylose – – – – – – – ↑ ↓ ↑ ↑ – 
succinnic acid – – – – – – – – ↓ ↑ – – 
L-rhamnose – – – – – – ↑ – – – – – 
Note:  – depicts substrates for which that particular mutant and the parental strain EDL933 (OI) or Sakai (SL 72) do not have a 
significant difference in level of substrate utilization. 
↑ depicts substrates for which EDL933 or Sakai has a higher level of substrate utilization compared to its deletion mutant. 
↓ depicts substrates for which EDL933 or Sakai has a lower level of substrate utilization compared to its deletion mutant. 
Note: The OI deletion mutant OI-135 was not included in this table because it was shown to not have any significant differences in 
level of substrate utilization in comparison to EDL933
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mutants have significant differences in level of substrate utilization for substrates 
involved in glycolysis. Glycolysis is a pathway known to occur in bacteria (Lodish et al. 
2000) and is thought to have a role in growth of E. coli in the intestine of animals such as 
mice (Miranda et al. 2004). Miranda et al. (2004) studied colonization of E. coli 
O157:H7 strain EDL933 and E. coli K-12 strain MG1655 in mice and found that when 
EDL933 was the sole bacterium to colonize the mice it utilized glycolytic substrates for 
growth and survival.  When in the presence of MG1655 in the intestine, EDL933 used 
glycolytic substrates for rapid growth for one day suggesting that it either out-competed 
MG1655 for the glycolytic substrates or that MG1655 used alternate substrates during 
that time period.  The results from this study show that there are differences in level of 
substrate utilization for substrates that are part of the glycolytic pathway. Two of the 
mutants OI-102 and the SL 72 had a higher utilization rate compared to EDL933 and 
Sakai suggesting that they may give the bacteria an advantage in colonization of the 
mouse intestine.  The remaining mutants OI-39, 55, 172 and 176 had a reduced rate of 
utilization compared to EDL933 suggesting they may not be as effective in colonizing the 
mouse intestine.   
 The OI-51, 87, 89, 102 and 172 and the SL 72 have differences in level of 
substrate utilization for one or more of the following, L-arabinose, D-galactose and D-
ribose.  These sugars have also been shown to have a role in growth of O157:H7 strain 
EDL933 in the intestine (Fabich et al, 2008). Two of the above mentioned sugars D- 
galactose and D-ribose have been shown by Fabich et al. (2008) to be used exclusively 
by EDL933 compared to E. coli K-12 MG1655. The OI-51, 89, 102 and 172 deletion 
mutants have a reduced level of utilization for one or more of these sugars, suggesting 
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that they may not be as effective in colonizing or maintaining growth in the intestine 
compared to EDL933.  The OI-51, 87, 89 and the SL72 deletion mutants have an 
increased level of utilization for these sugars suggesting that they could have an 
advantage in colonization or maintenance of growth levels in the intestine compared to 
EDL933 (OI deletion mutants) or Sakai (SL deletion mutant).  Two of the mutants OI-51 
and 59 have increases and decreases in substrate utilization depending on the sugar 
suggesting that these mutants may have defects affecting only colonization or 
maintenance of growth levels in the intestine.  
 Four of the mutants OI-51, 55, 59 and 87 had a different level of substrate 
utilization for thymidine in comparison to EDL933.  Thymidine is a DNA nucleoside and 
is needed/used in DNA replication (Moran et al. 1997).  The OI-59 mutant had an 
increased level of utilization while the other 3 mutants exhibited a decrease in level of 
utilization. The change in substrate utilization level for thymidine could have an impact 
on processes such as DNA replication. 
 The OI-102, 108, 172 and 176 deletion mutants exhibited differences in level of 
substrate utilization for D-xylose. D-xylose is a sugar that can be used by E. coli as a 
carbon source (Hernandez-Montalvo et al. 2001; Watanabe et al. 2008). Hernandez-
Montalvo et al. (2001) studied sugar consumption of glucose, arabinose and xylose for a 
mutant strain of E. coli and compared it to the parental strain. Overall they found that the 
parental strain’s metabolism of arabinose and xylose was repressed by the presence of 
glucose and that in a mixed sugar medium glucose was metabolized first, followed by 
arabinose and then xylose.  Three of the deletion mutants OI-102, 172 and 176 showed a 
decrease in xylose utilization compared to EDL933 suggesting that xylose metabolism 
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could be upregulated by these OIs. The OI-108 mutant exhibited higher utilization for D-
xylose which could suggest a possible loss of repression for this substrate by removal of 
this OI.  Studies of sugar mixtures with these mutants should be undertaken to see if 
repression of D-xylose is affected by glucose for these islands; since the Biolog system 
only tests one substrate at a time, we cannot determine if repression by glucose is affected 
in these mutants. 
 The OI-108 and 172 deletion mutants also saw effects on the level of substrate 
utilization for succinic acid. Succinic acid is a substrate that has a role in the citric acid 
cycle (Lodish et al. 2000).  The OI-108 exhibited increased utilization for this substrate 
while the OI-172 mutant exhibited decreased utilization for succinic acid. The decrease in 
utilization in OI-172 could be due to the loss of function of α-keto butyric acid, which has 
been shown to have a role in the citric acid cycle. Further tests looking at the citric acid 
cycle for these mutants could elucidate roles for these OIs that could show a role in 
regulation of this process. The OI-98 mutant only exhibited one difference in substrate 
utilization in comparison to EDL933. The OI-98 mutant had a decrease in utilization for 
L-rhamnose. L-Rhamnose is a sugar that can be metabolized into dihydroxyacetone 
phosphate which can be metabolized in glycolysis (Wegerer et al. 2008). This suggests 
that under specific conditions the glycolysis pathway could be affected by the decrease in 
substrate utilization by this OI.  
The PM method has previously been shown to be able to find differences in how 
substrates are utilized between mutants and parental strains. Koo et al. (2004) compared a 
mutant E. coli K12 strain BM101 to the parental K12 strain MG1655 and found that there 
were no differences in substrate utilization between the two strains. However, they found 
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that the mutant showed faster color development than the parental strain. This supports 
my results since the majority of the OI deletion mutants did not show any differences in 
substrate utilization but did exhibit differences in level of utilization for substrates that 
are important in this bacterium. All of the mutants except for the OI-135 deletion mutant 
exhibited differences in level of substrate utilization which is similar to the outcome seen 
in the study done by Koo et al. (2004).  
 
3.4.5 Comparison of substrate utilization patterns in E. coli O157:H7 deletion 
mutants with the E. coli K-12 reference strain DH5α for significant 
differences in level of substrate utilization 
 
All of the deletion mutants showed similarities and differences in level of 
substrate utilization relative to the E. coli K-12 reference strain DH5α (Table 3.20).  
However, the OI-39, 108 and 135 deletion mutants did not show a significant difference 
in substrate utilization relative to DH5α (compared to EDL933 and DH5α) for substrates  
involved in glycolysis, a pathway thought to have a role in colonization of the mouse 
intestine (Miranda et al. 2004).  Glycolysis has been shown to have a crucial role in 
colonization of the mouse intestine in E. coli K-12 MG1655 (Chang et al. 2004).   
 The OI-51, 55, 59, 87, 89, 172 and 176 deletion mutants did not show a 
significant difference in substrate utilization for substrates involved in glycolysis and 
other sugars shown to be important in colonization of the mouse intestine (Miranda et al. 
2004; Fabich et al. 2008).  The OI-172 mutant and the SL 72 mutant also behaved like 
DH5α for succinic acid (OI-172) and α-keto glutaric acid (SL 72), substrates with roles in 
the citric acid cycle (Lodish et al. 2000). These mutants appeared to behave like the E. 
coli K-12 reference strain DH5α for these substrates.  
  
 
Table 3.20.  Comparison of the E. coli K-12 DH5α and the OI and SL deletion mutants for significant differences in level of substrate 
utilization for substrates that have an important role in the bacterium. 
 
 E. coli OI and SL deletion mutants 
Substrates OI-39 OI-51 OI-55 OI-59 OI-87 OI-89 OI-98 OI-102 OI-108 OI-135 OI-172 OI-176 SL 72 
α-D-glucose – * – * – * – – – * * * – 
Glucose-6-phosphate * – – – – – – – – – * * – 
Fructose-6-phosphate * * * * * * * * * * * * – 
L-arabinose – * * * * – – – – – – – – 
D-galactose – – – – – * – – – – * * – 
succinnic acid – – – – – – * – – – * – – 
L-glutamic acid – – – – – – * – – – – – – 
D-serine – – – – – – – * – – – – – 
Sucrose – – – – – – – * – – – – – 
α-keto-glutaric acid – – – – – – – – – – – – * 
                            
# of cases no longer 
significantly different 7 5 2 3 3 7 9 8 7 6 20 7 5 
Note:  – depicts substrates for which that particular mutant and the DH5α do not have a significant difference in level of substrate 
utilization. 
* depicts a substrates for which there is no longer a significant difference in level of substrate utilization between the mutant 
and the DH5α strain. 
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Shading depicts substrates which are gains in function in the PM profile of the mutant in the EDL933 comparison that are no 
longer different in the DH5α comparison.
  
 
The OI-98 and 102 mutants also showed similarity to the DH5α strain for 
substrates involved in glycolysis and the citric acid cycle. However, these mutants also 
behaved like the reference strain DH5α for L-glutamic acid (OI-98) and D-serine and 
sucrose (OI-102). These were gains in function by the removal of the OI seen when 
comparing the mutant to EDL933; these gains in function model the E. coli K-12 
reference strain DH5α. 
These cases for each mutant where we no longer see differences in substrate 
utilization for the mutant and DH5α comparison mean that the mutant is behaving more 
like the reference strain for utilization of these substrates than the pathogenic strains 
EDL933 or Sakai.  Also each mutant was similar in substrate utilization for substrates 
known to have an important role in processes such as glycolysis. This lends support to the 
theory that removal of a PAI from a pathogen can result in bacteria that behave more like 
a reference strain. 
3.4.6  Future tests and Final conclusions 
 The PM method has a wide range of uses and can pick up on differences between 
bacteria in a quick and straight forward fashion (Potera 2006) as seen with our results. In 
our study we gathered valuable information on the effect of removal of specific OIs and 
SLs from O157:H7 but, we still lack sufficient information to make conclusive 
statements about the nature of genes on these blocks of DNA. More tests with different 
PM plates or tests targeting specific gene functions may give us insight into the roles that 
these OI’s and SLs play in E. coli O157:H7. Differences in levels of substrate utilization 
were often for substrates such as L-arabinose or fructose-6-phosphate which have been 
shown to have a role in colonization of the gut by bacteria such as E. coli (Fabich et al. 
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2008; Miranda et al. 2004).  Further tests looking at gut colonization of the OI and SL 
deletion mutants could reveal other properties of these mutants relating to pathogenesis of 
the bacteria.      
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Chapter IV 
 
Cell Growth in E. coli O157:H7 
4.1 Introduction 
EHEC forms an important class of STEC that are intestinal pathogens that have 
potential to cause severe infections such as haemolytic uremic syndrome (HUS), 
hemorrhagic colitis (HC) and can lead to complications such as seizures and even coma 
(Cleary 2004; Karch et al. 2005). One of the most important serotypes found in EHEC is 
E. coli O157:H7, as it typically associated with exceptionally virulent strains (Cleary 
2004). E. coli O157:H7 is involved in many outbreaks and is the predominant strain 
found in outbreaks in North America (Yoon and Hovde 2008). Ingestion of contaminated 
meat and unpasteurized milk represents one of the main ways that EHEC pathogens enter 
the food chain (Karch et al. 1999). Contamination of processed meat products such as 
ground beef has been responsible for various outbreaks of E. coli O157:H7 including an 
outbreak in France in 2005 (King et al. 2009) and in the state of Washington in the USA 
in 1992 and 1993 (Bell et al. 1994). In both cases the source was frozen hamburger 
patties. E. coli O157:H7 outbreaks have also occurred by contamination of fresh produce 
like lettuce, berries and bean sprouts (Sivapalasingam et al. 2004).  
Growth of E. coli O157:H7 is an important factor in its survivability and 
pathogenecity and has been studied under different conditions (Coleman et al. 2003). 
Conner and Kotrola (1995) studied growth of E. coli O157:H7 under acidic conditions at 
different temperatures. Their preliminary studies found that as temperature was increased, 
growth under acidic conditions (a lower pH) also increased. They also found that the E. 
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coli O157:H7 strains were susceptible to mandelic acid and that lactic and acetic acid did 
not seem to affect growth of the cells. Ding et al. (2010) examined growth of E. coli 
O157:H7 on beef patties that were untreated, or treated with high or low levels of acidic 
electrolyzed oxidizing water at different temperatures. The study showed that growth on 
beef patties treated with acidic electrolyzed oxidizing water or with slightly acidic 
electrolyzed oxidizing water had lower numbers of bacteria growing on the patties than 
the control (untreated patty) and it took bacteria growing on the acidic patties (treated) 
longer to arrive at the stationary phase of the curve. Ukuku et al. (2009) studied growth 
of E. coli O157:H7, Salmonella spp., and L. monocytogenes in apple cider supplemented 
with the anti-bacterial peptide, nisin plus EDTA at various temperatures. E. coli O157:H7 
was found to have a shorter lag phase in non sterile apple cider which suggests that the 
bacteria can survive and grow better in an un-sterilized environment. 
The ability to grow on various food surfaces and in varying growth conditions  is 
most likely related to bacterial virulence and the virulence genes and factors found on 
PAIs in these bacteria (Ferianc et al. 2002). PAIs are important since they add DNA to 
pathogenic bacterial genomes that, is not found in commensal strains. PAIs are 
characterized as large chunks of DNA that contain genes relating to virulence, are usually 
surrounded by insertion sequences and often contain genes related to transposases and 
integrases found on the island (Hacker et al. 1997). Identification of differences in 
growth of bacteria containing different PAIs could help clarify the contribution of PAIs 
to development of pathogenesis in bacteria. 
 142
  
 
In this study, growth curves for each of three controls (E. coli DH5α and 
O157:H7 strains Sakai and EDL933) plus 13 PAI deletion mutants grown in LB broth 
were compared. Specific objectives of the study were to: 
1) Create growth curves for each of the mutants and the three controls. 
2) To compare O157:H7 strains EDL933 and Sakai to the reference E. coli K12 
strain DH5α. 
3) To compare the OI deletion mutants and an SL deletion mutant to the reference 
E. coli K12 strain DH5α and the respective parental O157:H7 strains EDL933 or 
Sakai 
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4.2 Materials and Methods 
4.2.1. Bacteria and Cultures 
In this experiment E. coli O157:H7 strains EDL933 and Sakai were compared to 
the reference E. coli K-12 strain DH5α and to their respective E. coli O157:H7 OI and SL 
deletion mutants. The deletion mutants were also compared to the reference E. coli K-12 
strain DH5α. All bacterial strains were grown on LB agar overnight. A single colony 
from each of the following strains: 3 controls (EDL933, Sakai and DH5α) and the 13 
deletion mutants were streaked on LB Agar and grown overnight (12-16 h) at 37 ºC. This 
step was repeated twice to ensure pure colonies and to ensure the bacterial strains were in 
the same physiological state. After the final incubation a single colony from each plate 
was used to inoculate a 250 ml Erlenmeyer flask containing 25 ml of pre-warmed LB 
broth. These flasks were then incubated for 12-13 h at 37 ºC in a shaking incubator set at 
220 rpm. 
4.2.2. Preparing the cultures for the Growth curve assay and sample sampling. 
The cultures for the growth curve were made by removing 1 ml from the 
overnight cultures and adding this to a 250 ml Erlenmeyer flask containing 99 ml of pre-
warmed LB broth. This flask was then incubated at 37 ºC in a shaking incubator set at 
220 rpm. Samples were taken at time equals zero and every hour for the first two hours of 
the assay and every half an hour for the remaining 12 hours of the assay. At each time 
point a 1 ml sample was removed from the flask and inserted into a clean cuvette in order 
to obtain a spectrophotometer reading at an OD of 600 nm. As the OD reading 
approached the limits of the spectrophotometer (i.e., an OD reading of 1.000) a 1/10 
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dilution of the sample was made by removing a 100 μl sample from the flask and mixing 
it with 900μl of LB broth. A reading for the diluted sample was taken as described above. 
This process was repeated three times with three different cultures.   
4.2.3. Growth curve analysis 
All data collected was inserted into an Excel (Microsoft Office) spreadsheet.  
Growth curves were generated by plotting the OD600 data versus time. The data was 
analyzed using an SPSS statistical program (SPSS Inc, IBM, Chicago).  Curves generated 
were analyzed using a linear regression. The linear regression for the linear part of the 
growth curves for each OI and SL deletion mutant and the three controls (DH5α, EDL933 
and Sakai) was calculated using the model: Y = Bo + BiX, where Y = OD, Bo = the 
intercept, Bi = the slope and X = time. The equations generated were then compared 
using a univariate analysis.  
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4.3  Results and Discussion 
 Bacterial growth curves, including those for E. coli typically are sigmoidal in 
shape (Coleman et al. 2003); each curve possesses an initial lag phase in which the 
inoculated culture prepares to grow, a linear portion or log phase in which the slope of 
the line is indicative of the growth rate for the bacteria and, a plateau or stationary phase 
where the culture reaches a maximum cell density allowed by available nutrients found in 
the growth medium. In this study, careful pre-treatment of bacterial cultures to help 
ensure that they were in a similar physiological state at the beginning of each experiment 
and exact replication of the growth conditions used during experimental trials, allowed 
accurate duplication of the growth curves generated with little variation from one 
experiment to next; e.g., standard error for the log phase slope varied from + 0.003 to + 
0.014 in the 16 growth curves examined (Table 4.1 and Table 4.2). This approach 
allowed a detailed comparison of the growth curves generated for each of the bacterial 
strains examined in order to determine if deletion of PAIs from E. coli O157:H7 can 
affect ability of the bacteria to grow. 
4.3.1.  Growth of OI and SL deletion mutants relative to their O157:H7 
 parents EDL933 and Sakai. 
  All growth curves generated in the study were unique to the specific strains 
examined; i.e., the curve for each strain fit a linear equation (Table 4.1 and Table 4.2) 
with a specific slope.  Analysis of these curves showed that nine of the OI mutants (OI-
39, 51, 59, 89, 98, 108, 135, 172 and 176) had the same rate of growth (slope) as the 
EDL933 parental control (Table 4.1); i.e., removal of these PAIs from the parental strain 
EDL933 did not affect growth rate of the cells. Of the remaining OI mutants, two (OI-55  
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Table 4.1.  Linear regression of the growth curve data for the 12 OI deletion mutants, the 
O157:H7 parental strain EDL933 and the E. coli K-12 reference strain DH5α.  The 
regression model used was Y= bo + biX, where Y= OD, bo identifies the y intercept, bi is 
the slope and, X is time. 
 
Strain N Slope* 
Standard Error for 
Slope 
DH5 (control) 54 0.320 b, x ± 0.014 
EDL933 (parent) 340 0.358 a, y ± 0.003 
    
OI-39 mutant 54 0.349a, x ± 0.004 
OI-51 mutant 54 0.352 a, y ± 0.006 
OI-55 mutant 54 0.339 b, x ± 0.004 
OI-59 mutant 54 0.356 a, y ± 0.005 
OI-87 mutant 54 0.339 b, x ± 0.003 
OI-89 mutant 54 0.354 a, y ± 0.003 
OI-98 mutant 54 0.353 a, y ± 0.006 
OI-102 mutant 54 0.379b, y ± 0.004 
OI-108 mutant 54 0.355 a, y ± 0.005 
OI-135 mutant 54 0.353 a, y ± 0.004 
OI-172 mutant 54 0.345 a, x ± 0.005 
OI-176 mutant 53 0.358 a, y ± 0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The first letter of the superscript identifies significant differences (P<0.05) from the 
parental strain E. coli O157:H7 EDL933 where a = same and b = different; the second 
letter identifies significant differences (P<0.05) from the reference strain E. coli 
DH5α, where x = same and y = different. N corresponds to the number of OD readings.
  
 
Table 4.2.  Linear regression of the growth curve data for the SL deletion mutant, the 
O157:H7 parental strain Sakai and the E. coli K-12 reference strain DH5α. The 
regression  model used was Y= bo + biX, where Y= OD, bo is the intercept, bi is the slope 
and, X is time.   
 
Strain N Slope*  
Standard Error 
for Slope 
DH5α (control) 54 0.320 b, x ± 0.014 
Sakai (parent) 108 0.367 a, y ± 0.006 
    
SL 72 mutant 
54 0.345 b, x ± 0.006 
 
* The first letter of the superscript identifies significant differences (P<0.05) from the 
parental strain E. coli O157:H7 EDL933 where a = same and b = different; the second 
letter identifies significant differences (P<0.05) from the reference strain E. coli 
DH5α, where x = same and y = different. N corresponds to the number of OD readings. 
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 and OI-87) had a significantly slower growth rate (P<0.05) than EDL933 and, one (OI-
102) had a significantly higher growth rate (P<0.05) than the parent strain. The OI 55 
contains ORFs of unknown function and ORFs that have a role in transport.  The change 
in growth rate seen by the OI-55 deletion mutant may be related to the removal of the 
transport proteins which could result in a mutant that is not able to transport molecules as 
effectively as the wildtype parental strain which could result in the slower growth rate 
seen by this deletion mutant.  The OI-87 contains an ORF of unknown function and an 
unclassified ORF, the results suggest that these ORFs contribute the growth of E. coli 
O157:H7 since the removal of this OI results in a mutant that does not grow as effectively 
as the wildtype parental strain in rich medium.  The OI-102 contains ORFs of unknown 
function, as well as ORFs coding for putative prophage DNA injection proteins, an ORF 
coding for a putative resolvase, a sucrose permease, a D-fructokinase, a sucrose 
hydrolase and a sucrose specific transcriptional regulators. The OI-102 deletion mutant is 
also unable to use sucrose as a carbon source (Biolog results, Figure 3.26, pg.75) and this 
loss of ability could also affect its growth rate since the change in carbon utilization of 
the bacterium could change the order E. coli O157:H7 consumes sugars and these sugars 
could be easier to degrade than sucrose allowing the bacterium to replicate faster in rich 
medium. In E. coli O157:H7 strain Sakai, removal of SL 72 produced a PAI deletion 
mutant that grew significantly slower (P<0.05) than the parent (Table 4.2). The SL 72 
contains ORFs coding for hypothetical proteins, ORFs related to tellurium resistance, 
ORFs relating to urease synthesis, as well as, ORFs coding for transposases and adhesins, 
ORFs related to synthesis of membrane proteins, ORFs coding for regulatory proteins 
and transcriptional regulators.  The slower growth rate of the SL 72 deletion mutant 
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suggests that this SL has an important role in growth of E. coli O157:H7 strain Sakai.  
This change in growth could be due to the loss of the regulatory proteins or the 
transcriptional regulators that are coded for on this PAI.   
 Survival strategies of bacteria grown under different environmental conditions 
have been examined by Roszak and Colwell (1987). They observed that typical 
laboratory media have higher concentrations of nutrients than most natural environments. 
For example most nutrient media used in the laboratory have ~2 g or more of carbon per 
liter while the environmental conditions examined in their studies had only ~1-15 mg 
carbon per liter. They suggested that bacteria grown under lower nutrient conditions 
likely would show more variation in growth than those grown under optimal conditions. 
In contrast, Vebø et al. (2010) looked at the growth curves from bacterial strains from 
different origins that were grown in urine (a relatively rich medium) and did not find any 
significant differences in growth. This suggests that the relatively low number of 
differences seen between the OI mutants examined in this study and the EDL933 parent 
might be the result of using LB, a complete bacterial growth medium with lots of 
nutrients. If true, the deletion mutants examined in this study might have shown more 
differences in growth patterns compared to the parental strains if growth of the bacteria 
was compared in minimal and complete media. 
4.3.2.  Growth of OI and SL deletion mutants relative to the reference E. coli K12 
strain DH5α. 
 Comparison of E. coli O157:H7 strain EDL933 and Sakai with the reference E. 
coli K12 strain DH5α showed that both pathogenic O157:H7 strains grew significantly 
faster (P<0.05) than the reference DH5α strain (Table 4.1 and Table 4.2). Similarly, eight 
 150
  
 
of the 12 OI deletion mutants (OI-51, 59, 89, 98, 102, 108, 135 and 176) grew 
significantly faster (P<0.05) than the reference DH5α strain (Table 4.1); i.e., these 
deletion mutants grew similar to the parental O157:H7 strain EDL933. However, deletion 
of PAIs from OI-39, 55, 87 and 172 from O157:H7 strain EDL933 produced a growth 
rate in these strains that was not significantly different (P>0.05) from the reference E. coli 
K12 strain DH5α. Similarly, deletion of SL 72 from E. coli O157:H7 strain Sakai 
resulted in production of a deletion mutant with a growth rate that was not significantly 
different (P>0.05) from the reference E. coli K12 strain DH5α (Table 2). It appears that 
removal of some PAIs from E. coli O157:H7 results in production of bacteria that grow 
in a manner more characteristic of the reference strain. 
 Baba et al. (2006) created single gene knock out mutants for all of the non-
essential genes found in E. coli K-12 strain BW25113 and compared growth of these 
mutants on minimal and rich media. They were able to classify their mutants into three 
distinct groupings; i.e., mutant strains that grew well on minimal medium, mutant strains 
that grew well in rich medium and mutant strains that grew well in both types of media. 
In this study, growth rates for the PAI deletion mutants also were divided into groups 
(two) indicating that some PAIs are capable of increasing and decreasing the growth rate 
of E. coli. Moreover, comparison of these changes in growth rate to that of the reference 
E. coli strain DH5α suggests that removal of some PAIs from O157:H7 results in a 
mutant that grows more like the reference strain then the parental O157:H7 strain..  
Roos et al. (2006) compared the growth of asymptomatic bacteriuria (ABU) E. 
coli strains to uropathogenic E. coli strain CFT073 for differences in adhesion and 
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growth. Results from their experiments showed, that differences in growth between nine 
ABU E. coli strains and the uropathogenic E. coli strain CFT073 existed. Two of the 
ABU E. coli strains had higher growth rates than the pathogenic CFT073 strain and the 
remaining seven ABU strains had lower growth rates than the pathogenic CFT073 E. coli 
strain. They showed that differences in growth rate exist among strains of the same 
species. This result is similar to results from my experiments where different growth rates 
were seen for mutant strains originating from the same O157:H7 isolate.  
4.3.3. Influence of PAIs on bacterial cell density at stationary phase 
 Comparison of the maximum cell density obtained at stationary phase by cultures 
of E. coli O157:H7 strains EDL933 and Sakai with the reference E. coli K12 strain DH5α 
showed that both O157:H7 strains reached a higher cell density when grown in LB 
medium than the reference E. coli strain DH5α (Figure. 4.1 and Figure. 4.2); i.e., the 
O157:H7 strains EDL933 and Sakai reached a maximum cell density at an OD600 of 4.2 
and 4.6 respectively cv. 3.7 for the reference DH5α strain. This also was true for the 
O157:H7 PAI deletion mutants. When the maximum cell density reached during growth 
of the PAI deletion mutant cultures was compared to the maximum cell density reached 
by the reference strain DH5α, the maximum cell density reached by all of the O157:H7 
PAI deletion mutants was always higher than that reached by the reference strain DH5α 
(Figure. 4.3 to 4.6); i.e., maximum cell densities reached by the EDL933 PAI deletion 
mutants ranged from an OD660 of 4.0 seen for the OI-55 deletion mutant (Figure. 4.4) to 
4.7 in the OI-172 deletion mutant (Figure. 4.4) cv. an OD660 of 3.7 for the reference strain 
DH5α. Similarly, the maximum cell density reached by the SL 72 deletion mutant (an  
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Figure. 4.1. Comparison of the reference K-12 strain DH5α growth curve with the parental strain O157:H7 EDL933. The linear part of 
the curves are different and appear to have a different growth rate between them.  The O157:H7 pathogenic EDL933 parental strain 
diverges from the reference strain DH5α and they do not have the same growth pattern. 
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Figure. 4.2.Comparison of the reference K-12 strain DH5α growth curve with the parental strain O157:H7 Sakai.  The linear part of 
the curves are different and appear to have a different growth rate between them.  The O157:H7 pathogenic Sakai parental strain 
diverges from the reference strain DH5α and they do not have the same growth pattern.
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Figure. 4.3. Comparison of OI 51, 59, 89, 135 and 176 deletion mutant growth curves with the reference K-12 strain DH5α. The linear 
part of the curves are different and appear to have a different growth rate between them.  The O157:H7 deletion mutants diverged 
from the reference strain DH5α and they did not have the same growth pattern.
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Figure. 4.4.  Comparison of OI 39, 55 and 172 deletion mutant growth curves with the reference K-12 strain DH5α. The linear part of 
the curves appear to have a similar growth rate despite having different intercepts.  The O157:H7 deletion mutants did not diverge 
from the reference strain DH5α and they did have the same growth pattern. 
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Figure. 4.5. Comparison of OI 98, 102 and 108 deletion mutant growth curves with the reference K-12 strain DH5α. The linear part of 
the curves appears to have a different growth rate but a similar intercept.  The O157:H7 deletion mutants did diverge from the 
reference strain DH5α in growth rate but not for the intercept. 
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Figure. 4.6. Comparison of OI 87 deletion mutant growth curve with the reference K-12 strain DH5α. The linear part of the curves 
appear to have a similar growth rate and intercept.  The O157:H7 deletion mutant did not diverge from the reference strain DH5α in 
either growth rate or intercept.
  
 
OD660 of 4.3) was greater than that reached by the reference strain DH5α (an OD660 of 
3.7) (Figure. 4.7).  
 Many of the EDL933 PAI deletion mutants reached a maximum cell density 
similar to that of the O157:H7 parent strain EDL933 (Figure. 4.8 to 4.11); i.e., the 
maximum cell density in six of the 12 OI mutants (OI-39, 51, 59, 89, 135, 176 - Figure. 
4.8) was the same as that seen in the O157:H7 parental EDL933 strain (i.e., an OD660 of 
4.2). However, some PAI deletion mutants reached a cell density less than the O157:H7 
parental strain (i.e., an OD660 of 4.1 in the OI-55 deletion mutant – Figure. 4.9, and an 
OD660 of 4.0 in the OI-87 mutant – Figure. 4.11 cv. an OD660 of 4.2 for the parental 
strain) while others reached a cell density higher than the O157:H7 parental strain; i.e., 
the maximum cell density reached by the deletion mutant OI-102 was an OD660 of 4.4 
(Figure.4.9), while the OD660 for OI-98, 108 and 172 was 4.3, 4.3 and 4.6 respectively cv. 
an OD660 of 4.2 for the O157:H7 parent (Figure. 4.10). The SL 72 deletion mutant 
(Figure. 4.12) also reached a lower cell density (OD660 of 4.3) than the O157:H7 parent 
strain Sakai (OD660 of 4.6). 
  The data suggest that some PAIs in E. coli O157:H7 may have a role in substrate 
utilization and may help to increase the efficiency of substrate utilization in the 
environment. This increase in efficiency appeared to result in production of higher 
numbers of bacteria (a higher OD660) in cultures as compared to the reference K-12 
strain, E. coli DH5α. This effect, together with the higher growth rates observed in the 
O157:H7 cultures, suggests that these bacteria may be better adapted for survival in some  
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Figure. 4.7. Comparison of SL 72 deletion mutant growth curve with the reference K-12 strain DH5α. The linear part of the curves 
appear to have a similar growth rate and intercept.  The O157:H7 deletion mutant did not diverge from the reference strain DH5α in 
either growth rate or intercept. 
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Figure. 4.8. Comparison of OI 39, 51, 59, 89, 135, and 176 deletion mutant growth curves with the parental strain EDL933.  The 
curves are very similar and appear to have the same growth rate among them.  The deletion mutants do not diverge from the EDL933 
control in this case and mimic the same growth pattern as the control. 
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Figure. 4.9. Comparison of OI 55 and 102 deletion mutant growth curves with the parental strain EDL933.  The curves are different 
and have different rates of growth.  The OI-55 mutant has a slower growth rate than the EDL933 control.  The OI-102 mutant has a 
faster growth rate than the EDL933 control. 
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Figure. 4.10. Comparison of OI 98, 108 and 172 deletion mutant growth curves with the parental strain EDL933.  The curves have a 
similar growth rate.The deletion mutants do not diverge from the EDL933 control in this case and mimic the same growth pattern as 
the control. 
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Figure. 4.11. Comparison of OI 87 deletion mutant growth curve with the parental strain EDL933.  The curves have a different growth 
rate with the OI-87 mutant having a slower growth rate than the EDL933 control.  
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Figure. 4.12. Comparison of SL 72 deletion mutant growth curves with the parental strain Sakai.  The curves were different since they 
had a different growth rate. The SL 72 mutant had a slower growth rate than the Sakai control.
  
 
environments than other reference E. coli strains.  However, further studies are required 
in order to determine if this trend is common among other enteric bacterial pathogens. 
4.3.4.  Future directions 
  The growth of E. coli O157:H7 is a factor in its survivability and pathogenesis 
and has been studied under different growth conditions (Coleman et al., 2003). Future 
studies looking at growth of the O157:H7 deletion mutants and the controls DH5α, 
EDL933 and Sakai need to be undertaken to fully elucidate the roles that these PAIs have 
in regulation of growth of these bacteria. The data provided in this study suggests that 
some PAIs have a role in growth and that those roles may increase efficiency of use of 
nutrients in the environment. Thus for some PAIs removal of the PAI creates a strain that 
behaves more like a reference strain than an O157:H7 pathogen. However, these findings 
need to be explored in more detail. 
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Chapter V 
Cell Viability in E. coli O157:H7 
5.1 Introduction 
E. coli O157:H7 is an intestinal pathogen that can cause a wide range of 
symptoms and complications from bloody diarrhea to more serious complications such as 
HUS (Klein et al. 2002; Cleary 2004).  One of the main routes of E. coli O157:H7 
infections is by ingesting contaminated food or drink (Karch et al., 2005). Food related 
outbreaks due to consumption of contaminated ground beef and other food products such 
as spinach have been implicated in E. coli outbreaks (Bopp et al. 2003; Grant et al. 
2008). Some outbreaks have been waterborne due to drinking or swimming in 
contaminated water (Bopp et al. 2003; Fremaux et al. 2008).  In a study by Rangel et al. 
(2005) which looked at outbreaks of E. coli O157:H7 in the Unites States from 1982-
2002, 31 out of 350 outbreaks were waterborne (9.0%).  
Waterborne outbreaks have the potential to infect many people (Rangel et al. 
2005) and are important because pathogenic bacteria such as E. coli O157:H7 can be 
spread over a large geographic area and to a wide range of people in a short period of 
time (Olsen et al. 2002). A well known Canadian outbreak is the Walkerton incident. In 
2000 a waterborne outbreak implicating E. coli O157:H7 and Campylobacter jejuni 
occurred in Walkerton Ontario (Holme 2003).  Over 2000 people were infected and 7 
people died.  Outbreaks have also occurred in the United States. One outbreak occurred at 
the New York State Fair in 1999 where 775 people were infected with E. coli O157:H7 
by a contaminated well water supply (Bopp et al. 2003). Another E. coli O157:H7 
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outbreak occurred in Missouri where 243 people were infected and 4 people died after 
drinking contaminated water from a rural township’s un-chlorinated water supply 
(Swerdlow et al. 1992).  The ability of E. coli O157:H7 to cause outbreaks from drinking 
contaminated water may be related to its ability to survive for long periods of time in 
water (Flint 1987). 
Studies looking at survival of E. coli O157:H7 in different water environments 
have been undertaken.  Cook and Bolster (2007) compared survival of E. coli O157:H7 
and Campylobacter jejuni in ground water and found that E. coli O157:H7 could survive 
just as well in nutrient free water as in water containing carbon or nitrogen while C. 
jejuni died off 2.5 to 13 times quicker than E. coli in groundwater.   Rozen and Belkin 
(2001) looked at survivability of enteric bacteria including E. coli in seawater.  Overall 
they found that E. coli was able to survive for a long period of time in seawater, but lost 
the ability to form colonies and entered into a viable but non culturable state (VBNC) that 
allowed them to survive in the marine environment for extended periods.  Smith et al. 
(1994) exposed E. coli to a polar marine environment for 54 days and at the conclusion of 
their experiments found that the cells were no longer able to grow on selective medium, 
although direct viable counts indicated that the cells were still present but in a VBNC 
state.  E. coli can enter a VBNC state when exposed to stresses such as changes in pH, 
available nutrients and/or temperature or when subjected to starvation conditions (Liu et 
al., 2008).  
The ability to enter a VBNC state (Liu et al. 2008) as well as the ability to survive 
for long periods of time in water (Mori 2001) is possibly encoded on or influenced by 
pathogenicity islands (PAIs) found in these cells.  PAIs are sections of the bacterial 
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genome that are found in pathogens such as E. coli O157:H7 that encode virulence 
factors or proteins that have a role in disease (Ferianc et al. 2002).  These islands are not 
found in commensal strains of E. coli (Ferianc et al. 2002). 
One method that can be used to study survival of E. coli in water is to use vital 
stains to identify living and dead cells after transfer of the bacteria to water. Liu et al. 
(2008) used a Live/Dead kit (Invitrogen, Carlsbad, California) to count the number of E. 
coli O157:H7 cells present in water during a starvation experiment designed to force E. 
coli O157:H7 into a VBNC state for subsequent tests. After 13 weeks cells were no 
longer culturable and after 16 weeks were found to be still viable as determined by 
Live/Dead staining. 
The ability of the E. coli K-12 reference strain DH5α and the pathogenic E. coli 
O157:H7 strains Sakai and EDL933 plus 13 O157:H7 deletion mutants produced from 
these bacteria to survive in water was examined by creating survivability curves and 
examining them over a period of 10 days using a Live/Dead viability test. Specific 
objectives of this study were to: 
1) Create survivability curves for each of the mutants and the three controls. 
2) To compare O157:H7 strains EDL933 and Sakai to the reference   
 strain DH5α. 
3) To compare the OI deletion mutants and the SL deletion mutant to the 
reference control DH5α and their respective parental strains EDL933 and Sakai.  
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5.2 Materials and Methods 
5.2.1. Bacterial cultures 
Single colonies from each of E. coli O157:H7 strains EDL933 and Sakai, E. coli 
K-12 strain DH5α and the 13 OI and SL deletion mutants were streaked on LB Agar and 
grown overnight (12-16 h) at 37 ºC. This step was repeated twice to ensure that 
individual pure colonies of each strain were used and to ensure that the bacteria were in 
the same physiological state. After the final incubation a single colony from each plate 
was used to inoculate a 15 ml Falcon tube containing 10 mL of pre-warmed LB broth. 
These tubes were then incubated for 12-13 hr at 37 ºC in a shaking incubator set at 220 
rpm. 
5.2.2. Sample preparation and staining to test for cell survivability  
Overnight cultures of cells (10 mL) were centrifuged at 2800 x g in an eppendorf 
A-4-44 rotor (Eppendorf Centrifuge, Model 5810R, Needham, Massachusetts) for 15 
min.  The supernatant was removed and the cells washed twice in 5 mL of sterile MilliQ 
water (Millipore) as described above. The supernatant was removed and the cells re-
suspended in 1 mL of sterile MilliQ water. This mixture of cells and water was added to a 
test tube containing 9 mL of sterile MilliQ water. The tubes were then incubated at 25 ºC 
in a shaking incubator set at 220 rpm.                                                                           
Preliminary testing indicated that taking samples every 24 h was not necessary 
since there was very little difference in cell survival between time points sampled closer 
than 48 h apart (data not shown). Consequently, bacterial samples were taken at time zero 
 
 
170
  
 
(immediately after preparation), at day 2 (48 h), day 4 (96 h), day 6 (144 h), day 8 (192 
h), and day 10 (240 h).  All cells were stained using the BacLightTM Live/Dead Bacterial 
Viability Kit (kit #L7007, Molecular Probes, Eugene, Oregon) following the 
manufacturer’s directions. (The dye mixture was made by mixing equal amounts of 
compound A and compound B from the kit as per the manufacturer’s instructions.) A 200 
µl sample of cells was removed from each test sample, placed in a 1 mL microcentrifuge 
tube and then returned to the incubator until the next sample time. Tubes were spun in a 
microcentrifuge (Beckman Microcentrifuge 11, Palo Alto, California) for 5 min at 10,000 
rpm. The supernatant was removed and the cells re-suspended in 200 µl of 0.85 % NaCl.  
To this mixture 1 µl of the LIVE/DEAD Baclight dye mixture was added to the 
microcentrifuge tube and mixed thoroughly by inversion. The tubes were then incubated 
in the dark at room temperature for 15 min. 
5.2.3. Slide preparation and analysis  
After incubation of the cells, 5 µl of the stained bacterial suspension was placed 
on a microscope slide and a cover slip added. The slides were then viewed and counted 
using a fluorescent microscope.  Cells were viewed using a Zeiss AxioScope equipped 
with a standard fluorescein longpass filter set. For each strain ~1000 bacteria were 
counted and recorded as being alive (green) or dead (red) (Figure 5.1).  These numbers 
were used to generate a ratio of live cells to dead cells and then used to compare the 
strains graphically to each other. The ratios were compared statistically using a 2-tailed 
T-test assuming equal variance with a P value of 0.05. The ratios were further analyzed 
using a statistical program (SPSS) to perform a linear regression and compare the results  
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Figure. 5.1. E. coli O157:H7 strain EDL933 after treatment with the LIVE/DEAD 
Baclight dye.  The green dots are live bacterial cells and the red dots are dead bacterial 
cells. Cells were viewed using a Zeiss AxioScope equipped with a standard fluorescein 
longpass filter set and a 100 X magnification lens using immersion oil. 
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using a univariate analysis. A linear regression for each of the OI and SL deletion mutant 
survivability curves and the parental controls (O157:H7 strain EDL933 and Sakai) was 
calculated using the model Y = Bo + BiX, where Y = OD, Bo = the intercept, Bi = the 
slope and X = time. This process was repeated three times with three different cultures.  
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5.3  Results and Discussion 
E. coli O157:H7 strains EDL933 and Sakai were placed in sterile distilled water 
and their survival over the next 10 days compared to that of E. coli K-12 reference strain 
DH5α as well as to their respective E. coli O157:H7 OI (OI) and SL deletion mutants. 
The reference E. coli K-12 strain DH5α did not survive as long as the O157:H7 parental 
controls EDL933 and Sakai (Figure. 5.2); i.e., E. coli K-12 strain DH5α showed the 
greatest percentage decrease in live cells (63.80%) over a 10 day period (Table 5.1). This 
decrease was significantly greater (P < 0.05) than that seen in both O157:H7 parental 
strains EDL933 (25.08 %) and Sakai (18.26 %).  
Lui et al. (2008) found that E. coli O157:H7 appears to enter a VBNC state in 
response to stresses such as lack of nutrients. In contrast, in this experiments E. coli 
DH5α had low survivability in water and did not appear to enter a VBNC state in 
response to this type of stress. This suggests that the VBNC state could be an acquired 
trait by the O157:H7 pathogen, attained in order to increase survivability. Bogosian et al. 
(1996) also looked at survival of a reference E. coli K-12 strain W3110 in sterile artificial 
sea and river water, and found that plate counts of cells from each of these environments 
remained stable for over 50 days. However, they also found that the E. coli W3110 cells 
did not appear to enter a VBNC state. The E. coli DH5α strain looked at in my 
experiments had a limited ability to survive in sterile water as less than 5 % of the cells 
transferred to water were alive after 10 days, a result quite different from that of 
Bogosian et al. (1996). This difference in survival could be due to a lack of nutrients 
present in the sterile Milli-Q water used in my experiments while the sea and 
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Figure. 5.2. Comparison of the E. coli strains EDL933 and Sakai with the reference K-12 E. coli strain DH5α.  Survivability of E. coli 
O157:H7 strains EDL933 and Sakai relative to E. coli K-12 reference strain DH5α in sterile MilliQ water. 
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Table 5.1. Difference in percentage of live cells after 10 days in sterile MilliQ water for the E. coli O157:H7 strains EDL933 and 
Sakai relative to the reference E. coli K12 strain DH5α. 
 
E. coli Strain 
Percentage 
of live cells 
Day 0  
Percentage of live 
cells Day 10 
Difference over 10 
days 
Standard 
Error 
Probability 
value (P) 
O157:H7 strain EDL933 77.07 51.99 25.08 + 0.71 _a 
O157:H7 strain SAKAI  83.20 64.94 18.26 + 1.21 _a 
      
K12 strain DH5α 68.31 4.51 63.80 + 2.30 0.000b* 
 
 
*Significant differences in the overall percentage drop over 10 days (Comparison of O157:H7 strains EDL933 and Sakai to E. coli 
K12 strain DH5α) are bolded. 
  
 
 
river water tested by Bogosian et al. (1996) may have contained some nutrients. Still, my 
data does support one aspect of the Bogosian et al. (1996) experiment that suggests that 
E. coli DH5α does not enter a VBNC state in the same way as E. coli K-12 strain W3110.  
5.3.1  Comparison of the survivability of E. coli O157:H7 Strains EDL933 and the 
 O157:H7 OI deletion mutants. 
Each of the OI deletion mutants and the parental O157:H7 strain EDL933 showed 
a decline in the percentage of live cells over the course of 10 days (Table 5.2). While the 
parental O157:H7 control EDL933 showed a 25.08% drop in the number of live cells 
during this period (Table 5.2), the OI deletion mutants exhibited a range in the percentage 
decrease in live cells. The EDL933 deletion mutant OI-87 showed the largest drop in the 
percentage of live cells (24.84%), a value which was not significantly different (P < 0.05) 
from the percentage decrease in cell number compared to the EDL933. Other strains 
exhibiting a similar trend were the deletion mutants OI-55, 59, 89, 102 and 172. By 
contrast, the deletion mutant OI-51 showed a much smaller decline (12.05%); however, 
this value was significantly less (P > 0.05) than that of the O157:H7 EDL933 parent. 
Other deletion mutants exhibiting a decline significantly less (P > 0.05) than that of the 
O157:H7 EDL933 parent were OI-39, 98, 108, 135 and 176. In each case, these cells 
were able to survive longer in water lacking any nutrients than the O157:H7 EDL933 
parent.   
 Both E. coli O157:H7 strain Sakai and the SL deletion mutant produced from 
Sakai showed an overall decline in the percentage of live cells that survived over the  
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Table 5.2. Difference in percentage of live cells after 10 days for each of the E. coli O157:H7 OI deletion mutants, the SL 72 deletion 
mutant and the O157:H7 parental controls EDL933 and Sakai. 
 
E. coli Strain Percentage of live cells Day 0  
Percentage of live 
cells Day 10 
Overall 
percentage 
difference over 10 
days 
Standard 
Error 
Probability 
value (P)* 
EDL933 77.07 51.99 25.08 + 0.71 _ 
OI-39 66.74 45.25 21.48 + 0.90 0.035 
OI-51 60.32 48.28 12.05 + 2.02 0.004 
OI-55 64.98 47.76 17.22 + 3.09 0.068 
OI-59 70.74 51.45 19.29 + 6.92 0.452 
OI-87 71.03 46.19 24.84 + 2.02 0.915 
OI-89 70.33 47.71 22.63 + 1.80 0.275 
OI-98 68.98 51.76 17.22 + 0.46 0.001 
OI-102 71.95 50.73 21.22 + 1.34 0.064 
OI-108 78.32 60.88 17.44 + 0.92 0.003 
OI-135 75.92 60.12 15.80 + 0.49 0.000 
OI-172 73.03 55.39 17.64 + 3.62 0.114 
OI-176 73.69 56.66 17.03 + 2.74 0.047 
      
SAKAI  83.20 64.94 18.26 + 1.21 - 
SL 72 70.29 56.50 13.79 + 0.94 0.044 
 
*Significant differences in the overall percentage drop over 10 days (Comparison of O157:H7 strain 
EDL933 to the OI-deletion mutants and O157:H7 strain Sakai to the SL deletion mutant) are bolded. 
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course of 10 days. The parental O157:H7 control Sakai showed a drop of 18.26% in the 
percentage of live cells over 10 days (Table 5.2) while the SL 72 mutant showed a 
significantly lower (P < 0.05) percentage drop in live cells of 13.79%.; i.e., more of the 
SL deletion mutant cells survived in water over 10 days than the O157:H7 strain Sakai 
parent cells. 
Waterborne outbreaks of E. coli O157:H7 are important because of the possibility 
to infect many people and to cover a wide geographical area (Olsen et al. 2002). E. coli 
O157:H7 has been shown to survive for long periods of time in water (Flint 1987). The 
results from this study show a slow decline in number of live cells over the course of 10 
days and, none of the curves lead to 100% cell death (Figure. 5.3, 5.4, 5.5). In fact after 
10 days, the percentage of live O157:H7 cells remaining in water was at least ~45% 
suggesting that all of the O157:H7 strains examined could survive in water for several 
weeks.  
This slow decline in live cell numbers was previously shown in a study by Mori 
(2001). She showed that E. coli O157:H7 can take several weeks to completely die off in 
a water sample. These results are similar to those found in this study because there is still 
a large number of live cells in the water mixture and the slow decline in cell numbers 
suggest they would continue to survive for an extended period of time.. Liu et al. (2008) 
had similar results and concluded that a VBNC state was induced in E. coli O157:H7 
under reduced nutrient conditions. In their studies E. coli O157:H7 were no longer 
culturable after 13 weeks, but were still detected as being alive (viable) after 16 weeks 
using a Live/Dead bacterial viability kit. Wang and Doyle (1998) also looked at E. coli 
survivability in water; they concluded that “O157:H7 is a hardy pathogen” and that it is  
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Figure. 5.3. Comparison of the O157:H7 mutants OI-39, OI-59, OI-87, OI-89 and OI-102 with the O157:H7 parental strain EDL933.  
The curves each show an overall slow decline with different survivability patterns over ten days with none of the OI mutants or the 
EDL933 control reaching 100% cell death.
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Figure. 5.4. Comparison of the O157:H7 mutants OI-51, OI-55, OI-98, OI-108, OI-135, OI-172 and OI-176 with the O157:H7 
parental strain EDL933. The curves each show a slow overall decline over ten days with neither the OI mutants nor the EDL933 
control reaching 100% cell death. The curves have different survivability patterns. 
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Figure. 5.5. Comparison of the SL 72 mutant with the O157:H7 parental strain Sakai.  The curves each show a slow overall decline 
over ten days with neither the SL 72 mutant nor the Sakai control reaching 100% cell death. The curves have a similar survivability 
pattern
  
 
capable of surviving in water for long periods of time, especially at cold temperatures.  
The rate of decline for each of the O157:H7 strains looked at in my study was 
examined using a best fit linear regression model. Five of the OI mutants (OI-39, 59, 87, 
89 and 102) and the SL 72 mutant had statistically similar (P < 0.05) rates of decline that 
were not different from the parent O157:H7 strains EDL933 (OIs) and Sakai (SL) (Figure 
5.3 and 5.4) (Table 5.3). An effect of removal of specific PAIs was not seen in these 
mutants. The remaining seven OI mutants (OI-51, 55, 98, 108, 135, 172 and 176) did 
show a significant difference (P > 0.05) in the rate of decline in cell number (slope) 
within cultures compared to O157:H7 strain EDL933 (Figure. 5.4) (Table 5.3). This 
suggests that survivability of these bacteria in water was affected by removal of a PAI 
from the parental O157:H7 strain. It appears that survivability in sterile water is an 
acquired trait by the pathogen (O157:H7) since the reference strain (DH5α) was unable to 
survive well in sterile water. Traits of pathogens such as E. coli O157:H7 that cause 
disease are found on PAIs and these PAIs are not present in commensal strains of E. coli 
(Ferianc et al., 2002). The results also suggests that more than one PAI can affect 
survivability of the bacterium since 7 mutants each with a different PAI removed showed 
a significant difference in rate of decline.  Each of these removed OI has different ORFs 
found within them.  The OI 51 contains ORFs from the prophage CP-933C; most of these 
ORFs from this prophage code for unknown proteins. The OI 55 contains ORFs of 
unknown function and ORFs that have a transport role. The OI 98 contains an ORF of 
unknown function. The OI 108 has unknown ORFs that are phage or prophage related; 
i.e., ORFs  that code for proteins that are phage or prophage related and ORFs similar to 
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Table 5.3.  Linear regression of the survivability curve data for 13 OI and SL deletion mutants and the O157:H7 parent strains 
EDL933 and Sakai.  The regression model used was Y= bo + biX, where Y= OD, bo is the intercept, bi is the slope and, X is time. 
 
E. coli Strain N Intercept 
Standard Error 
for Intercept Slope 
Standard Error 
for Slope 
EDL933 control 18 7.49E+01 ± 0.766 -2.430 ± 0.126 
OI-39 mutant 18 6.43E+01 ± 0.942 -2.076 ± 0.155 
OI-51 mutant 18 5.98E+01 ± 1.496 -1.093 ± 0.247 
OI-55 mutant 18 6.50E+01 ± 0.913 -1.685 ± 0.151 
OI-59 mutant 18 6.71E+01 ± 2.155 -1.848 ± 0.356 
OI-87 mutant 18 7.19E+01 ± 1.072 -2.458 ± 0.177 
OI-89 mutant 18 6.66E+01 ± 1.243 -2.088 ± 0.205 
OI-98 mutant 18 6.74E+01 ± 1.274 -1.704 ± 0.210 
OI-102 mutant 18 6.97E+01 ± 1.058 -2.059 ± 0.175 
OI-108 mutant 18 7.46E+01 ± 1.295 -1.576 ± 0.214 
OI-135 mutant 18 7.15E+01 ± 1.397 -1.292 ± 0.231 
OI-172 mutant 18 7.19E+01 ± 1.002 -1.731 ± 0.165 
OI-176 mutant 18 7.08E+01 ± 1.264 -1.452 ± 0.209 
      
Sakai control 18 7.71E+01 ± 1.875 -1.671 ± 0.310 
SL 72 mutant 18 6.79E+01 ± 1.296 -1.388 ± 0.214 
 
N is the number of data points collected for each strain.
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transposases. The OI 135 contains two ORFs of unknown function. The OI 172 contains 
ORFs unknown function, ORFs coding for two putative intergrases, a transposase, a 
putative resolvase, a putative ATP-dependent helicase and two putative helicases; i.e., 
genes likely involved in bacteriophage propagation and DNA synthesis, as well as 
regulation of cell growth and cell division. The OI 176 contains an ORF of unknown 
function. Each of the PAIs removed have specific role/roles in this bacteria and one role 
of each of the seven PAIs (OI 51, 55, 98, 108, 135, 172 and 176) is in survivability of E. 
coli O157:H7 in water. This suggests that traits that are important to the survival of the 
bacteria are found on many different PAIs. 
5.4 Summary 
 E. coli O157:H7 has been shown to survive for over a 100 days in water (Mori, 
2001; Liu et al., 2008), an ability that appears to far exceed that of reference E. coli K12 
strain DH5α(in sterile water). This ability appears to be due, at least in part, to the 
presence of one or more PAIs in the bacteria. Presence of these islands seems to increase 
the efficiency with which these bacteria are able to use reserve nutrients in the cell and/or 
metabolized cellular components, allowing them to survive over extended periods of 
time.  This observation is consistent with current approaches to culture of environmental 
isolates of E. coli O157:H7 which requires resuscitation of the bacteria into supplemented 
nutrient broth before using standard culture techniques for maintaining the bacteria in a 
laboratory setting. This property of the bacteria to survive in water for long periods of 
time may allow them to survive long enough to be able to be ingested and infect the 
intestines of animals, giving them a selective advantage over other bacteria. 
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Chapter VI 
Summary of General Conclusions 
 
6.1  Phenotypic Microarray Conclusions 
6.1.1  Comparison of the PM profiles of the OI and SL deletion mutants to the 
parental controls Sakai and EDL933 
 
 The PM method showed various differences in substrate utilization when 
comparing the deletion mutants to the parental controls.  Most of the changes were 
differences in level of substrate utilization while only 5 mutants showed true differences 
in substrate utilization (positive or negative for a substrate and the opposite result was 
seen for the parental strain).  These changes helped elucidate or clarify possible roles for 
these OIs and the SL deletion mutants.  As mentioned the bulk of the OI deletion mutants 
(OI-39, 51,55,59,89, 108, 135 and 176) did not have any differences in PM profile with 
the EDL933 parental control for substrate utilization.  The remaining 4 OI deletion 
mutants (OI-87, 98, 102 and 172) and the SL 72 deletion mutant each had differences in 
substrate utilization in comparison to the EDL933 (OI) or Sakai (SL) parental control. 
The OI-87 mutant gained the ability to use tween 20 as a carbon source, the OI-98 mutant 
gained the ability to use L-glutamic acid, the OI-102 mutant gained the ability to use D-
serine and D-threonine as carbon sources but lost the ability to use sucrose, the OI-172 
deletion mutant gained the ability to use tween 20, M-tartaric acid and loss the ability to 
use α-ketobutyric acid and α-hydroxybutyric acid and the SL 72 mutant gained the ability 
to use L-glutamine as a carbon source.  These differences were seen when comparing the 
PM profiles of the mutants and its respective parental control.  Each of these gains or loss 
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of functions could potentially have an impact on adaptability, survivability and 
pathogenesis of E. coli O157:H7. 
 All of the deletion mutants except the OI-135 deletion mutant had differences in 
level of substrate utilization in comparison to the parental controls, EDL933 and Sakai. 
There were similarities seen across the mutants for differences in level of substrate 
utilization, where many of the same substrates showed differences in level of utilization 
in comparison to the parental controls.  This suggests that processes or substrates that 
have an important role in E. coli O157:H7 are regulated by more than one PAI and that 
differences in level of substrate utilization could result in a less efficient pathogen and 
further tests need to be undertaken to see if this is the case. 
 
6.1.2 Comparison of the PM profiles of the OI and SL deletion mutants to the E. 
coli K-12 reference strain DH5α 
 
 In each of the comparisons of the E. coli O157:H7 deletion mutants and the 
reference E. coli  K-12 DH5α there were substrates that showed similarities in level of 
substrate utilization that were originally differences in level of substrate utilization in the 
DH5α and the O157:H7 EDL933 and Sakai parental strain comparisons. This suggests 
that the mutants are behaving more like the reference strain for these substrates than the 
pathogenic parental supporting the hypothesis that by removing a PAI from a pathogen 
results in a mutant that is less pathogenic than the parent. There was also a pattern seen 
where these similarities in substrate utilization between the mutants and the DH5α 
control were for many of the same substrates. 
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6.2  Cell Growth Conclusions 
6.2.1  Comparison of the OI and SL deletion mutants to the parental controls Sakai 
and EDL933 growth curves 
 
The growth curves generated were unique to each strain tested and allowed for 
comparison between the mutants and the controls which showed the differences and 
similarities between the growth rates of the mutants and the 3 controls EDL933, Sakai 
and DH5α.  Analysis of the mutant and parental curves showed that nine of the OI 
mutants (OI-39, 51, 59, 89, 98, 108, 135, 172 and 176) had the same rate of growth 
(slope) as the EDL933 parental, meaning the removal of these OIs did not affect the  
growth of mutants compared to EDL933 in LB broth. Three of the mutants OI-55, OI-87 
and the SL 72 mutant had a slower rate of growth compared to EDL933 (OI) and Sakai 
(SL) and the OI-102 mutant had a higher rate of growth compared to EDL933. This 
shows that removal of these 3 OIs and the SL 72 had an impact on the growth of the 
bacterium in LB broth suggesting these PAIs have a role in growth of E. coli O157:H7. 
6.2.2 Comparison of the OI and SL deletion mutants to the E. coli K-12 reference 
strain DH5α growth curves 
 
Comparison of E. coli O157:H7 mutants with the reference E. coli K12 strain 
DH5α showed that some of the strains had a similar growth patterns while others had a 
different pattern.  Eight of the 12 OI deletion mutants (OI-51, 59, 89, 98, 102, 108, 135 
and 176) grew faster than the reference DH5α strain same as the EDL933 parental strain. 
The remaining four OI deletion mutants, OI-39, 55, 87, 172 and the SL 72 deletion 
mutant had a growth rate that was similar to the reference strain DH5α which is different 
than the parental strains EDL933 (OI) and Sakai (SL). This suggests that the mutants are 
behaving or have a growth pattern that is more similar to the DH5α strain in this 
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comparison, suggesting that the removal of some PAIs from E. coli O157:H7 results in a 
mutant that grows in a manner more characteristic of a reference strain in a rich medium. 
6.3  Cell Viability Conclusions 
6.3.1  Comparison of cell viability of the OI and SL deletion mutants to the 
parental controls Sakai and EDL933 
 
The survivability curves generated in sterile water for each of the mutants and the 
parental controls EDL933 and Sakai were unique to each strain and also allowed for 
comparison to show similarities and differences between the mutants and their respective 
parental controls.  The comparison showed that 6 of the deletion mutants (OI-39, 59, 87, 
89, 102 and the SL 72) showed no difference in rate of decline (survival) in comparison 
to the parental strains EDL933 (OI) and Sakai (SL).  The removal of these above 
mentioned PAIs appear to not have an effect on survivability of the pathogen in sterile 
water.  The remaining 7 OI deletion mutants (51, 55, 98, 108, 135, 172 and 176) did 
show a difference in rate of decline in comparison to EDL933, suggesting that these PAIs 
have a role in survivability of the bacterium in sterile water. 
6.4. Future Directions 
 Further tests need to be undertaken with these mutants to fully elucidate the roles 
of these OI and SL in E. coli O157:H7 strains EDL933 and Sakai.  Each method used to 
study the deletion mutants did open further area’s of research.  The PM method could be 
expanded to include more types of PM plates such as, nitrogen utilization or phosphorus 
utilization which could elucidate roles for the ORFs of unknown function.  The growth 
curves could be undertaken under different growth conditions to see if growth is affected 
if the deletion mutants are grown in minimal media or at a different temperature.  The 
survivability curves could be undertaken for a longer period of time.  E. coli O157:H7 
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had been shown to survive for over 100 days in water (Mori, 2001; Liu et al, 2008).  The 
removal of specific PAI could affect long term survivability of the mutants in water. 
 Other future experiments could be to do partial deletions of the islands and SL 
removed to narrow down the ORF causing the differences in substrate utilization, growth 
and/or survivability. Also the removed islands could be transferred to E. coli K-12 to see 
if the addition of the PAI would cause the E. coli K-12 reference strain DH5α to behave 
like the pathogen E. coli O157:H7 with the addition of the new DNA. Also a few of the 
OI deletion mutants contain genes that are prophage related, 51, 102, 108 and 172.  It has 
been shown that these phage and prophage play an important role in E. coli O157:H7 
pathogenesis (Hallewell, 2008) and the removal of these islands with ORFs related to 
phages may change the virulence of this pathogen. Studies looking at phage and phage 
production should be undertaken to see if removal of the island affects the pathogenicity 
of E. coli O157:H7.  These types of experiments described above would help clarify the 
roles these specific PAIs have in E. coli O157:H7.  
 
6.5  Overall conclusions 
 The three tests used to compare the O157:H7 deletion mutants with the O157:H7 
controls EDL933 and Sakai and the E. coli K-12 reference strain DH5α have elucidated 
possible roles for these specific PAIs or elucidated further areas of study to determine the 
specific roles of these PAIs.  Each of the tests found similarities and/or differences 
between the deletion mutants and the three controls giving valuable information about the 
role the specific PAI has in the bacterium.  In some cases such as with the OI-39 deletion 
mutant the role of the OI was not specific but suggested areas for further study in order to 
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determine the specific role of this island.  In other cases such as the OI-102 deletion 
mutant it was found to have a role in sucrose metabolism indicating a specific role for 
this island.   
 
The results suggest that removal of a PAI has an effect on the resulting bacterium. 
The effects on the mutant can range from differences in substrate utilization, differences 
in how substrates are utilized, to differences in growth or survivability.  In six cases the 
deletion mutants showed differences with the O157:H7 parental control for more than 
one test.  The OI 87, 102 and the SL 72 deletion mutants each had significant differences 
in substrate utilization and growth compared to the O157:H7 parental strains EDL933 
(OI) and Sakai (SL). The OI 98 and 172 deletion mutants had significant differences in 
substrate utilization and survivability compared to the EDL933 O157:H7 parental. The 
OI-55 deletion mutant had significant differences in growth and survivability compared 
to EDL933. This demonstrates that PAIs can have more than one role in E. coli O157:H7 
strains EDL933 and Sakai and these roles can affect various systems in this bacterium. 
The removal of a PAI also suggest that the resulting mutant behaves more like a 
reference strain depending on the tests suggesting the resultant mutant is becoming less 
pathogenic.  Overall it can be concluded that PAIs have an important role in E. coli 
O157:H7 and the removal of these PAIs affect the bacterium and may likely affect the 
pathogenesis or pathogenicity of the bacterium. 
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Appendix I 
Genes and ORFs of each OI from E. coli O157:H7 strain EDL933 and SL from E. 
coli O157:H7 strain Sakai deleted.  
OI and SL ORFs and genes 
PAI Type # ORFs and Genes 
OI 39 ORF; Unknown function 
OI 39 ORF; Unknown function 
      
OI 51 putative integrase of prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 putative single stranded DNA-binding protein of prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 putative capsid protein of prophage CP-933C 
OI 51 putative head maturation protease of prophage CP-933C 
OI 51 putative portal protein of prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 putative holin protein of prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 putative terminase of prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
OI 51 unknown protein encoded by prophage CP-933C 
      
OI 55 putative molybdenum transport protein 
OI 55 ORF; Unknown function 
OI 55 putative iron compound ABC transporter, ATP-binding protein 
OI 55 putative iron compound ABC transporter, permease protein 
OI 55 ORF; Unknown function 
OI 55 ORF; Unknown function 
      
OI 59 putative regulator; Not classified 
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OI 59 ORF; Unknown function 
      
OI 87 ORF; Unknown function 
OI 87 ORF; Not classified 
      
OI 89 ORF; Unknown function 
OI 89 ORF; Unknown function 
OI 89 ORF; Unknown function 
OI 89 ORF; Unknown function 
      
OI 98 ORF; Unknown function 
      
OI 102 putative prophage DNA injection protein 
OI 102 putative prophage DNA injection protein 
OI 102 ORF; Unknown function 
OI 102 ORF; Unknown function 
OI 102 ORF; Unknown function 
OI 102 ORF; Unknown function 
OI 102 ORF; Unknown function 
OI 102 ORF; Unknown function 
OI 102 putative resolvase 
OI 102 sucrose permease 
OI 102 D-fructokinase 
OI 102 sucrose hydrolase 
OI 102 sucrose specific transcriptional regulator 
      
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF, hypothetical protein 
OI 108 putative chaperone protein 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 putative transposase 
OI 108 ORF; Unknown function (Insertion Sequence Associated) 
OI 108 partial putative transposase 
OI 108 partial putative transposase 
OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 putative antiterminator of prophage CP-933Y 
OI 108 unknown protein encoded by prophage CP-933Y 
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OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 unknown protein encoded by prophage CP-933Y 
OI 108 IS30 transposase 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
OI 108 putative enzyme; Integration, recombination (Phage or Prophage Related) 
OI 108 putative enzyme; Integration, recombination (Phage or Prophage Related) 
OI 108 putative DNA binding protein 
OI 108 ORF; Other or unknown (Phage or Prophage Related) 
      
OI 135 ORF; hypothetical protein 
OI 135 ORF; hypothetical protein 
      
OI 172 putative integrase 
OI 172 ORF; hypothetical protein in IS 
OI 172 putative transposase 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 putative resolvase 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 partial putative integrase 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
OI 172 putative ATP-dependent helicase 
OI 172 ORF; Unknown function 
OI 172 putative helicase 
OI 172 putative helicase 
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OI 172 ORF; Unknown function 
OI 172 ORF; Unknown function 
      
OI 176 ORF; Unknown function 
      
SL 72 putative integrase 
SL 72 putative membrane protein 
SL 72 transposase 
SL 72 putative regulatory protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 IS30 transposase 
SL 72 putative transposase 
SL 72 putative complement resistance protein precursor 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative diacylglycerol kinase 
SL 72 putative outer membrane protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 urease-associated protein UreD 
SL 72 urease gamma subunit 
SL 72 urease beta subunit 
SL 72 urease alpha subunit 
SL 72 urease accessory protein UreE 
SL 72 urease accessory protein UreF 
SL 72 urease accessory protein UreG 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 ribosomal protein L31-like protein 
SL 72 hypothetical protein 
SL 72 putative colicin immunity protein 
SL 72 putative membrane protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
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SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 TerW protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative tellurium resistance protein TerZ 
SL 72 putative tellurium resistance protein TerA 
SL 72 putative tellurium resistance protein TerB 
SL 72 putative tellurium resistance protein TerC 
SL 72 putative tellurium resistance protein TerD 
SL 72 putative tellurium resistance protein TerE 
SL 72 hypothetical protein 
SL 72 putative tellurium resistance protein TerF 
SL 72 hypothetical protein 
SL 72 Iha adhesin 
SL 72 hypothetical protein 
SL 72 hypotheical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative glucosyl-transferase 
SL 72 ferric enterochelin esterase 
SL 72 transposase 
SL 72 InsA protein of insertion sequence IS1 
SL 72 putative membrane protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
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SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative transposase ORFB protein of insertion sequence IS629 
SL 72 putative transposase ORFA protein of insertion sequence IS629 
SL 72 HecB-like protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative transcriptional regulator 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 BfpM-like protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 AidA-I adhesin-like protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 putative DNA repair protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
SL 72 hypothetical protein 
* The OI data is taken from the sequenced O157:H7 strain EDL933 
** The SL data is taken from the sequenced O157:H7 strain Sakai 
 
